US20140335591A1 - Increased production of secreted proteins by recombinant eukaryotic cells - Google Patents
Increased production of secreted proteins by recombinant eukaryotic cells Download PDFInfo
- Publication number
- US20140335591A1 US20140335591A1 US14/272,629 US201414272629A US2014335591A1 US 20140335591 A1 US20140335591 A1 US 20140335591A1 US 201414272629 A US201414272629 A US 201414272629A US 2014335591 A1 US2014335591 A1 US 2014335591A1
- Authority
- US
- United States
- Prior art keywords
- protein
- nucleic acid
- hac1
- upr
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 224
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 171
- 230000001965 increasing effect Effects 0.000 title abstract description 29
- 238000004519 manufacturing process Methods 0.000 title description 26
- 210000003527 eukaryotic cell Anatomy 0.000 title description 6
- 230000004906 unfolded protein response Effects 0.000 claims abstract description 146
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 106
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 93
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 93
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 claims abstract description 55
- 102100030013 Endoribonuclease Human genes 0.000 claims abstract description 54
- 230000000694 effects Effects 0.000 claims abstract description 53
- 102100036894 Protein patched homolog 2 Human genes 0.000 claims abstract description 34
- 101710161395 Protein patched homolog 2 Proteins 0.000 claims abstract description 34
- 241000499912 Trichoderma reesei Species 0.000 claims description 93
- 241000351920 Aspergillus nidulans Species 0.000 claims description 52
- 230000001939 inductive effect Effects 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 241000228245 Aspergillus niger Species 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 101000664600 Homo sapiens Tripartite motif-containing protein 3 Proteins 0.000 abstract description 158
- 102100038798 Tripartite motif-containing protein 3 Human genes 0.000 abstract description 157
- 238000000034 method Methods 0.000 abstract description 49
- 108090000637 alpha-Amylases Proteins 0.000 abstract description 18
- 102000004139 alpha-Amylases Human genes 0.000 abstract description 17
- 229940024171 alpha-amylase Drugs 0.000 abstract description 17
- 108010059892 Cellulase Proteins 0.000 abstract description 6
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 abstract description 6
- 102000004316 Oxidoreductases Human genes 0.000 abstract description 6
- 108090000854 Oxidoreductases Proteins 0.000 abstract description 6
- 102100022624 Glucoamylase Human genes 0.000 abstract description 5
- 108091005804 Peptidases Proteins 0.000 abstract description 5
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 abstract description 5
- 239000004365 Protease Substances 0.000 abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 5
- 102000001253 Protein Kinase Human genes 0.000 abstract description 4
- 229940106157 cellulase Drugs 0.000 abstract description 4
- 108060006633 protein kinase Proteins 0.000 abstract description 4
- 102000004195 Isomerases Human genes 0.000 abstract description 3
- 108090000769 Isomerases Proteins 0.000 abstract description 3
- 108090001060 Lipase Proteins 0.000 abstract description 3
- 102000004882 Lipase Human genes 0.000 abstract description 3
- 239000004367 Lipase Substances 0.000 abstract description 3
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 abstract description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 abstract description 3
- 108010059820 Polygalacturonase Proteins 0.000 abstract description 3
- 102000004357 Transferases Human genes 0.000 abstract description 3
- 108090000992 Transferases Proteins 0.000 abstract description 3
- 108010089934 carbohydrase Proteins 0.000 abstract description 3
- 108010093305 exopolygalacturonase Proteins 0.000 abstract description 3
- 229940059442 hemicellulase Drugs 0.000 abstract description 3
- 108010002430 hemicellulase Proteins 0.000 abstract description 3
- 108010062085 ligninase Proteins 0.000 abstract description 3
- 235000019421 lipase Nutrition 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000003262 industrial enzyme Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 153
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 99
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 97
- 239000002299 complementary DNA Substances 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 74
- 239000012634 fragment Substances 0.000 description 68
- 108020004999 messenger RNA Proteins 0.000 description 55
- 150000001413 amino acids Chemical class 0.000 description 53
- 239000013612 plasmid Substances 0.000 description 49
- 101150040444 hacA gene Proteins 0.000 description 48
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 47
- 239000000523 sample Substances 0.000 description 47
- 238000009396 hybridization Methods 0.000 description 45
- 239000013598 vector Substances 0.000 description 44
- 239000013615 primer Substances 0.000 description 39
- 230000006698 induction Effects 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 30
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 29
- 101150049031 HAC1 gene Proteins 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 230000037361 pathway Effects 0.000 description 23
- 108020005029 5' Flanking Region Proteins 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 101100407358 Aspergillus niger pdiA gene Proteins 0.000 description 18
- 108090000746 Chymosin Proteins 0.000 description 18
- 108091034117 Oligonucleotide Proteins 0.000 description 18
- 238000009739 binding Methods 0.000 description 18
- 241001513093 Aspergillus awamori Species 0.000 description 17
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 17
- 108700026244 Open Reading Frames Proteins 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 230000002018 overexpression Effects 0.000 description 17
- 230000009466 transformation Effects 0.000 description 16
- 230000004568 DNA-binding Effects 0.000 description 15
- 241000233866 Fungi Species 0.000 description 15
- 229940080701 chymosin Drugs 0.000 description 15
- 238000010367 cloning Methods 0.000 description 14
- 230000002441 reversible effect Effects 0.000 description 14
- 108010006519 Molecular Chaperones Proteins 0.000 description 13
- 241000223259 Trichoderma Species 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 108091060211 Expressed sequence tag Proteins 0.000 description 12
- 239000013614 RNA sample Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- 239000011543 agarose gel Substances 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000003155 DNA primer Substances 0.000 description 10
- 108010029541 Laccase Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 10
- 239000001573 invertase Substances 0.000 description 10
- 235000011073 invertase Nutrition 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 108091005749 foldases Proteins 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 9
- 229960000367 inositol Drugs 0.000 description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 9
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 8
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 8
- -1 cDNA Chemical class 0.000 description 8
- 238000004925 denaturation Methods 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 8
- 102000005431 Molecular Chaperones Human genes 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 102000035175 foldases Human genes 0.000 description 7
- 101150087371 gpd1 gene Proteins 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000012340 reverse transcriptase PCR Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 108020005087 unfolded proteins Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010058643 Fungal Proteins Proteins 0.000 description 6
- 101150108358 GLAA gene Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091092195 Intron Proteins 0.000 description 6
- 101150108662 KAR2 gene Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229940094991 herring sperm dna Drugs 0.000 description 6
- 101150082283 ire1 gene Proteins 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 101150104624 ptcB gene Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 241000228212 Aspergillus Species 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 5
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 5
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 5
- 108091058545 Secretory proteins Proteins 0.000 description 5
- 102000040739 Secretory proteins Human genes 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000013611 chromosomal DNA Substances 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 239000010432 diamond Substances 0.000 description 5
- 101150073906 gpdA gene Proteins 0.000 description 5
- 101150095733 gpsA gene Proteins 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 102000016227 Protein disulphide isomerases Human genes 0.000 description 4
- 108050004742 Protein disulphide isomerases Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000012807 shake-flask culturing Methods 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000001384 succinic acid Substances 0.000 description 4
- 101150063973 tdh1 gene Proteins 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 3
- BQIMPGFMMOZASS-CLZZGJSISA-N (6r,7r)-7-amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 BQIMPGFMMOZASS-CLZZGJSISA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 3
- 101000775727 Bacillus amyloliquefaciens Alpha-amylase Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 101100452790 Dictyostelium discoideum ireA gene Proteins 0.000 description 3
- 101100189610 Dictyostelium discoideum pdi1 gene Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 3
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 101150052795 cbh-1 gene Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 102100021868 Calnexin Human genes 0.000 description 2
- 108010056891 Calnexin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000221960 Neurospora Species 0.000 description 2
- 241000221961 Neurospora crassa Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 2
- 241000222354 Trametes Species 0.000 description 2
- 241000222355 Trametes versicolor Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 101150028578 grp78 gene Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000007003 mineral medium Substances 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 101150079312 pgk1 gene Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 101150093656 ptc2 gene Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 101150089778 pyr-4 gene Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 101150016309 trpC gene Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- PRTGXBPFDYMIJH-KSFLKEQHSA-N 7-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-methylchromen-2-one Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC1=CC=2OC(=O)C=C(C=2C=C1)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O PRTGXBPFDYMIJH-KSFLKEQHSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
- 101100216041 Aspergillus niger GLAA gene Proteins 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 101000914103 Bos taurus Chymosin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 101150080924 CNE1 gene Proteins 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004082 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102000003813 Cis-trans-isomerases Human genes 0.000 description 1
- 108090000175 Cis-trans-isomerases Proteins 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 241001465328 Eremothecium gossypii Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 241000125500 Hedypnois rhagadioloides Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000700735 Homo sapiens Serine/arginine-rich splicing factor 7 Proteins 0.000 description 1
- 101000596741 Homo sapiens Testis-specific protein TEX28 Proteins 0.000 description 1
- 101000802109 Homo sapiens Transducin-like enhancer protein 3 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 101710205153 Laccase-1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 241000222397 Phlebia radiata Species 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108090001087 RNA ligase (ATP) Proteins 0.000 description 1
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 102100029287 Serine/arginine-rich splicing factor 7 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 101150078565 TEF gene Proteins 0.000 description 1
- 101150074253 TEF1 gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102100035104 Testis-specific protein TEX28 Human genes 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- 101100074140 Trametes versicolor LCC4 gene Proteins 0.000 description 1
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 1
- 102100034698 Transducin-like enhancer protein 3 Human genes 0.000 description 1
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 101150069003 amdS gene Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000020054 awamori Nutrition 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 102000039554 bZIP family Human genes 0.000 description 1
- 108091067354 bZIP family Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 101150114858 cbh2 gene Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 101150066032 egl-1 gene Proteins 0.000 description 1
- 101150003727 egl2 gene Proteins 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 101150070719 ireA gene Proteins 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001533 ligninolytic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 101150093025 pepA gene Proteins 0.000 description 1
- 101150047627 pgk gene Proteins 0.000 description 1
- 101150095149 pgkA gene Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010064037 prorennin Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 101150054232 pyrG gene Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 108700040909 yeast KAR2 Proteins 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
Definitions
- This invention relates to cells which have been genetically manipulated to have an elevated unfolded protein response (UPR) resulting in an increased capacity to produce secreted proteins.
- URR unfolded protein response
- the secretory pathway of eukaryotic organisms is of interest since cells can be engineered to secrete a particular protein of interest.
- the secretory pathway starts by translocation of the protein into the lumen of the endoplasmic reticulum (ER).
- ER endoplasmic reticulum
- a quality control mechanism involving the proteins calnexin and calreticulin also resides in the ER, letting only completely folded proteins continue on the secretory pathway to the next compartment (Hammond and Helenius, 1995, Curr. Opinion Cell Biol. 7:523-529).
- Secretory proteins that do not fold properly are transported back to the cytoplasm by the translocation machinery and are degraded by the proteasome system (Wiertz et al., 1996, Nature 384:432-438).
- the folding and glycosylation of the secretory proteins in the ER is assisted by numerous ER-resident proteins.
- the chaperones like Bip (GRP78), GRP94 or yeast Lhs1p help the secretory protein to fold by binding to exposed hydrophobic regions in the unfolded states and preventing unfavourable interactions (Blond-Elguindi et al., 1993 , Cell 75:717-728).
- the chaperones are also important for the translocation of the proteins through the ER membrane.
- the foldase proteins like protein disulphide isomerase and its homologs and prolyl-peptidyl cis-trans isomerase assist in formation of disulphide bridges and formation of the right conformation of the peptide chain adjacent to proline residues, respectively.
- a machinery including many protein components also resides in the ER for the addition of the N-linked core glycans to the secretory protein and for the initial trimming steps of the glycans.
- the levels of the chaperone and foldase proteins found in the ER are regulated at the transcriptional level. For each gene there is a basic level of transcription that can be increased in response to various stimuli. A large amount of secretory protein in the ER (secretory load) can induce the mammalian GRP78 gene, and this induction is mediated through the NF- ⁇ B transcription factor (Pahl and Baeuerle, 1995, EMBO J. 14:2580-2588). Furthermore, the ER chaperone and foldase genes are upregulated when the amount of unfolded protein increases in the ER.
- This induction has been named unfolded protein response (UPR) and it has been described in mammalian cells, yeast and filamentous fungi (McMillan et al., 1994, Curr. Opinion in Biotechnol. 5:540-545).
- the induction can be caused by treatment of cells with reducing agents like DTT, by inhibitors of core glycosylation like tunikamycin or by Ca-ionophores that deplete the ER calcium stores.
- the promoters of mammalian and yeast genes regulated by UPR have a conserved sequence region called UPR element, where the transcription factor responsible for the induction binds.
- a signal is tranduced from the ER lumen to the transcription machinery in the nucleus.
- a protein implicated in the UPR induction is the IRE1 protein of yeast (Cox et al., 1993 , Cell 73:1197-1206, Mori et al., 1993 , Cell 74:143-156). It is large protein having a transmembrane segment anchoring the protein to the ER membrane. A segment of the IRE1 protein has homology to protein kinases and the C-terminal tail has some homology to RNAses.
- the IRE1 protein may be the first component of the UPR signal transduction pathway, sensing the ER lumen for the presence of unfolded proteins and transmitting the signal eventually to a transcription factor inducing the ER-protein genes. It has been reported that the IRE1 protein oligomerizes and gets phosphorylated when the UPR is activated (Shamu and Walter, 1996, EMBO J. 15:3028-3039). Over-expression of the IRE1 gene in yeast leads to constitutive induction of the UPR (Id.). Phosphorylation of the IRE1 protein occurs at specific serine or threonine residues in the protein.
- PTC2 a yeast protein phosphatase encoded by the PTC2 gene
- the IRE1 protein is phosphorylated when the UPR pathway is turned on (Shamu and Walter, 1996, EMBO J. 15:3928-3039), and PTC2 dephosphorylates the IRE1 protein and regulates the UPR.
- yeast transcription factor mediating the UPR induction of the chaperone and foldase genes is the HAC1 protein (Cox and Walter, 1996 , Cell 87:391-404, Sidrauski et al., 1996 , Cell 87:405-413). It belongs to the bZIP family of transcription factors, having a basic DNA-binding region and a leucine zipper dimerisation domain. The binding of the HAC1 protein to the UPR element of ER-protein gene promoters has been demonstrated (Mori et al., 1998 , J. Biol. Chem. 273: 9912-9920).
- the action of the HAC1 protein is regulated by its amount in the cells; none of the protein can be found in uninduced cells and upon UPR induction it appears rapidly.
- the HAC1 protein amount is dependent of the splicing of the respective mRNA.
- the intron present in the HAC1 gene close to the translation termination codon is not spliced off, and this intron prevents the formation of HAC1 protein by preventing the translation of the mRNA (Chapman and Walter, 1997, Curr. Biol. 7, 850-859, Kawahara et al., 1997, Mol. Biol. Cell 8, 1845-1862).
- the intron When UPR is induced, the intron is spliced and the mRNA is translated to form HAC1 protein that activates the promoters of its target genes.
- the HAC1 intron is spliced by an mechanism not currently described for any other system, involving the RNAse activity of the IRE1 protein and a tRNA ligase (Sidrauski and Walter, 1997 , Cell 90, 1031-1039, Gonzales et al., 1999, EMBO J. 18, 3119-3132, Sidrauski et al., 1996 , Cell 87, 405-413).
- the unfolded protein response can be induced constitutively in yeast by transformation with a UPR inducing version of the HAC1 gene. (Cox and Walter, supra.)
- yeast ER foldase or chaperone genes have been increased yields of secreted heterologous proteins in yeast by either over-expression or deletion of the yeast ER foldase or chaperone genes on an individual or pairwise basis.
- over-expression of either the protein disulphide isomerase (PDI) or the KAR2 (homologous to the gene for the mammalian ER chaperone BiP) genes in yeast has been shown to increase the extracellular accumulation of certain secreted heterologous proteins (Robinson et al., 1996, Bio/Technology, 12:381-384; Harmsen, et al., 1996, Appl. Microbiol. Biotechnol., 46:365-370).
- PDI protein disulphide isomerase
- KAR2 homologous to the gene for the mammalian ER chaperone BiP
- deletion of the CNE1 gene encoding an ER chaperone homologous to mammalian calnexin, reportedly can lead to increased secretion of a heterologous protein (Parlati et al., 1995, J. Biol. Chem. 270:244-253, Harmsen, supra.).
- the effect of over-expression or deletion of individual or pairs of ER chaperones or foldases has also been reported on in filamentous fungi, however, increased secretion was not obtained. (Punt, et al., 1998, Appl. Microbiol. Biotech, 50:447-454; Wang, et al., 2000, Current Genetics, 37:57-64).
- the method includes inducing the elevated UPR by increasing the presence of the HAC1 protein in the cell.
- the presence of the HAC1 protein can be increased by a number of methods.
- the HAC1 gene can be overexpressed compared to its native state. Overexpression can be achieved by a variety of ways including the use of preferred vectors and promoters as further described herein.
- the HAC1 protein is increased in a cell by transformation of said cell by a nucleic acid comprising a UPR inducing form of a HAC1 recombinant nucleic acid.
- HAC1 nucleic acid encoding a HAC1 protein can be from a variety of sources. It is understood that in one embodiment, HAC1 is used interchangeably with hac1, hacA, etc., and one embodiment is meant to encompass HAC1 homologs. Additionally, the skilled artisan can ascertain by the context whether the HAC1 is a nucleic acid, protein or either. In one embodiment, a HAC1 nucleic acid is isolated from yeast. In another embodiment, a HAC1 nucleic acid is isolated from filamentous fungi such as Trichoderma or Aspergillus.
- the elevated UPR is induced by modulating the levels of IRE1 protein or PTC2 protein in said cell.
- Nucleic acids encoding IRE1 or PTC2 can be isolated from yeast or filamentous fungi such as Trichoderma or Aspergillus .
- the nucleic acid encoding IRE1 or PTC2 is isolated from T. reesei, A. nidulans or A. niger.
- the cell from which the protein is secreted can be any cell having an UPR.
- Cells having an UPR include all eukaryotes including but not limited to mammalian cells, insect cells, yeast and filamentous fungi.
- an isolated nucleic acid encoding a HAC1 protein wherein said HAC1 has unfolded protein response inducing activity and has less than 50% similarity to yeast HAC1 protein.
- an isolated nucleic acid encoding a HAC1 protein is provided, wherein said HAC1 protein has unfolded protein response inducing activity and wherein said HAC1 comprises a DNA binding region that has greater than 70% similarity to the DNA binding region of filamentous fungi HAC1.
- Embodiments of a DNA binding region are shown at amino acids 84-147 of the T. reesei protein shown in FIG. 10 , at amino acids 53-116 of the A. nidulans protein shown in FIG.
- the HAC1 protein encoded by the HAC1 nucleic acid provided herein has an amino acid sequence having greater than 70% similarity to the sequence of FIG. 7 , FIG. 8 or FIG. 28 .
- the proteins encoded by such nucleic acids are also provided herein.
- the nucleic acid provided herein encodes an amino acid sequence as set forth in FIG. 7 , FIG. 8 or FIG. 28 .
- the nucleic acid provided herein has a nucleic acid sequence as set forth in FIG. 7 , FIG. 8 or FIG. 28 .
- the proteins encoded by such nucleic acids are also provided herein.
- an isolated nucleic acid encoding a PTC2 protein wherein said PTC2 protein modulates unfolded protein response and wherein said PTC2 protein has at least 70% similarity to the amino acid sequence of FIG. 24 or FIG. 25 .
- the PTC2 protein has preferably at least 80%, more preferably at least 90% or more preferably at least 95% similarity to said amino acid sequences.
- the PTC2 protein has an amino acid sequence as set forth in FIG. 24 or FIG. 25 .
- the PTC2 nucleic acid has a nucleic acid sequence as set forth in FIG. 24 or FIG. 25 .
- the proteins encoded by such nucleic acids are also provided herein.
- PTC2 can be used interchangeably with ptc2 and ptcB, and that in one embodiment, PTC2 encompasses homologs. Moreover, the context in which the term is used will determine whether PTC2 is a nucleic acid, a protein or either.
- a nucleic acid encoding an IRE1 protein having unfolded protein response modulating activity and having at least 60% similarity to an amino acid sequence as shown in FIG. 26 or FIG. 27 .
- the IRE1 protein has at least 70%, preferably at least 80%, more preferably at least 90% or even more preferably at least 95% similarity to said amino acid sequences.
- IRE1 has an amino acid or nucleic acid sequence as shown in FIG. 26 or FIG. 27 . It is understood that as used herein, IRE1, Ire1 and IreA can be used interchangeably, and that in one embodiment, IRE1 includes homologs.
- the context in which the term is used will determine whether IRE1 is a nucleic acid, a protein or either.
- nucleic acids provided herein may be obtained from a variety of sources including but not limited to filamentous fungi such as Trichoderma and Aspergillus .
- the nucleic acids are obtained from T. reesei, A. nidulans or A. niger.
- a cell containing a heterologous nucleic acid encoding a protein having unfolded protein response modulating activity and a heterologous nucleic acid encoding a protein of interest to be secreted is also provided herein.
- said protein having unfolded protein response modulating activity is selected from the group consisting of HAC1, PTC2 and IRE1.
- said protein of interest is selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase, alpha-amylase, glucoamylase, lignocellulose hemicellulase, pectinase and ligninase.
- FIG. 1 depicts a map of the plasmid pMS109, an embodiment of a plasmid constructed for the expression of the truncated yeast HAC1 gene.
- FIG. 2 depicts a graph showing activity of ⁇ -amylase produced from yeast containing pMS109 (squares) or an empty control vector pKK1 (diamonds) in the vertical bar, over time, horizontal bar, and further showing the activity is greater wherein pMS109 is present.
- FIG. 3 depicts a bar graph showing activity of invertase produced from yeast containing pMS109 (black bars) or an empty control vector pKK1 (shaded bars) in the vertical bar, over time, horizontal bar, and further showing the activity is greater wherein pMS109 is present.
- FIG. 4 depicts a graph showing activity of ⁇ -amylase produced from yeast wherein HAC1 has been disrupted (diamonds) or from its parental control strain (squares) in the vertical bar, over time, horizontal bar, and further showing that the activity is greater wherein HAC1 has not been disrupted.
- FIG. 5 depicts a graph showing activity of Trichoderma reesei ( T. Reesei ) endoglucanase EGI produced from yeast wherein HAC1 has been disrupted (diamonds) or from its parental control strain (squares) in the vertical bar, over time, horizontal bar, and further showing that the activity is greater wherein HAC1 has not been disrupted.
- FIG. 6 depicts a map of the plasmid pMS119, where the full-length T. reesei HAC1 cDNA without the 20 bp intron is in the pBluescript SK ⁇ vector.
- FIGS. 7A-C depict an embodiment of a nucleotide (SEQ ID No. 1) and deduced amino acid sequence (SEQ ID No. 2) of T. reesei HAC1. The introns are shown in lower case letters.
- FIGS. 8A-B depict an embodiment of a nucleotide (SEQ ID No. 3) and deduced amino acid sequence (SEQ ID No. 4) of Aspergillus nidulans ( A. nidulans ) hacA. The introns are shown in lower case letters.
- FIG. 9 depicts the hairpin loop structures forming at the 5′ end of the 20 bp introns in the T. reesei HAC1 and A. nidulans hacA mRNAs and at the 3′ end of the intron of the S. cerevisiae HAC1 mRNA.
- the conserved nucleotides in the loop region are shown in bold.
- FIG. 10 depicts an amino acid sequence alignment of the T. reesei HAC1 , A. niduans hacA and S. cerevisiae HAC1 proteins. Identical amino acids are shown by asterisks and similar ones by dots.
- Yeast HAC1 is homologous to the other sequences at the DNA binding domain area. The DNA binding domain is approximately at amino acids 84-147 for T. reesei (SEQ ID No. 5), and approximately at amino acids 53-116 for A. nidulans (SEQ ID No. 6).
- FIG. 11 depicts Northern hybridization of RNA samples derived from T. reesei mycelia treated with DTT (+DTT) and untreated control mycelia ( ⁇ DTT). The timepoints (in minutes) after DTT addition are shown. The probes used for hybridization are shown on the left.
- FIG. 12 depicts Northern hybridization of RNA samples derived from A. nidulans mycelia treated with DTT (+DTT) and untreated control mycelia ( ⁇ DTT). The timepoints after DTT addition are shown. The probes are shown on the left.
- FIG. 13 depicts a map of the plasmid pMS131, where the full-length T. reesei HAC1 cDNA without the 20 bp intron is under the yeast PGK1 promoter in the vector pAJ401.
- FIG. 14 depicts a map of the plasmid pMS132, where the T. reesei HAC1 cDNA without the 5′ flanking region and without the 20 bp intron is under the yeast PGK1 promoter in the vector pAJ401.
- FIGS. 15A-D depict complementation of S. cerevisiae HAC1 and IRE1 disruptions (DHAC1 and DIRE1, respectively) with different forms of the T. reesei HAC1 cDNA.
- the growth of transformants on media with and without inositol is shown.
- pAJ401 is the expression vector without any insert.
- pMS131 has the full-length T. reesei HAC1 cDNA in pAJ401.
- pMS132 has the T. reesei HAC1 cDNA without its 5′ flanking region in pAJ401.
- FIG. 16 depicts bandshift experiments, where the binding of the malE-HACI fusion protein to the putative UPR element sequences found in T. reesei pdi1 and bip1 promoters was tested.
- the oligonucleotides used in the binding reactions are shown on the top. Lanes 1, 12 and 16, no protein; lanes 2, 4-7, 8-11, 13-15 and 17-19, malE-HACI fusion protein; lane 3, malE protein alone.
- the binding was competed with unlabelled oligonucleotides on lanes 5 (20 ⁇ excess); lanes 6, 10, 14 and 18 (50 ⁇ excess) and lanes 7, 11, 15, and 19 (200 ⁇ excess). Alignment of the UPR element sequences that bind the HACI-malE protein is shown below.
- FIG. 17 depicts a graph which shows activity of ⁇ -amylase by yeast strains expressing the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron (pMS132) (squares) and control strains with the expression vector alone (pAJ401) (diamonds) in the vertical bar over time, horizontal bar, and which further shows that activity is greater wherein pMS132 is present.
- FIG. 18 depicts a bar graph which shows activity of invertase by yeast strains expressing the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron (pMS132) and control strains with the expression vector alone (pAJ401) in the vertical bar, over time (horizontal bar) and which further shows that activity is greater is greater wherein pMS132 is present.
- FIG. 19A depicts Northern hybridization of RNA samples from a yeast strain expressing the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron (pMS132) and a control strain with the expression vector alone (pAJ401). The probes used for hybridization are shown. The signals were quantified with a phosphoimager and the KAR2 signal intensities were normalised with respect to the TDH1 signal intensities.
- FIG. 19B shows the normalised KAR2 signals, wherein it is shown that pMS132 has greater signal.
- FIG. 20 depicts a map of the plasmid pMS136, where the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron is under the A. nidulans gpdA promoter in the vector pAN52-NotI.
- FIG. 21A depicts Northern hybridization of RNA samples derived from transformation of the plasmid pMS136 into a T. reesei strain producing CBHI-chymosin fusion protein. Samples from the parental strain (lanes 1, 5 and 9), two positive transformants (lanes 2, 3, 6, 7, 10 and 11) and a HAC1 mutant strain designated number 31 generated in the transformation (lanes 4, 8 and 12) are shown. The growth times are shown on the top and the probes used for the hybridization on the left.
- FIG. 21B shows quantifications of the pdi1 and bip1 signals normalised with respect to gpd1 signals.
- FIG. 22A depicts Northern hybridization of RNA samples derived from mycelia of the HAC1 mutant strain number 31 treated with DTT (+DTT) and untreated control mycelia ( ⁇ DTT). The timepoints after DTT addition are shown on the top and the probes used for hybridization on the left.
- FIG. 22B shows quantifications of the pdi1 signals normalised with respect to gpd1 signals.
- FIG. 23 is a graph depicting production of calf chymosin by the HAC1 mutant transformant number 31 (diamonds) and its parental strain (squares) during a shake flask culture.
- the chymosin (CHV) units per ml of culture are shown (vertical bar) over time (horizontal bar), and it is shown that the control has more units than the mutant.
- FIG. 24 depicts an embodiment of a nucleotide (SEQ ID No. 7) and deduced amino acid sequence (SEQ ID No. 8) of the fragment isolated from the A. nidulans ptcB gene. The intron is shown in lower case.
- FIG. 25 depicts an embodiment of a nucleotide (SEQ ID No. 9) and deduced amino acid sequence (SEQ ID No. 10) of the T. reesei ptc2 cDNA.
- FIG. 26 depicts an embodiment of a nucleotide (SEQ ID No. 11) and deduced amino acid sequence (SEQ ID No. 12) of the fragment isolated from the A. nidulans ireA gene. The intron is shown in lower case.
- FIGS. 27A-27C depict an embodiment of a nucleotide (SEQ ID No. 13) and deduced amino acid sequence (SEQ ID No. 14) of the T. reesei IRE1 gene.
- the intron is shown in lower case.
- FIG. 28A-28C The nucleotide (SEQ ID No. 15) and deduced amino acid sequence (SEQ ID No. 16) of Aspergillus niger var. awamori hacA cDNA.
- the 20 bp unconventional intron (SEQ ID No. 17) is shown in lower case letters.
- the amino acid sequences of the upstream open reading frame (SEQ ID No. 18) and the HACA protein (SEQ ID No. 19) are shown below the nucleotide sequence.
- FIG. 29 Map of the plasmid pMS152 where the Aspergillus niger var. awamori hacA without the 5′ flanking region and the 20 bp intron is under control of the Aspergillus niger var. awamori glaA promoter.
- FIG. 30 The levels of chymosin activity measured in supernatants from duplicate cultures of strain ⁇ AP3pUCpyrGRG3#11 (ctrl) and transformants (#1, #2, #3 and #4) of this strain with pMS152.
- FIG. 31 The levels of laccase activity measured in supernatants from duplicate cultures of strain ⁇ AP4:pGPTIaccase (ctrl) and transformants (#1, #2, #3, #4, #5, #6, #7 and #8) of this strain with pMS152.
- compositions for increasing the secretion of a protein in a cell comprising inducing an elevated unfolded protein response (UPR).
- the compositions provided herein include nucleic acids, proteins, and cells.
- UPR refers to the unfolded protein response which occurs in response to an increase in unfolded protein in the ER.
- the UPR is elevated.
- “elevated” UPR refers to an increase in the response compared to the response which would have been induced based on the amount of unfolded protein in the ER.
- elevated refers to an increase with respect to the length of time the response occurs.
- the elevated UPR results in an increased capacity for the cell to produce secreted proteins compared to another cell of the same type containing the same amount of unfolded protein in the ER.
- the cell having an elevated UPR in accordance with the present invention produces more secreted protein in the same amount of time as a cell not having an elevated UPR.
- the method includes inducing the elevated UPR by modulating the amount or presence of one or more UPR modulating proteins in said cell.
- the UPR modulating protein is selected from the group consisting of HAC1, PTC2 or IRE1.
- UPR modulating proteins are further discussed below. It is understood that the modulating protein can be obtained by increasing the presence of a nucleic acid which encodes a modulating protein.
- the protein used in the methods herein have UPR modulating activity as further discussed below, and the nucleic acids encode a protein which has UPR modulating activity. Modulating means that an increase in the protein can lead to an increase or a decrease in the UPR.
- the presence of a modulating protein is increased as further discussed below to reach an elevated UPR.
- the modulating protein is decreased or eliminated to reach an elevated UPR.
- HAC1 and/or IRE1 are increased so as to reach an elevated UPR.
- inducing UPR means that the unfolded protein response as a whole is induced or maintained as it would be by unfolded protein in the ER.
- the unfolded protein response involves increased expression and regulation of multiple ER foldases and chaperones.
- manipulation of ER foldases or chaperones on an individual gene basis would not be considered an induction of UPR.
- UPR modulating activity results in an elevated UPR wherein an elevated UPR results in upregulation of ER chaperones and foldases and increased secretion of proteins.
- the nucleic acids encoding the UPR modulating proteins can be obtained from a variety of sources.
- Preferred organisms include but are not limited to Saccharomyces cerevisiae, Aspergillus spp. and Trichoderma spp.
- yeasts and other fungi such as Schizosaccharomyces pombe, Kluyveromyces lactis, Pichia spp., Hansenula spp., Fusarium spp., Neurospora spp. and Penicillium spp. can be used.
- Homologous genes from other organisms can also be used.
- homologous genes refer to genes which are related, but not identical, in their DNA sequence and/or perform the same function are homologous with each other and are called each other's homologues.
- HAC1, PTC2, or IRE1 amino acid and nucleic acid sequences have been described for yeast.
- GenBank is known in the art, see, e.g., Benson, D A, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/.
- HAC1, PTC2, or IRE1 are isolated from a species other than yeast, preferably a filamentous fungi, insect cell, mammalian cell or other eukaroyote. Sequences for HAC1 are provided in FIGS. 7 , 8 and 28 . Sequences for PTC2 are provided in FIGS. 24 and 25 . Sequences for IRE1 are provided in FIGS. 26 and 27 .
- the UPR modulating sequences are identified by hybridization to other nucleic acids. Additionally, sequence homology determinations can be made using algorithms.
- the UPR modulating nucleic acid hybridizes to a complement of a nucleic acid encoding HAC1, PTC2 or IRE1.
- the HAC1, PTC2 or IRE1 encoding sequence is selected from the sequences provided in the respective figures.
- the stringency conditions are moderate. In another embodiment, the conditions used are high stringency conditions.
- “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology , Wiley Interscience Publishers, (1995).
- “Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5 ⁇ SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 ⁇ Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ml), 0.1% SDS, and 10% dextran
- Modely stringent conditions may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual , New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent that those described above.
- washing solution and hybridization conditions e.g., temperature, ionic strength and % SDS
- An example of moderately stringent conditions is overnight incubation at 37° C.
- Homologous (similar or identical) sequences can also be determined by using a “sequence comparison algorithm.” Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection.
- sequence comparison algorithm e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:44
- HSPs high scoring sequence pairs
- the word hits are expanded in both directions along each of the two sequences being compared for as far as the cumulative alignment score can be increased. Extension of the word hits is stopped when: the cumulative alignment score falls off by the quantity X from a maximum achieved value; the cumulative score goes to zero or below; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
- the BLAST algorithm then performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)).
- One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
- an amino acid sequence is considered similar to a protein such as a protease if the smallest sum probability in a comparison of the test amino acid sequence to a protein such as a protease amino acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- the HAC1 protein provided herein has less than 80% sequence similarity than the HAC1 yeast protein, see for example, GenBank accession number E15694, more preferably, less than 70%, more preferably, less than 60%, more preferably less than 50%, more preferably, less than 45% or 40% similarity. In another embodiment, identity is substituted for similarity.
- the HAC1 protein provided herein has at least 40% similarity to the amino acid sequence set forth in FIG. 7 or FIG. 8 . More preferably, the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity.
- the HAC1 protein provided herein comprises a DNA binding domain that has at least 70% similarity to the DNA binding domain set forth in FIG. 10 . More preferably, the similarity is at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity.
- DNA binding domain refers to the domain which binds to the conserved sequence called the UPR element in promoters of genes regulated by UPR.
- Embodiments of a DNA binding region are shown approximately at amino acids 84-147 of the T. reesei protein shown in FIG. 10 , approximately at amino acids 53-116 of the A. nidulans protein shown in FIG. 10 and approximately amino acids 45-109 of the A. niger protein shown in FIG. 28 .
- HAC1 homologs will have DNA binding domains which can be identified by activity or by alignment to the binding domains in FIG. 10 .
- the PTC2 protein provided herein has less than 80% sequence similarity than the PTC2 yeast protein, see for example, GenBank accession number U472498, more preferably, less than 70%, more preferably, less than 60%, more preferably less than 50%, more preferably, less than 45% or 40% similarity. In another embodiment, identity is substituted for similarity.
- the PTC2 protein provided herein has at least 40% similarity to the amino acid sequence set forth in FIG. 24 or FIG. 25 . More preferably, the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity.
- the IRE1 protein provided herein has less than 80% sequence similarity than the IRE1 yeast protein, see for example, GenBank accession number Z11701, more preferably, less than 70%, more preferably, less than 60%, more preferably less than 50%, more preferably, less than 45% or 40% similarity. In another embodiment, identity is substituted for similarity.
- the IRE1 protein provided herein has at least 40% similarity to the amino acid sequence set forth in FIG. 26 or FIG. 27 . More preferably, the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity.
- UPR modulating sequences can be identified for example by using PCR primers based on the sequences provided herein.
- naturally occurring allelic variants of the sequences provided herein may be used.
- a protein has UPR modulating activity if it is able to regulate the induction of UPR. Regulate means causing an increase or decrease in the induction of the UPR.
- a UPR modulating protein can increase or decrease UPR induction whether or not there is a change in the amount unfolded protein in the ER.
- a UPR modulating protein has one or more of the following activities: HAC1 activity, PTC2 activity, IRE1 activity, or binds to HAC1.
- Modulating the amount of or activity of the UPR modulating protein can occur by a variety of methods. For example, to increase the presence or activity of a protein in a cell, one can over-express the nucleic acid encoding the UPR modulating protein.
- Over-expression as used herein means that the protein encoded by the said gene is produced in increased amounts in the cell.
- over-expression can be used interchangeably with constitutive expression or upregulation. This can be achieved by increasing the copy number of the gene by introducing extra copies of the gene into the cell on a plasmid or integrated into the genome. Over-expression can also be achieved by placing the gene under a promoter stronger than its own promoter.
- the amount of the protein in the cell can be varied by varying the copy number of the gene and/or the strength of the promoter used for the expression.
- manipulation of genes to cause induction of UPR may involve insertion into the host of multiple copies of a gene with its native promoter either on a replicating autosomal plasmid or by integration into the chromosomal DNA. It may involve fusion of the gene with a promoter region and/or transcriptional control sequences from other genes to further increase expression or to allow controlled, inducible expression. Agonists and enhancers may also be used.
- a number of methods may be used such as deletion of a gene or the use of antisense nucleic acids to reduce the expression of a gene. It may involve alteration of a gene to provide a mutant form of the protein or include the use of an inhibitor of a UPR modulating protein.
- UPR is elevated by using a UPR inducing form of a recombinant nucleic acid encoding a UPR-modulating protein.
- a UPR-inducing form of a recombinant nucleic acid encoding a UPR-modulating protein is a nucleic acid which has been modified to give rise to a translatable mRNA. The translatable form mimics the modified mRNA which appears in the cell on induction of UPR and which can be translated to an active UPR-modulating protein.
- a UPR-inducing form of a recombinant nucleic acid includes coding sequence.
- Coding sequence as used herein includes the nucleic acid sequence which leads to the amino acid sequence of the protein in its active form.
- a nucleic acid consisting essentially of a coding sequence explicitly excludes, lacks or omits at least internal sequence which does not get translated when the active protein is encoded.
- Internal sequence refers to sequence which is internal to the carboxyl terminus and the amino terminus. Examples of excluded internal sequence are shown in small letters in FIGS. 7 , 8 , 24 , 26 , 27 and 28 . The sequence may be excluded by deletion or truncation by methods known in the art.
- a nucleic acid comprises a sequence consisting essentially of coding sequence.
- the nucleic acid may comprise vector sequence on either side of the coding sequence but the coding sequence excludes internal sequence which does not get translated in the encoded protein's active form.
- a UPR modulating protein is a variant UPR modulating protein which has been varied to have increased activity.
- the activity of a UPR modulating protein is increased to elevate UPR.
- the activity of a UPR modulating protein is increased by maintaining the protein in its active state. For example, IRE1 is phosphorylated when the UPR pathway is turned on. Therefore, in one embodiment herein, maintaining IRE1 in its phosphorylated induces an elevated UPR.
- IRE1 is mutated so as to constitutively have the activity of phosphorylated IRE1.
- serine and/or threonine residues are substituted with aspartic acid to form to form an IRE1 variant having constitutive UPR inducing activity.
- Other substitutions to mimic a protein in its phosphorylated state are known in the art.
- the mutations are performed on the nucleic acid encoding the protein.
- nucleic acid By the term “recombinant nucleic acid” herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid by polymerases and endonucleases, in a form not normally found in nature. Generally, a nucleic acid refers to DNA, RNA or mRNA and includes a gene or gene fragment. Thus, an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e.
- nucleic acids once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.
- a “recombinant protein” is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above.
- the term protein and peptide can be used interchangeably herein.
- a recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics.
- the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure.
- an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample.
- a substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred.
- the definition includes the production of a protein from other than its host cell, or produced by a recombinant nucleic acid.
- the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels.
- the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.
- a recombinant cell generally refers to a cell which has been manipulated to contain a recombinant nucleic acid or protein therein.
- the protein of interest to be secreted can be any protein. Wherein the protein is not naturally secreted, the nucleic acid encoding the protein may be modified to have a signal sequence in accordance with techniques known in the art.
- the proteins which are secreted may be endogenous proteins which are expressed naturally, but in a greater amount in accordance with the present invention, or the proteins may be heterologous. In a preferred embodiment, the proteins are heterologous.
- Heterologous as used herein means the protein is produced by recombinant means. Therefore, the protein may be native to the cell, but is produced, for example, by transformation with a self replicating vector containing the nucleic acid encoding the protein of interest. Alternatively, recombinant could be wherein one or more extra copies of the nucleic acid are integrated into the genome by recombinant techniques.
- the protein of interest is selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase, alpha-amylase, glucoamylase, lignocellulose hemicellulase, pectinase and ligninase.
- the protein of interest is a therapeutic selected from the group consisting of vaccines, cytokines, receptors, antibodies, hormones, and factors including growth factors.
- the cell in which the proteins are secreted is any cell having an upregulated protein response.
- the host to be transformed with the genes of the invention can be any eukaryotic cell suitable for foreign or endogenous protein production, e.g., any S. cerevisiae yeast strain, (e.g., DBY746, BMA64-1A, AH22, S150-2B, GYPY55-15bA, vtt-a-63015) any Trichoderma spp. such as T. longibrachiatum and the T.
- reesei strains derived from the natural isolate QM6a such as RUTC-30, RL-P37, QM9416 and VIT-D-79125, any Kluyveromyces spp/. Sch. pombe, H. polymorpha, Pichia, Aspergillus, Neurospora, Yarrowia, Fusarium, Penicillium spp. or higher eukaryotic cells.
- mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51).
- COS-7 monkey kidney CV1 line transformed by SV40
- human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al.,
- a plant cell can be utilized.
- a baculovirus infected insect cell is utilized. The selection of the appropriate host cell is deemed to be within the skill in the art.
- Transfer of the genes into these cells can be achieved, for instance, by using the conventional methods of transformation described for these organisms.
- General aspects of mammalian cell host system transfections have been described in U.S. Pat. No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci . ( USA ), 76:3829 (1979).
- other methods for introducing DNA into cells such as by nuclear microinjection, electroporation, etc.
- For various techniques for transforming mammalian cells see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).
- the nucleic acid (e.g., cDNA, coding or genomic DNA) encoding the UPR modulating protein may be inserted into a replicable vector.
- Various vectors are publicly available.
- the vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage.
- the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures.
- DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
- Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.
- the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces ⁇ -factor leaders, the latter described in U.S. Pat. No. 5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 Apr. 1990), or the signal described in WO 90/13646 published 15 Nov. 1990.
- mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
- Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv.
- Enzyme Req. 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
- enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isome
- yeast promoters which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
- Transcription from vectors in mammalian host cells can be controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 Jul. 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
- viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 Jul. 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retro
- Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription.
- Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, ⁇ -fetoprotein, and insulin).
- an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
- the enhancer may be spliced into the vector at a position 5′ or 3′ to the coding sequence, but is preferably located at a site 5′ from the promoter.
- Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5′ and, occasionally 3′, untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the protein.
- the gene is cloned into a suitable expression vector, such as pKK1 or similar vectors comprising the appropriate regulatory regions depending on the selected host.
- these regulatory regions can be obtained from yeast genes such as the ADH1, GAL1-GAL 10, PGK1, CUP1, GAP, CYC1, PHO5, or asparagine synthetase gene, for instance.
- yeast genes such as the ADH1, GAL1-GAL 10, PGK1, CUP1, GAP, CYC1, PHO5, or asparagine synthetase gene, for instance.
- the regulatory regions of, for example, HAC1 can be used to express the gene in S. cerevisiae .
- the plasmid carrying the gene is capable of replicating autonomously when transformed into the recipient yeast strain and is maintained stably in a single copy due to the presence of a yeast centromeric sequence.
- a multicopy replicating plasmid could be used or integration of the plasmid into the yeast genomic DNA could be provided for
- HAC1 cDNA preferably truncated in Trichoderma
- the coding region of the inducing form of the Trichoderma HAC1 gene is coupled for instance between the A. nidulans gpdA promoter and terminator and the expression cassette is transformed into a Trichoderma strain producing for instance bovine chymosin or another foreign protein.
- the unconventional introns are removed, as well as any remaining terminal end adjacent to said intron.
- An uncoventional intron is one which is present in the mRNA in the cell which is not undergoing UPR, but which is removed from the mRNA upon induction of the UPR. UPR would be thus induced constitutively.
- a higher level of expression which was inducible according to the carbon source used for growth of the fungus could be achieved by fusion of the inducing form of HAC1 with the promoter of the T. reesei cbh 1 gene.
- the HAC1 gene is preferably integrated into the genome using methods known in the art.
- Suitable promoters in addition to the gpdA or cbh1 promoters or promoter of the HAC1 gene itself are for instance the other cellulase promoters, cbh2, egl1, egl2, or tef1, pgk, pki, the glucoamylase, alpha-amylase or the alcohol dehydrogenase promoter.
- filamentous fungi transformation usually results in strains with varying copies of expression vector integrated into the genome (Penttilä et al., 1987) and from these the strain with optimal level of truncated HAC1 expression for growth and enhanced secretion can be screened.
- the methods provided herein may further include cultivating said recombinant host cells under conditions permitting expression of said secreted protein.
- the proteins can be collected and purified as desired.
- hydrolytic enzymes are secreted.
- the secreted proteins are used in improved alcohol production or in processes where efficient hydrolysis of raw material is desired.
- a truncated version of the yeast HAC1 gene was expressed from a centromeric plasmid.
- the truncated version does not include the intron of HAC1 that in normal conditions prevents the translation of the mRNA.
- the appropriate HAC1 gene fragment was first amplified from yeast chromosomal DNA by PCR.
- This fragment starts 24 bp before the translation start codon of the HAC1 gene and ends with a translation stop codon inserted after the proline codon at amino acid position 220 of the deduced protein.
- the oligonucleotide primers used were: 5′ ATC GCA GGA TTC CCA CCT ACG ACA ACA ACC GCC ACT 3′ (forward primer) (SEQ ID No. 20) and 5′ TAC AGC GGA TCC CTA TGG ATT ACG CCA ATT GTC AAG3′ (reverse primer) (SEQ ID No. 21). BamHI restriction sites were included into both of the primers to facilitate cloning.
- the PCR reaction was carried out with the Vent DNA polymerase (New England Biolabs) in conditions recommended by the manufacturer.
- the PCR program used started with heating to 94° C. for three minutes followed by 30 cycles with denaturation at 94° C. for 45 seconds, annealing at 55° C. for 45 seconds and synthesis at 72° C. for one minute.
- the fragment was digested with BamHI and cloned into the BamHI site of the pZERO vector (Invitrogen) with methods known in the art.
- the HAC1 fragment was released from pZERO by BamHI digestion and cloned into the BgIII site of the vector pKK1 between the promoter and terminator of the yeast PGK1 gene with methods known in the art.
- pKK1 contains the LEU2 selectable marker gene and the centromere (CEN6) and ARS sequences for maintenance in yeast as a single-copy plasmid.
- the final expression plasmid was named pMS109 ( FIG. 1 ).
- the plasmid pMS109 and the control plasmid pKK1 were transformed into a yeast strain producing Bacillus amyloliquefaciens ⁇ -amylase.
- the expression cassette with the ⁇ -amylase coding region inserted between the yeast ADH1 promoter and terminator had been integrated into the TRP1 locus of the yeast strain DBY746 ( ⁇ , his3 ⁇ 1, leu2-3, ura3-52, trp1-289, Cyh r ).
- Four pMS109 transformants and four strains transformed with the vector pKK1 were selected for cultivations.
- the cultivation medium was synthetic complete yeast medium without leucine (SC-Leu, described by Sherman 1991 , Meth. Enzymol.
- the ⁇ -amylase amounts produced by each of the pMS109 transformants were higher than the amounts produced by any of the pKK1 transformants.
- the average production level of pMS109 transformants was 70% higher in the end of the cultivation than the average of pKK1 clones ( FIG. 2 ).
- the growth of the pMS109 strains was slightly retarded when compared with the control.
- the cells were washed with 5 ml of 10 mM NaN 3 and resuspended in 0.2 M NaAc buffer, pH5.0 with 10 mM NaN 3 .
- the invertase activity of the cells was measured by incubating them with 0.166 M sucrose in 0.2 M NaAc buffer, pH 5.0 for 6 minutes.
- the reaction was stopped by adding one volume of 0.5 M KPO 4 , pH 7.0 and by separating the cells rapidly from the reaction mixture by filtration.
- the glucose formed into the reaction mixture was measured by the GOD-Perid kit (Boehringer Mannheim) according to the manufacturer's protocols.
- the invertase production of the pMS109 transformants was about 2 times higher than that of the pKK1 transformants in all the timepoints that were tested ( FIG. 3 ).
- the yeast HAC1 gene was disrupted by replacing it in the genome with a DNA fragment containing the G418 antibiotic resistance cassette flanked by 48 bp sequences from the 5′ and 3′ ends of the HAC1 open reading frame.
- the G418 resistance cassette consists of the E. coli kanamycin resistance gene cloned between the promoter and terminator of the Ashbya gossypii TEF gene encoding translation elongation factor 1.
- the DNA fragment used in the disruption of the yeast HAC1 was produced by PCR from the kanMX2 module (Wach et al., 1994 , Yeast 10, 1793-1808) with the oligonucleotide primers 5′ CCA CCT ACG ACA ACA ACC GCC ACT ATG GAA ATG ACT GAT TTT GAA CTA CTT GCC TCG TCC CCG CCG GGT CAC 3′ (forward primer) (SEQ ID No. 22) and 5′ AAT TAT ACC CTC TTG CGA TTG TCT TCA TGA AGT GAT GAA GAA ATC ATT GAC ACT GGA TGG CGG CGT TAG TAT CGA 3′ (reverse primer) (SEQ ID No. 23).
- the PCR reaction was done with the Dynazyme DNA polymerase (Finnzymes) in conditions recommended by the manufacture.
- the PCR program started by denaturation at 94° C. for 3 minutes, followed by 30 cycles of denaturation at 94° C. for 45 seconds, annealing at 52° C. for 30 seconds and elongation at 72° C. for 1 minute. A final elongation step of 5 minutes was performed at 72° C.
- the PCR product of about 1.5 kb was run in an 0.8% agarose gel and purified from the gel with the Qiaquick kit (Qiagen).
- the fragment was transformed into the yeast strain BMA64-1A (a, ura3-1, trp1- ⁇ , leu2-3, 112, his3-11, ade2-1, can1-100) with a method described (Gietz et al., 1992 , Nucl. Acids Res. 20, 1425).
- the transformants were first grown over night on YPD plates (Sherman, 1991 , Meth. Enzymol. 194, 3-21) and then replicated onto YPD plates with 200 ⁇ g/ml of the antibiotic G418.
- the transformants resistant to G418 were tested on plates with yeast mineral medium (Verduyn et al, 1992 , Yeast 8, 501-517) with and without inositol.
- the effect of the HAC1 disruption on the production of two heterologous proteins was tested.
- the ⁇ -amylase was expressed from a multicopy plasmid with the LEU2 marker gene, B485 (Ruohonen et al., 1991 , J. Biotechnol.
- the plasmid is called YEp ⁇ a6 in this article), where the ⁇ -amylase gene has been cloned between the yeast ADH1 promoter and terminator.
- the EGI was expressed from the plasmid pMP311 (Penttilä et al., 1987, Yeast 3, 175-185), where the endoglucanase cDNA has been cloned between the yeast PGK1 promoter and terminator in a multicopy vector with the LEU2 marker gene.
- the B485 and pMP311 plasmids were transformed into the HAC1 disruptant and its parental strain with a described method (Gietz et al., 1992 , Nucl. Acids Res.
- a homology search was performed against a public database (http://bioinfo.okstate.edu/pipeonline_db/anesquery.html) containing Aspergillus nidulans EST (expressed sequence tag) sequences with the yeast HAC1 protein sequence using the program BLAST (Altschul et al., 1990 , J. Mol. Biol. 215, 403-410). The search identified one EST cDNA clone (c7a10a1.r1) which has homology to yeast HAC1p at the DNA binding domain.
- EST c7a10a1.f1 another region of the same cDNA clone, designated as EST c7a10a1.f1 in the database, had no obvious similarity with HAC1 and there was no annotation within the database to indicate similarity between the ESTs and HAC1. Therefore, it was unclear if the A. nidulans cDNA clone encoded a functional homolog of HAC1 or a different protein having a version of a DNA-binding motif.
- the region corresponding to the c7a10a1 EST cDNA was amplified by PCR from A. nidulans genomic DNA isolated with methods known in the art.
- the sequences of the ends of the EST cDNA clone found from the database were used to design the 5′ end primer (5′ GCC ATC CTT GGT GAC TGA GCC 3′) (SEQ ID No. 24) and 3′ end primer (5′ CAA TTG CTC GCT CTT ACA TTG AAT 3′) (SEQ ID No. 25).
- the PCR reaction was performed as described in Example 2.
- the PCR product of 1.6 kb in length was run in an 0.8% agarose gel, purified from the gel with the Qiaquick gel extraction kit (Qiagen) and cloned into the pGEM-AT vector (Promega) with methods known in the art.
- the whole fragment was sequenced from the resulting plasmid using internal oligonucleotide primers.
- the proper hybridisation temperature for cDNA library screening were determined by genomic Southern hybridization with the genomic hacA fragment cloned from A. nidulans as a probe.
- the probe fragment was labelled with 32 P-dCTP using the Random primed DNA labelling kit (Boehringer Mannheim) as instructed by the manufacturer.
- the hybridization was performed as described (Sambrook et al., 1989, in Molecular Cloning: a Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) at 48° C., 50° C., 55° C. and 60° C.
- the genomic copy of the T. reesei gene was isolated by hybridization of a genomic ⁇ -library in the vector ⁇ EMBL3 (Kaiser and Murray, 1985, in DNA Cloning: a Practical Approach , pp. 1-47, ed. Glover, IRL Press, Oxford).
- the library was plated with the appropriate E. coli host strain and ⁇ -DNA was lifted onto nitrocellulose filters (Schleicher & Schull) as instructed by the manufacturer. The filters were hybridized at 42° C.
- a hybridization mixture containing 50% formamide, 5 ⁇ Denhardt's, 5 ⁇ SSPE, 0.1% SDS, 100 ⁇ g/ml herring sperm DNA and 1 ⁇ g/ml polyA-DNA (SSPE is 0.18 M NaCl, 1 mM EDTA, 10 mM NaH 2 PO 4 , pH 7.7).
- SSPE is 0.18 M NaCl, 1 mM EDTA, 10 mM NaH 2 PO 4 , pH 7.7.
- the filters were washed for 10 minutes at room temperature with 2 ⁇ SSC, 0.1% SDS and 30 minutes at 65° C. in 0.1 ⁇ SSC, 0.1% SDS.
- ⁇ -DNA was isolated from clones hybridizing with the probe with a described method (Sambrook et al., 1989, in Molecular Cloning: a Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.), and the genomic region corresponding to the HAC1 cDNA was sequenced from this DNA with internal sequencing primers.
- the sequences of the Trichoderma reesei HAC1 and Aspergillus nidulans hacA genes are shown in FIGS. 7 and 8 , respectively. Comparison of the genomic and cDNA sequences from both fungi (the cDNA sequence of hacA available in the EST database) reveals a conventional intron with consensus border sequences at a conserved position in both of the genes. A second intron of 20 bp is found in the T. reesei HAC1 gene. This intron does not have the consensus 5′ border sequence (GT). The sequence around the 5′ end of this intron is predicted to have a strong tendency to form a RNA secondary structure called hairpin loop.
- GT consensus 5′ border sequence
- the area between the stems of the loop has a sequence very similar to the consensus sequence found at both of the intron borders of the unconventional intron of 252 bp found in yeast HAC1 ( FIG. 9 , Gonzalez et al., 1999 , EMBO. J. 18, 3119-3132).
- yeast UPR pathway When the yeast UPR pathway is induced, the IRE1 protein cleaves the HAC1 mRNA at these intron borders, and thus initiates the splicing of the intron and formation of an active HAC1 protein.
- Aspergillus nidulans hacA gene there is a sequence almost identical to the hairpin-unconventional intron region of T. reesei HAC1.
- the 20 bp intron is removed from the T. reesei HAC1 and A. nidulans hacA mRNAs upon UPR induction (Example 4).
- the 250 bp intron in yeast HAC1 prevents translation of the mRNA probably by forming a specific secondary structure (Chapman and Walther, 1998 , Curr. Biol. 7, 850-859).
- the 20 bp intron in the HAC1/hacA genes of filamentous fungi can not form such secondary structures, and thus the activation mechanism of these genes is different from yeast HAC1.
- the T. reesei HAC1 cDNA encodes an open reading frame of 451 amino acids and the A.
- nidulans hacA a protein of 350 amino acids, when the 20 bp introns have been removed from the both sequences.
- the putative T. reesei and A. nidulans HACI/A proteins have an identity of 37.4% with each other and both have a DNA binding domain conserved with yeast HAC1 protein ( FIG. 10 ).
- the yeast HAC1 binding site has approximately 64% similarity and 53% identity to the binding site of T. reesei , and approximately 65% similarity and 56% identity to the binding site of A. nidulans .
- the HAC1 cDNA clone sequenced from T. reesei has a 5′ flanking region of 471 bp, containing two short open reading frames encoding 17 and 2 amino acids.
- the 5′ flanking region sequenced from A. nidulans hacA is 187 bp in length, containing one upstream open reading frame of 7 amino acids.
- RNA samples were collected from the culture treated with DTT and the untreated control culture before DTT addition and 30, 60, 90, 120 240 and 360 minutes after the addition of DTT.
- Total RNA was isolated from the samples with the TRIzol reagent (Gibco-BRL) according to manufacturer's protocols. RNA samples of 5 ⁇ g were treated with glyoxal and run in a 1% agarose gel in 10 mM Na-phosphate buffer, pH 7.0. Capillary blotting onto a Hybond-N nylon filter (Amersham) was done as instructed by the manufacturer. The full-length HAC1 cDNA that was used as a probe was labelled as described in Example 3. Hybridization was performed for 18 hours at 42° C.
- FIG. 11 show that the length of the HAC1 mRNA does not change in the control samples not treated with DTT. In the samples treated with DTT a shorter mRNA of about 2.2 kb appears in addition to the 2.5 kb mRNA observed in the control samples.
- the full-length HAC1 cDNA probe was removed from the Northern filter by incubating it in 0.1% SDS at 100° C. for 10 minutes. The filter was then hybridized with a probe containing a 160 bp sequence from the 5′ flanking region of the HAC1 gene.
- This probe was made by PCR from the plasmid pMS119 ( FIG. 6 ) with the T3 primer (5′ AAT TAA CCC TCA CTA AAG GG 3′) (SEQ ID No. 26) binding to the pBluescript vector as the forward PCR primer and the oligonucleotide 5′ TGG TTG ATG ACG ACG ATGCGA ACA GTC ATG ACA GGC AAC G 3′ (SEQ ID No. 27) as the reverse primer.
- the PCR reaction was performed as described in Example 2.
- the probe preparation was done as in Example 3.
- the Northern hybridisation with the short fragment was done as described above for the full-length HAC1 cDNA probe.
- the short probe fragment derived from the 5′ flanking region of the HAC1 cDNA hybridized with the full-length HAC1 mRNA of 2.5 kb but not with the 2.2 kb mRNA that appears when UPR is induced by DTT, indicating that the 5′ end is the segment absent in the 2.2 kb mRNA. It has previously been shown that the T. reesei pdi1 gene is controlled by the UPR (Saloheimo et al., 1999, Mol. Gen Genet. 262, 35-45).
- the filter was probed with the pdi1 and gpd1 probes.
- the pdi1 mRNA becomes more abundant in the mycelium treated with DTT, whereas the gpd1 mRNA remains at an almost constant level.
- the isolated mRNA was used in synthesis of double-stranded cDNA.
- An oligonucleotide adapter was ligated to the ends of the cDNA, and the 5′ ends of the HAC1 cDNAs in each sample were amplified by PCR with the HAC1-specific primer and a primer supplied in the kit that binds to the ligated adapter.
- the PCR program consisted of 5 cycles with denaturation at 94° C. for 5 seconds and synthesis at 72° C. for 3 minutes followed by 5 cycles with denaturation at 94° C. for 5 seconds and synthesis at 70° C.
- PCR products were analysed in a 1% agarose gel.
- a fragment of the expected size (about 550 bp, including the 5′ flanking region of the HAC1 gene and the adapter ligated to the end), corresponding to the 2.5 kb mRNA, was obtained from the control sample derived from mycelia not treated with DTT.
- the 550 bp fragment of the control sample and the 250 bp fragment from the DTT-treated sample were isolated from the agarose gel with the Qiaquick gel extraction kit (Qiagen) as instructed by the manufacturer, and cloned into the pCR2.1-TOPO vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer.
- Two independent clones derived from the control RNA and carrying the 550 bp insert were sequenced. They had their 5′ end 8 bp and 16 bp downstream from the 5′ end of the full-length cDNA (nucleotides 8 and 16 in the sequence in FIG. 7 ) and the sequence continued until the end of the HAC1-specific primer as in FIG. 7 .
- RT-PCR reverse transcriptase-PCR
- the mRNA samples used in RACE-PCR one treated with 10 mM DTT and the other not treated, were subjected to first strand cDNA synthesis with the Riboclone cDNA synthesis system (Promega) according to manufacturer's instructions.
- the PCR program consisted of denaturation at 94° C. for 2 minutes followed by 30 cycles with denaturation at 94° C. for 45 seconds, annealing at 50° C. for 30 seconds and synthesis at 72° C. for 1 minute. A final synthesis step of 5 minutes at 72° C. was performed.
- the DNA fragments obtained in the PCR were cloned into the pCR2.1 vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. Ten fragments derived from both the DTT-treated sample and the nontreated control sample were sequenced.
- the A. nidulans strain FGSC A26 was grown for three days in shake flasks in a medium containing 3% glucose, 2.5% corn steep liquor, 15 g/l KH 2 PO 4 , 5 g/l (NH 4 ) 2 SO 4 , 5 mg/l FeSO, 1.6 mg/l MnSO 4 , 1.4 mg/l ZnSO 4 , 3.7 mg/l CoCl 2 , pH 6.8.
- the probe hybridizes with a single 1.7 kb mRNA band in samples not treated with DTT. In the samples treated with DTT for 120 and 240 minutes, an additional band of about 1.55 kb is detected, showing that the hacA mRNA is truncated upon UPR induction ( FIG. 12 ).
- the Northern was then probed with a short probe derived from the 5′ end of the hacA gene.
- the probe fragment was made by PCR from the pGEM-AT vector carrying the hacA gene (Example 3) with the T7 primer (5′ GTA ATA CGA CTC ACT ATA GGG C 3′) (SEQ ID No.
- the PCR reaction was performed as described in the previous paragraph.
- the 5′ end probe has the first 90 bp of the sequence in FIG. 8 .
- the short 5′ end probe hybridizes only with the 1.7 kb mRNA, showing that the hacA mRNA is truncated from the 5′ end when the UPR pathway is induced.
- RT-PCR was performed.
- the total RNA samples isolated from mycelia treated with 20 mM DTT for 240 minutes and from control mycelia were subjected to RT-PCR reactions with the Robust RT-PCR kit (Finnzymes, Finland) as instructed by the manufacturer, using the forward primer 5′ CCC ATC CTT GGT GAC TGA GCC 3′ (SEQ ID No. 33) and the reverse primer 5′ AAG AGT CGG TGT CAG AGT TGG 3′ (SEQ ID No. 34).
- the DNA fragment of about 400 bp obtained in the PCR was cloned into the pCR2.1-TOPO vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. Twelve of the cloned fragments derived from DTT-treated and ten from control mycelia were sequenced. None of the fragments derived from the control mycelia had the intron spliced. Three of the fragments derived from the DTT-treated mycelia had the intron spliced.
- the S. cerevisiae IRE1 gene was disrupted in the same way as the HAC1 gene (described in Example 2).
- a fragment where a G418 resistance cassette is flanked by sequences from the 5′ and 3′ ends of the IRE1 open reading frame was made by PCR.
- the second construct has the T. reesei HAC1 cDNA truncated at the 5′ end but does not have the 20 bp intron.
- the truncated HAC1 cDNA fragment was made by PCR from the plasmid pMS119 ( FIG.
- the fragment was released from this vector with BamHI digestion and cloned between the EcoRI and XhoI restriction sites of the pAJ401 vector with methods known in the art.
- the resulting plasmid was named pMS132 ( FIG. 14 ).
- the third and fourth expression plasmids have the 20 bp intron added to the HAC1 cDNA forms either with or without the 5′ flanking region.
- plasmids were constructed by replacing a HpaI-KspI fragment of about 800 bp in pMS131 and pMS132 with a corresponding HpaI-KspI fragment from a cDNA which has the 20 bp intron, isolated from the cDNA library in ⁇ ZAP together with the cDNA in the plasmid pMS119 (Example 3).
- the four expression plasmids and the vector pAJ401 alone were transformed into the yeast HAC1 and IRE1 disruptants as described (Gietz et al., 1992 , Nucl. Acids Res. 20, 1425).
- Four transformants from each of the transformations were streaked on SC-Ura plates (Sherman, 1991 , Meth. Enzymol. 194, 3-21) and grown at 30° C. for three days.
- the plates were then replicated onto mineral medium plates (Verduyn et al., 1992, Yeast 8, 501-517) with inositol and on plates without inositol. These plates were incubated at 30° C.
- a fragment of the T. reesei HACI protein containing the putative DNA binding domain and leucine zipper region was produced in E. coli as a fusion protein with the E. coli maltose-binding protein mal E.
- a DNA fragment encoding this part of the HACI protein was prepared by PCR from the HAC1 cDNA with the oligonucleotide primers 5′ TCG AAC GGA TCC GAA AAG AAG CCC GTC AAG AAG AGG 3′ (forward primer) (SEQ ID No. 39) and 5′ ATC GCA GGA TCC CTA GGT TTG GCC ATC CCG CGA GCC AAA 3′ (reverse primer) (SEQ ID No. 40).
- the PCR reaction was performed as in Example 2.
- the PCR product of 360 bp was run in an 0.8% agarose gel and purified from the gel with the Qiaquick gel extraction kit (Qiagen).
- the fragment was digested with BamHI at the restriction sites included in the PCR primers and cloned into the BamHI restriction site of the vector pMAL-p2X (New England Biolabs) with methods known in the art.
- the HACI-malE protein was produced in E. coli and purified by amylose affinity chromatography using the pMAL Protein Fusion and Purification System (New England Biolabs) as recommended by the manufacturer. The E.
- coli cells were grown up to OD600 0.5 at 37° C., IPTG was added to the concentration of 0.3 mM, and production was carried out for 3 hour at 24° C.
- the HACI-malE fusion protein with the expected apparent molecular weight was purified.
- the oligonucleotides used in binding reactions were annealed in the concentration of 100 mg/ml in 50 mM Tris, pH 8.0, 10 mM MgCl 2 , 1 mM spermidine and 5 mM DTT by heating them at 65° C. for 10 minutes and letting them cool down to room temperature during 2 hours.
- the oligonucleotides were labelled by incubating 100 ng of the annealed oligonucleotide in 10 mM Tris, pH 8.0, 5 mM MgCl 2 with 20 ⁇ Ci of 32 P-dCTP and 2.5 U Klenow polymerase (Boehringer Mannheim) at 37° C. for 30 minutes.
- the binding reactions between the oligonucleotides having the putative UPR elements and the proteins were carried out with 0.5-2 ⁇ g of the HACI-malE fusion protein or 2 ⁇ g of the malE protein and 1 ng of the annealed and labelled oligonucleotide in a mixture containing 20 mM HEPES, pH 6.9, 50 mM KCl, 10 mM MgCl 2 , 0.25 mM EDTA, 0.5 mM DTT, 2% Ficoll, 5% glycerol and 100 ⁇ g/ml poly(dldC) DNA.
- the competing oligonucleotides were used in 20-200 times excess of the labelled oligonucleotide.
- the binding reaction mixtures were incubated for 30 minutes at 25° C. and run in a 5% polyacrylamide gel with 10% glycerol in 12.5 mM Tris-borate, pH 8.3, 0.6 mM EDTA for three hours.
- the gel was dried on a filter paper and exposed onto an X-ray film.
- the results ( FIG. 16 ) show that the HACI-malE fusion protein binds to the putative UPR element area found from the pdi1 promoter whereas the malE protein alone does not show any binding.
- the binding of the fusion protein is specific, since it is competed by an excess of unlabelled oligonucleotide.
- the fusion protein binds specifically also to the oligonucleotide pdiUPREII and not at all to pdiUPREI, and this indicates that the functional UPR element of the pdi1 promoter is UPREII.
- the HACI-malE fusion protein also binds specifically to both of the putative UPR elements found in the bip1 promoter. Alignment of the three T. reesei UPR element shows that the consensus sequence for binding is GC(C/G)A(G/A)N 1-2 GTG(G/T)C ( FIG. 16 ) (SEQ ID No. 46).
- the T. reesei HAC1 cDNA was expressed without its 5′ flanking region and without the 20 bp intron from the plasmid pMS132 ( FIG. 14 ).
- This plasmid and the control plasmid pAJ401 were transformed with a described method (Gietz et al., 1992 , Nucleic Acids Res. 20, 1425) into the yeast strain producing Bacillus amyloliquefaciens ⁇ -amylase described in Example 1.
- Two strains carrying pMS132 and two strains with pAJ401 were grown for six days in shake flasks (250 RPM, 30° C.) in SC-Ura medium (Sherman, 1991 , Meth. Enzymol.
- the yeast KAR2 gene is under the UPR pathway control (Cox and Walter, 1996, Cell 87, 391-404), and therefore the Northern filter was probed with a fragment derived from KAR2.
- This fragment was produced by PCR from yeast chromosomal DNA with the oligonucleotide primers 5′ GTG GTA ATA TTA CCT TTA CAG 3′ (SEQ ID No. 47) (forward primer) and 5′ CAA TTT CAA TAC GGG TGG AC 3′ (reverse primer) (SEQ ID No. 48).
- a fragment from the yeast TDH1 gene encoding glyceraldehyde phosphate dehydrogenase was used as a control probe, since this gene is expressed constitutively and is not expected to be affected by UPR.
- the TDH1 probe fragment was made from yeast chromosomal DNA by PCR with the oligonucleotide primers 5′ TGT CAT CAC TGC TCC ATC TT 3′ (forward primer) (SEQ ID No. 49) and 5′ TTA AGC CTT GGC AAC ATA TT 3′ (reverse primer) (SEQ ID No. 50).
- the PCR reaction was done as in Example 2 and the probes were prepared as described in Example 3.
- Northern blotting and hybridization were performed from the RNA samples as described in Example 4.
- the filter was exposed to the screen of the phosphoimager SI (Molecular Dynamics), and the signal intensities were quantified with the phosphoimager.
- the KAR2 signal intensities were normalized with reference to the TDH1 signal intensities.
- the results show that the KAR2 mRNA abundance is 2-4-fold higher in the pMS132 transformants than in the pAJ401 transformants in all the timepoints.
- T. reesei HAC1 cDNA that is truncated at its 5′ flanking region and does not have the 20 bp intron was expressed in T. reesei .
- the form of the HAC1 cDNA that was present in pMS132 was expressed in yeast as described in Example 5 was cloned with methods known in the art into the NcoI restriction site of the vector pAN52-NotI, between the gpdA promoter and trpC terminator of Aspergillus nidulans .
- the hygromycin resistance cassette consisting of the A.
- pMS136 T. reesei strain P37P ⁇ CBHIpTEX-CHY22 as described (Penttilä et al., 1987, Gene 61, 155-164).
- Strain P37P ⁇ CBHIpTEX-CHY22 was constructed by transformation of strain P37P ⁇ CBHIPyr-26 (U.S. Pat. No.
- Vector pTEX-CHY is a derivative of pTEX in which the coding region for the T. reesei cellobiohydrolase I (CBHI) signal sequence, catalytic core and linker region (amino acids 1-476 of CBHI, Shoemaker, et al., 1983, Bio/Technology, 1:691-696) fused to the coding region of bovine prochymosin B (Harris et al., Nucleic Acids Research, 10:2177-2187. was inserted between the cbh1 promoter and terminator region by methods known in the art.
- CBHI CBHI
- the Northern filter was first probed with the full-length HAC1 cDNA, and an mRNA derived from the expression construct which is about 2.0 kb in length can be observed in two of the transformants in addition to the 2.5 kb band that is derived from the native HAC1 gene ( FIG. 21 ).
- the HAC1 probe was removed from the Northern filter by incubating it in 0.1% SDS at 100° C. for 10 minutes. The filter was subsequently probed with the T. reesei pdi1, bip1 and gpd1 probes.
- Pdil encodes the protein disulphide isomerase and has been shown to be regulated by the UPR pathway (Saloheimo et al., 1999 , Mol. Gen. Genet. 262, 35-45).
- Bip1 (unpublished) encodes the T. reesei homologue of the ER-specific chaperone protein Bip.
- the gpd1 gene encodes glyceraldehyde phosphate dehydrogenase and was used as the constitutive control probe. After hybridization the filter was exposed to the screen of the Phosphoimager SI (Molecular Dynamics) and the signals were quantified with the phosphoimager. The pdi1 and bip1 signals were normalized with respect to the gpd1 signals.
- a Trichoderma reesei strain where the HAC1 gene is mutated was unexpectedly generated during the transformation of the plasmid pMS136 into the strain producing CBHI-chymosin fusion protein (Example 7).
- the transformants were analysed by Northern hybridization it was noticed that one of the transformants (number 31) produced several forms of the HAC1 mRNA that are considerably shorter than 2 kb ( FIG. 21 lanes 4, 8 and 12).
- the unfolded protein response is induced in the parental strain of the transformation, presumably by the production of the heterologous protein chymosin.
- the HAC1 mRNA of 2.2 kb is detected only 4 hours after DTT addition ( FIG. 22 ) and a 2-fold induction of the pdi1 gene is also apparent in this timepoint.
- the 2.2 kb HAC1 mRNA appears and the pdi1 induction takes place after 30 minutes of DTT treatment (Example 4, FIG. 11 ).
- the chymosin levels produced by the control strain and the transformant number 31 were measured daily from the media of the whey-peptone cultures described in example 7. The measurements were done from two parallel cultures with a milk clotting assay (Cunn-Coleman, et al., 1991, Bio/Technology, 9:976-981. Transformant number 31 produced roughly the same amount of chymosin as the parental strain on days 2 and 3 of the culture. On the later days the chymosin levels in the culture of the mutant strain started declining, whereas the control strain could still increase significantly the chymosin amount in its culture medium ( FIG. 23 ).
- the yeast protein phosphatase encoded by the PTC2 gene has been shown to be involved in the regulation of the UPR pathway (Welihinda et al., 1998 , Mol. Cell. Biol. 18, 1967-1977).
- the IRE1 protein is phosphorylated when the UPR pathway is turned on (Shamu and Walter, 1996, EMBO J. 15:3928-3039), and Ptc2 dephosphorylates IRE1p and regulates the UPR negatively.
- a BLAST search Altschul et al., 1990 , J. Mol. Biol.
- the resulting PCR fragment was cloned into the pCR2.1 vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. It was sequenced with internal oligonucleotide primers ( FIG. 24 ).
- the optimal hybridization conditions for isolation of the T. reesei ptc2 cDNA were determined by Southern hybridization of T. reesei genomic DNA with the A. nidulans ptcB fragment as described in Example 3.
- the putative PTC2 protein from Schizosaccharomyces pombe .
- the ptcB fragment cloned from Aspergillus nidulans is 1264 in length ( FIG. 24 ). Based on homology with other Ptc2 sequences, an intron has been identified in the fragment.
- the deduced amino acid sequence is 89% identical to T. reesei PTCII protein over an area of 117 amino acids.
- reesei genomic library constructed in ⁇ EMBL3 (Kaiser and Murray, 1985, in DNA Cloning: a Practical Approach , pp. 1-47, ed. Glover, IRL Press, Oxford) was then plated with the appropriate E. coli host strain and ⁇ -DNA was lifted onto nitrocellulose filters (Schleicher & Schull) as instructed by the manufacturer. The filters were hybridized over night at 50° C.
- IRE1 cDNA was isolated from a T. reesei library constructed in ⁇ ZAP (Stratagene). The cDNA library was plated with the appropriate E.
- the probe fragment used in the screening was obtained by digesting the 2.4 kb genomic subclone plasmid with BamHI and SmaI. The fragment of about 600 bp was run in a 0.8% agarose gel and isolated from the gel with the Qiaguick gel extraction kit (Qiagen) with manufacturer's instructions. The probe was labelled with 32 P-dCTP with the Random Primed DNA labelling kit (Boehringer Mannheim). The filters were hybridized at 42° C.
- a hybridization mixture containing 50% formamid, 5 ⁇ Denhardt's, 5 ⁇ SSPE, 0.1% SDS, 100 ⁇ g/ml herring sperm DNA and 1 ⁇ g/ml polyA-DNA (SSPE is 0.18 M NaCl, 1 mM EDTA, 10 mM NaH 2 PO 4 , pH 7.7).
- the filters were washed for 10 minutes at room temperature with 2 ⁇ SSC, 0.1% SDS and for 30 minutes at 65° C. in 0.1 ⁇ SSC, 0.1% SDS.
- ⁇ -clones giving a hybridization signal were converted into pBluescript plasmids by in vivo-excision as instructed (Stratagene).
- the T. reesei IRE1 cDNA was sequenced from one of the plasmids with internal oligonucleotide primers.
- the area sequenced from the T. reesei IRE1 gene is about 4.5 kb, and the open reading frame encodes a protein of 1233 amino acids ( FIG. 27 ). Comparison of the genomic and cDNA sequences revealed one intron.
- the T. reesei IREI protein starts with a predicted signal sequence of 25 amino acids. There is a putative transmembrane segment at positions 574-596 of the open reading frame. The N-terminal domain (before the transmembrane segment) presumably facing the lumen of the endoplasmic reticulum has 24% identity and 39% similarity over an area of 377 amino acids with yeast IRE1p.
- the C-terminal part with the kinase and RNAse domains is 42% identical and 59% similar over an area of 490 amino acids to yeast IRE1p.
- the cloned A. nidulans ireA fragment is 1570 bp in length ( FIG. 26 ). It encodes the kinase and RNAse domains of the IREA protein. Based in comparison with the yeast and T. reesei IRE1 sequences, an intron is identified in the sequence of the ireA fragment.
- the deduced A. nidulans IREA amino acid sequence has 52% identity over an area of 507 amino acids to the T. reesei IREI protein.
- the A. niger var. awamori hacA cDNA was isolated by heterologous hybridisation with the cloned Aspergillus nidulans hacA fragment described in Example 3.
- a cDNA library constructed from A. niger var. awamori RNA in the plasmid pYES2 (Invitrogen) was plated as E. coli colonies, lifted onto nitrocellulose filters and screened by colony hybridisation as described for the isolation of the T. reesei hac1 cDNA in Example 3. The hybridisation and the final washes were performed at 57° C. Positive colonies were found and examined by restriction analysis and sequencing of the cDNA ends. The longest cDNA was sequenced throughout its length from both strands.
- the encoded protein has 76% identity with A. nidulans HACA protein and 38% identity with T. reesei HACI protein.
- the A. niger var. awamori hacA cDNA has an upstream open reading frame encoding 44 amino acids.
- the region of the cDNA that, according to homology with the T. reesei and A. nidulans hac1/A genes, had a 20 bp intron was sequenced from five of the A. niger var. awamori hacA cDNA clones isolated.
- the UPR-induced form of the A. niger var. awamori hacA cDNA was expressed in A. niger var. awamori strains producing Trametes versicolor laccase or bovine preprochymosin which were constructed in the following manner.
- Strains ⁇ AP3 and ⁇ AP4 are equivalent strains which are deleted for the pepA gene (encoding the major extracellular aspartic proteinase) and which have a pyrG null mutation.
- Strain ⁇ AP3 was transformed with pUCpyrGRG3 to create strain ⁇ AP3pUCpyrGRG3#11 which produces bovine preprochymosin. This strain secretes and accumulates active chymosin (an aspartic proteinase) in the culture medium.
- the plasmid, pUCpyrGRG3, consists of the GRG3 expression cassette (encoding the Aspergillus niger glaA promoter, preprochymosin open reading frame and glaA terminator) obtained from pGRG3 (Cullen, D. et al., 1987, Bio/Technology 5:369-376) and the Neurospora crassa pyr4 gene inserted into pUC19.
- Transformants of strain ⁇ AP3 with this plasmid were selected on the basis of uridine auxotrophy. Transformants were screened in liquid culture for chymosin production and strain ⁇ AP3pUCpyrGRG3#11 was chosen as the best producer.
- Strain ⁇ AP4 was transformed with pGPT-LCC1 to create strain ⁇ AP4:pGPTIaccase which secretes Trametes versicolor laccase 1.
- the plasmid, pGPT-LCC1 is a derivative of plasmid pGPTpyrG1 (described in Berka, R. M. and Barnett, C. C., 1989, Biotechnol. Adv. 7:127-154) which contains the N. crassa pyr4 gene as fungal selectable marker and the A. niger glaA promoter and A. niger var. awamori glaA terminator region separated by cloning sites.
- hacA For the over expression of hacA, the induced form of the A. niger var. awamori hacA cDNA was first created by deleting the 20 bp intron and truncating the 5′ flanking region by about 150 bp, which omitted the upstream open reading frame. This was done by methods known in the art. The resulting hacA gene fragment was then cloned into an A. niger var. awamori expression vector with methods known in the art. In the final expression construct, pMS152 ( FIG. 29 ), the hacA gene fragment is between the A. niger var. awamori glaA (glucoamylase gene) promoter and terminator. The A. nidulans amdS gene endoding acetamidase was in the plasmid as a selection marker for fungal transformation.
- the hacA overexpression construct (pMS152) was transformed into either A. niger var. awamori strain ⁇ AP3pUCpyrGRG3#11 or strain ⁇ AP4:pGPTIaccase. The transformations were performed as described in Penttila et. al., 1987, Gene 61, 155-164. The transformants were selected for the ability to grow on acetamide as the sole nitrogen source. Transformants were passaged three times on selective medium before they were sporulated and single spores were plated on the selective medium.
- Eight transformants from the laccase-producing strain and four transformants from the chymosin-producing strain shown to contain the hacA overexpression cassette were cultivated again for Northern analysis and measurement of the enzymatic activities.
- the pMS152 transformants of the strain producing preprochymosin and the untransformed parental strain ( ⁇ AP3pUCpyrGRG3#11) were cultivated in Clofine special medium in shake flasks (28° C., 200 rpm) in two parallel cultures for six days. Mycelial samples for RNA isolations were taken on the third day of the cultivation.
- the pMS152 transformants of the strain producing Trametes laccase and the untransformed parental strain were cultivated in 8 g/litre Bacto Soytone (Difco), 12 g/litre Tryptone peptone (Difco), 15 g/litre (NH 4 ) 2 SO 4 , 12.1 g/litre NaH 2 PO 4 .H 2 O and 3.3 g/litre Na 2 HPO 4 .7H 2 O.
- RNA's were isolated from all the mycelial samples using the TRIZOL reagent (Gibco-BRL) as instructed by the manufacturer. RNA samples of 5 ⁇ g were treated with glyoxal and run in 1% agarose gel in 10 mM Na-phosphate buffer, pH 7.0. Northern blottings and hybridizations were done as described in Example 4. A fragment of the A. niger var. awamori hacA cDNA labeled as described in Example 3 was used as a probe.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Described herein are methods for increasing the amount of protein secreted by a cell. In one case, a cell is provided which contains a heterologous nucleic acid encoding a protein having unfolded protein response modulating activity and a heterologous nucleic acid encoding a protein of interest to be secreted. In one case, the protein having unfolded protein response modulating activity is selected from the proteins selected from the group consisting of HAC1, PTC2 and IRE1. The protein of interest can be any secreted protein such as a therapeutic or an industrial enzyme. For example the protein can be selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase, alpha-amylase, glucoamylase, lignocellulose hemicellulase, pectinase and ligninase.
Description
- This invention relates to cells which have been genetically manipulated to have an elevated unfolded protein response (UPR) resulting in an increased capacity to produce secreted proteins.
- This application is a Continuation-In-Part of U.S. application Ser. No. 09/534,692, filed Mar. 24, 2000, and is hereby incorporated by reference in its entirety.
- The secretory pathway of eukaryotic organisms is of interest since cells can be engineered to secrete a particular protein of interest. The secretory pathway starts by translocation of the protein into the lumen of the endoplasmic reticulum (ER). In the ER the proteins fold into their final three-dimensional conformation and the core part of the N-glycans are attached to them. A quality control mechanism involving the proteins calnexin and calreticulin also resides in the ER, letting only completely folded proteins continue on the secretory pathway to the next compartment (Hammond and Helenius, 1995, Curr. Opinion Cell Biol. 7:523-529). Secretory proteins that do not fold properly are transported back to the cytoplasm by the translocation machinery and are degraded by the proteasome system (Wiertz et al., 1996, Nature 384:432-438).
- The folding and glycosylation of the secretory proteins in the ER is assisted by numerous ER-resident proteins. The chaperones like Bip (GRP78), GRP94 or yeast Lhs1p help the secretory protein to fold by binding to exposed hydrophobic regions in the unfolded states and preventing unfavourable interactions (Blond-Elguindi et al., 1993, Cell 75:717-728). The chaperones are also important for the translocation of the proteins through the ER membrane. The foldase proteins like protein disulphide isomerase and its homologs and prolyl-peptidyl cis-trans isomerase assist in formation of disulphide bridges and formation of the right conformation of the peptide chain adjacent to proline residues, respectively. A machinery including many protein components also resides in the ER for the addition of the N-linked core glycans to the secretory protein and for the initial trimming steps of the glycans.
- The levels of the chaperone and foldase proteins found in the ER are regulated at the transcriptional level. For each gene there is a basic level of transcription that can be increased in response to various stimuli. A large amount of secretory protein in the ER (secretory load) can induce the mammalian GRP78 gene, and this induction is mediated through the NF-κB transcription factor (Pahl and Baeuerle, 1995, EMBO J. 14:2580-2588). Furthermore, the ER chaperone and foldase genes are upregulated when the amount of unfolded protein increases in the ER. This induction has been named unfolded protein response (UPR) and it has been described in mammalian cells, yeast and filamentous fungi (McMillan et al., 1994, Curr. Opinion in Biotechnol. 5:540-545). The induction can be caused by treatment of cells with reducing agents like DTT, by inhibitors of core glycosylation like tunikamycin or by Ca-ionophores that deplete the ER calcium stores. The promoters of mammalian and yeast genes regulated by UPR have a conserved sequence region called UPR element, where the transcription factor responsible for the induction binds.
- When the unfolded protein response pathway is active, a signal is tranduced from the ER lumen to the transcription machinery in the nucleus. A protein implicated in the UPR induction is the IRE1 protein of yeast (Cox et al., 1993, Cell 73:1197-1206, Mori et al., 1993, Cell 74:143-156). It is large protein having a transmembrane segment anchoring the protein to the ER membrane. A segment of the IRE1 protein has homology to protein kinases and the C-terminal tail has some homology to RNAses. It is believed that the IRE1 protein may be the first component of the UPR signal transduction pathway, sensing the ER lumen for the presence of unfolded proteins and transmitting the signal eventually to a transcription factor inducing the ER-protein genes. It has been reported that the IRE1 protein oligomerizes and gets phosphorylated when the UPR is activated (Shamu and Walter, 1996, EMBO J. 15:3028-3039). Over-expression of the IRE1 gene in yeast leads to constitutive induction of the UPR (Id.). Phosphorylation of the IRE1 protein occurs at specific serine or threonine residues in the protein.
- Another protein reportedly implicated in the regulation of the UPR pathway is PTC2, a yeast protein phosphatase encoded by the PTC2 gene (Welihinda et al., 1998, Mol. Cell. Biol. 18, 1967-1977). The IRE1 protein is phosphorylated when the UPR pathway is turned on (Shamu and Walter, 1996, EMBO J. 15:3928-3039), and PTC2 dephosphorylates the IRE1 protein and regulates the UPR.
- It has further been reported that the yeast transcription factor mediating the UPR induction of the chaperone and foldase genes is the HAC1 protein (Cox and Walter, 1996, Cell 87:391-404, Sidrauski et al., 1996, Cell 87:405-413). It belongs to the bZIP family of transcription factors, having a basic DNA-binding region and a leucine zipper dimerisation domain. The binding of the HAC1 protein to the UPR element of ER-protein gene promoters has been demonstrated (Mori et al., 1998, J. Biol. Chem. 273: 9912-9920). The action of the HAC1 protein is regulated by its amount in the cells; none of the protein can be found in uninduced cells and upon UPR induction it appears rapidly. The HAC1 protein amount is dependent of the splicing of the respective mRNA. In uninduced conditions the intron present in the HAC1 gene close to the translation termination codon is not spliced off, and this intron prevents the formation of HAC1 protein by preventing the translation of the mRNA (Chapman and Walter, 1997, Curr. Biol. 7, 850-859, Kawahara et al., 1997, Mol. Biol. Cell 8, 1845-1862). When UPR is induced, the intron is spliced and the mRNA is translated to form HAC1 protein that activates the promoters of its target genes. The HAC1 intron is spliced by an mechanism not currently described for any other system, involving the RNAse activity of the IRE1 protein and a tRNA ligase (Sidrauski and Walter, 1997, Cell 90, 1031-1039, Gonzales et al., 1999, EMBO J. 18, 3119-3132, Sidrauski et al., 1996, Cell 87, 405-413). The unfolded protein response can be induced constitutively in yeast by transformation with a UPR inducing version of the HAC1 gene. (Cox and Walter, supra.)
- Thus, as indicated above, there are a number of reports regarding the secretory pathway. Additionally, there are reports on how to increase secretion so as to provide greater yields of heterologous proteins. Greater yields of protein are generally of interest to industry to provide more of a particular protein and to facilitate purification.
- For example, in one report random mutagenesis of the host organism has been performed followed by screening for increased yield of a secreted protein. In another report, there has been fusion of a heterologous protein to an efficiently secreted endogenous protein in order to increase the yield of secretion of the heterologous protein. Both of these methods have been of limited success and other methods to improve protein secretion are desirable.
- In other studies, there has reportedly been increased yields of secreted heterologous proteins in yeast by either over-expression or deletion of the yeast ER foldase or chaperone genes on an individual or pairwise basis. For example, over-expression of either the protein disulphide isomerase (PDI) or the KAR2 (homologous to the gene for the mammalian ER chaperone BiP) genes in yeast has been shown to increase the extracellular accumulation of certain secreted heterologous proteins (Robinson et al., 1996, Bio/Technology, 12:381-384; Harmsen, et al., 1996, Appl. Microbiol. Biotechnol., 46:365-370). In contrast, deletion of the CNE1 gene, encoding an ER chaperone homologous to mammalian calnexin, reportedly can lead to increased secretion of a heterologous protein (Parlati et al., 1995, J. Biol. Chem. 270:244-253, Harmsen, supra.). The effect of over-expression or deletion of individual or pairs of ER chaperones or foldases has also been reported on in filamentous fungi, however, increased secretion was not obtained. (Punt, et al., 1998, Appl. Microbiol. Biotech, 50:447-454; Wang, et al., 2000, Current Genetics, 37:57-64).
- Therefore, it is desirable to provide new methods to increase production of secreted proteins in eukaryotic cells which are simple and consistent. It is also desirable to provide compositions such as novel genes to be used in methods for the increased production of secreted proteins. It is further desirable to provide eukaryotic cells according to the invention which are transformed with heterologous genes so as to have an increased capacity to produce secreted proteins.
- Provided herein are methods for increasing the secretion of a heterologous protein in a cell comprising inducing an elevated unfolded protein response (UPR). The increase in protein secretion is compared to a level of protein secreted by the cell when the UPR is not elevated by the methods described herein. In one aspect, the method includes inducing the elevated UPR by increasing the presence of the HAC1 protein in the cell. In one aspect of the invention, the presence of the HAC1 protein can be increased by a number of methods. For example, the HAC1 gene can be overexpressed compared to its native state. Overexpression can be achieved by a variety of ways including the use of preferred vectors and promoters as further described herein. In one embodiment, the HAC1 protein is increased in a cell by transformation of said cell by a nucleic acid comprising a UPR inducing form of a HAC1 recombinant nucleic acid.
- The HAC1 nucleic acid encoding a HAC1 protein can be from a variety of sources. It is understood that in one embodiment, HAC1 is used interchangeably with hac1, hacA, etc., and one embodiment is meant to encompass HAC1 homologs. Additionally, the skilled artisan can ascertain by the context whether the HAC1 is a nucleic acid, protein or either. In one embodiment, a HAC1 nucleic acid is isolated from yeast. In another embodiment, a HAC1 nucleic acid is isolated from filamentous fungi such as Trichoderma or Aspergillus.
- In another aspect of the invention, the elevated UPR is induced by modulating the levels of IRE1 protein or PTC2 protein in said cell. Nucleic acids encoding IRE1 or PTC2 can be isolated from yeast or filamentous fungi such as Trichoderma or Aspergillus. In a preferred embodiment the nucleic acid encoding IRE1 or PTC2 is isolated from T. reesei, A. nidulans or A. niger.
- The cell from which the protein is secreted can be any cell having an UPR. Cells having an UPR include all eukaryotes including but not limited to mammalian cells, insect cells, yeast and filamentous fungi.
- Also provided herein is an isolated nucleic acid encoding a HAC1 protein, wherein said HAC1 has unfolded protein response inducing activity and has less than 50% similarity to yeast HAC1 protein. In another embodiment, an isolated nucleic acid encoding a HAC1 protein is provided, wherein said HAC1 protein has unfolded protein response inducing activity and wherein said HAC1 comprises a DNA binding region that has greater than 70% similarity to the DNA binding region of filamentous fungi HAC1. Embodiments of a DNA binding region are shown at amino acids 84-147 of the T. reesei protein shown in
FIG. 10 , at amino acids 53-116 of the A. nidulans protein shown inFIG. 10 , and at amino acids 45-109 of the A. niger protein shown inFIG. 28 . In one embodiment, the HAC1 protein encoded by the HAC1 nucleic acid provided herein has an amino acid sequence having greater than 70% similarity to the sequence ofFIG. 7 ,FIG. 8 orFIG. 28 . The proteins encoded by such nucleic acids are also provided herein. - In one embodiment, the nucleic acid provided herein encodes an amino acid sequence as set forth in
FIG. 7 ,FIG. 8 orFIG. 28 . In yet another embodiment, the nucleic acid provided herein has a nucleic acid sequence as set forth inFIG. 7 ,FIG. 8 orFIG. 28 . The proteins encoded by such nucleic acids are also provided herein. - Further provided herein is an isolated nucleic acid encoding a PTC2 protein wherein said PTC2 protein modulates unfolded protein response and wherein said PTC2 protein has at least 70% similarity to the amino acid sequence of
FIG. 24 orFIG. 25 . In preferred embodiments the PTC2 protein has preferably at least 80%, more preferably at least 90% or more preferably at least 95% similarity to said amino acid sequences. In one aspect, the PTC2 protein has an amino acid sequence as set forth inFIG. 24 orFIG. 25 . In another aspect, the PTC2 nucleic acid has a nucleic acid sequence as set forth inFIG. 24 orFIG. 25 . The proteins encoded by such nucleic acids are also provided herein. It is understood that as used herein, PTC2 can be used interchangeably with ptc2 and ptcB, and that in one embodiment, PTC2 encompasses homologs. Moreover, the context in which the term is used will determine whether PTC2 is a nucleic acid, a protein or either. - Also provided herein is a nucleic acid encoding an IRE1 protein having unfolded protein response modulating activity and having at least 60% similarity to an amino acid sequence as shown in
FIG. 26 orFIG. 27 . In preferred embodiments the IRE1 protein has at least 70%, preferably at least 80%, more preferably at least 90% or even more preferably at least 95% similarity to said amino acid sequences. In one aspect, IRE1 has an amino acid or nucleic acid sequence as shown inFIG. 26 orFIG. 27 . It is understood that as used herein, IRE1, Ire1 and IreA can be used interchangeably, and that in one embodiment, IRE1 includes homologs. Moreover, the context in which the term is used will determine whether IRE1 is a nucleic acid, a protein or either. - The nucleic acids provided herein may be obtained from a variety of sources including but not limited to filamentous fungi such as Trichoderma and Aspergillus. In a preferred embodiment the nucleic acids are obtained from T. reesei, A. nidulans or A. niger.
- Also provided herein is a cell containing a heterologous nucleic acid encoding a protein having unfolded protein response modulating activity and a heterologous nucleic acid encoding a protein of interest to be secreted. In one aspect, said protein having unfolded protein response modulating activity is selected from the group consisting of HAC1, PTC2 and IRE1. In another embodiment, said protein of interest is selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase, alpha-amylase, glucoamylase, lignocellulose hemicellulase, pectinase and ligninase.
- Further aspects of the invention will be understood by the skilled artisan as further described below.
-
FIG. 1 depicts a map of the plasmid pMS109, an embodiment of a plasmid constructed for the expression of the truncated yeast HAC1 gene. -
FIG. 2 depicts a graph showing activity of α-amylase produced from yeast containing pMS109 (squares) or an empty control vector pKK1 (diamonds) in the vertical bar, over time, horizontal bar, and further showing the activity is greater wherein pMS109 is present. -
FIG. 3 depicts a bar graph showing activity of invertase produced from yeast containing pMS109 (black bars) or an empty control vector pKK1 (shaded bars) in the vertical bar, over time, horizontal bar, and further showing the activity is greater wherein pMS109 is present. -
FIG. 4 depicts a graph showing activity of α-amylase produced from yeast wherein HAC1 has been disrupted (diamonds) or from its parental control strain (squares) in the vertical bar, over time, horizontal bar, and further showing that the activity is greater wherein HAC1 has not been disrupted. -
FIG. 5 depicts a graph showing activity of Trichoderma reesei (T. Reesei) endoglucanase EGI produced from yeast wherein HAC1 has been disrupted (diamonds) or from its parental control strain (squares) in the vertical bar, over time, horizontal bar, and further showing that the activity is greater wherein HAC1 has not been disrupted. -
FIG. 6 depicts a map of the plasmid pMS119, where the full-length T. reesei HAC1 cDNA without the 20 bp intron is in the pBluescript SK− vector. -
FIGS. 7A-C depict an embodiment of a nucleotide (SEQ ID No. 1) and deduced amino acid sequence (SEQ ID No. 2) of T. reesei HAC1. The introns are shown in lower case letters. -
FIGS. 8A-B depict an embodiment of a nucleotide (SEQ ID No. 3) and deduced amino acid sequence (SEQ ID No. 4) of Aspergillus nidulans (A. nidulans) hacA. The introns are shown in lower case letters. -
FIG. 9 depicts the hairpin loop structures forming at the 5′ end of the 20 bp introns in the T. reesei HAC1 and A. nidulans hacA mRNAs and at the 3′ end of the intron of the S. cerevisiae HAC1 mRNA. The conserved nucleotides in the loop region are shown in bold. The cleavage site of the yeast intron and the three possible cleavage sites of the T. reesei HAC1 intron are shown by arrows. Alignment of the 20 bp intron areas of the T. reesei HAC1 and A. nidulans hacA is shown below. The intron is in lower case. -
FIG. 10 depicts an amino acid sequence alignment of the T. reesei HAC1, A. niduans hacA and S. cerevisiae HAC1 proteins. Identical amino acids are shown by asterisks and similar ones by dots. Yeast HAC1 is homologous to the other sequences at the DNA binding domain area. The DNA binding domain is approximately at amino acids 84-147 for T. reesei (SEQ ID No. 5), and approximately at amino acids 53-116 for A. nidulans (SEQ ID No. 6). -
FIG. 11 depicts Northern hybridization of RNA samples derived from T. reesei mycelia treated with DTT (+DTT) and untreated control mycelia (−DTT). The timepoints (in minutes) after DTT addition are shown. The probes used for hybridization are shown on the left. -
FIG. 12 depicts Northern hybridization of RNA samples derived from A. nidulans mycelia treated with DTT (+DTT) and untreated control mycelia (−DTT). The timepoints after DTT addition are shown. The probes are shown on the left. -
FIG. 13 depicts a map of the plasmid pMS131, where the full-length T. reesei HAC1 cDNA without the 20 bp intron is under the yeast PGK1 promoter in the vector pAJ401. -
FIG. 14 depicts a map of the plasmid pMS132, where the T. reesei HAC1 cDNA without the 5′ flanking region and without the 20 bp intron is under the yeast PGK1 promoter in the vector pAJ401. -
FIGS. 15A-D depict complementation of S. cerevisiae HAC1 and IRE1 disruptions (DHAC1 and DIRE1, respectively) with different forms of the T. reesei HAC1 cDNA. The growth of transformants on media with and without inositol is shown. pAJ401 is the expression vector without any insert. pMS131 has the full-length T. reesei HAC1 cDNA in pAJ401. pMS132 has the T. reesei HAC1 cDNA without its 5′ flanking region in pAJ401. -
FIG. 16 depicts bandshift experiments, where the binding of the malE-HACI fusion protein to the putative UPR element sequences found in T. reesei pdi1 and bip1 promoters was tested. The oligonucleotides used in the binding reactions are shown on the top. 1, 12 and 16, no protein;Lanes lanes 2, 4-7, 8-11, 13-15 and 17-19, malE-HACI fusion protein;lane 3, malE protein alone. The binding was competed with unlabelled oligonucleotides on lanes 5 (20× excess); 6, 10, 14 and 18 (50× excess) andlanes 7, 11, 15, and 19 (200× excess). Alignment of the UPR element sequences that bind the HACI-malE protein is shown below.lanes -
FIG. 17 depicts a graph which shows activity of α-amylase by yeast strains expressing the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron (pMS132) (squares) and control strains with the expression vector alone (pAJ401) (diamonds) in the vertical bar over time, horizontal bar, and which further shows that activity is greater wherein pMS132 is present. -
FIG. 18 depicts a bar graph which shows activity of invertase by yeast strains expressing the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron (pMS132) and control strains with the expression vector alone (pAJ401) in the vertical bar, over time (horizontal bar) and which further shows that activity is greater is greater wherein pMS132 is present. -
FIG. 19A depicts Northern hybridization of RNA samples from a yeast strain expressing the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron (pMS132) and a control strain with the expression vector alone (pAJ401). The probes used for hybridization are shown. The signals were quantified with a phosphoimager and the KAR2 signal intensities were normalised with respect to the TDH1 signal intensities.FIG. 19B shows the normalised KAR2 signals, wherein it is shown that pMS132 has greater signal. -
FIG. 20 depicts a map of the plasmid pMS136, where the T. reesei HAC1 cDNA without the 5′ flanking region and the 20 bp intron is under the A. nidulans gpdA promoter in the vector pAN52-NotI. -
FIG. 21A depicts Northern hybridization of RNA samples derived from transformation of the plasmid pMS136 into a T. reesei strain producing CBHI-chymosin fusion protein. Samples from the parental strain ( 1, 5 and 9), two positive transformants (lanes 2, 3, 6, 7, 10 and 11) and a HAC1 mutant strain designatedlanes number 31 generated in the transformation ( 4, 8 and 12) are shown. The growth times are shown on the top and the probes used for the hybridization on the left.lanes FIG. 21B shows quantifications of the pdi1 and bip1 signals normalised with respect to gpd1 signals. -
FIG. 22A depicts Northern hybridization of RNA samples derived from mycelia of the HAC1mutant strain number 31 treated with DTT (+DTT) and untreated control mycelia (−DTT). The timepoints after DTT addition are shown on the top and the probes used for hybridization on the left.FIG. 22B shows quantifications of the pdi1 signals normalised with respect to gpd1 signals. -
FIG. 23 is a graph depicting production of calf chymosin by the HAC1 mutant transformant number 31 (diamonds) and its parental strain (squares) during a shake flask culture. The chymosin (CHV) units per ml of culture are shown (vertical bar) over time (horizontal bar), and it is shown that the control has more units than the mutant. -
FIG. 24 depicts an embodiment of a nucleotide (SEQ ID No. 7) and deduced amino acid sequence (SEQ ID No. 8) of the fragment isolated from the A. nidulans ptcB gene. The intron is shown in lower case. -
FIG. 25 depicts an embodiment of a nucleotide (SEQ ID No. 9) and deduced amino acid sequence (SEQ ID No. 10) of the T. reesei ptc2 cDNA. -
FIG. 26 depicts an embodiment of a nucleotide (SEQ ID No. 11) and deduced amino acid sequence (SEQ ID No. 12) of the fragment isolated from the A. nidulans ireA gene. The intron is shown in lower case. -
FIGS. 27A-27C depict an embodiment of a nucleotide (SEQ ID No. 13) and deduced amino acid sequence (SEQ ID No. 14) of the T. reesei IRE1 gene. The intron is shown in lower case. -
FIG. 28A-28C . The nucleotide (SEQ ID No. 15) and deduced amino acid sequence (SEQ ID No. 16) of Aspergillus niger var. awamori hacA cDNA. The 20 bp unconventional intron (SEQ ID No. 17) is shown in lower case letters. The amino acid sequences of the upstream open reading frame (SEQ ID No. 18) and the HACA protein (SEQ ID No. 19) are shown below the nucleotide sequence. -
FIG. 29 . Map of the plasmid pMS152 where the Aspergillus niger var. awamori hacA without the 5′ flanking region and the 20 bp intron is under control of the Aspergillus niger var. awamori glaA promoter. -
FIG. 30 . The levels of chymosin activity measured in supernatants from duplicate cultures of strain ΔAP3pUCpyrGRG3#11 (ctrl) and transformants (#1, #2, #3 and #4) of this strain with pMS152. -
FIG. 31 . The levels of laccase activity measured in supernatants from duplicate cultures of strain ΔAP4:pGPTIaccase (ctrl) and transformants (#1, #2, #3, #4, #5, #6, #7 and #8) of this strain with pMS152. - The invention will now be described in detail by way of reference only using the following definitions and examples. All patents and publications, including all sequences disclosed within such patents and publications, referred to herein are expressly incorporated by reference.
- Provided herein are methods and compositions for increasing the secretion of a protein in a cell comprising inducing an elevated unfolded protein response (UPR). The compositions provided herein include nucleic acids, proteins, and cells.
- In one embodiment UPR refers to the unfolded protein response which occurs in response to an increase in unfolded protein in the ER. In a method provided herein, the UPR is elevated. In one embodiment, “elevated” UPR refers to an increase in the response compared to the response which would have been induced based on the amount of unfolded protein in the ER. In one embodiment, elevated refers to an increase with respect to the length of time the response occurs. In each embodiment, the elevated UPR results in an increased capacity for the cell to produce secreted proteins compared to another cell of the same type containing the same amount of unfolded protein in the ER. Preferably, the cell having an elevated UPR in accordance with the present invention produces more secreted protein in the same amount of time as a cell not having an elevated UPR.
- In one aspect, the method includes inducing the elevated UPR by modulating the amount or presence of one or more UPR modulating proteins in said cell. In one embodiment, the UPR modulating protein is selected from the group consisting of HAC1, PTC2 or IRE1. UPR modulating proteins are further discussed below. It is understood that the modulating protein can be obtained by increasing the presence of a nucleic acid which encodes a modulating protein. The protein used in the methods herein have UPR modulating activity as further discussed below, and the nucleic acids encode a protein which has UPR modulating activity. Modulating means that an increase in the protein can lead to an increase or a decrease in the UPR. Thus, in one embodiment, the presence of a modulating protein is increased as further discussed below to reach an elevated UPR. In another embodiment, the modulating protein is decreased or eliminated to reach an elevated UPR. In a preferred embodiment, HAC1 and/or IRE1 are increased so as to reach an elevated UPR.
- In one embodiment, inducing UPR means that the unfolded protein response as a whole is induced or maintained as it would be by unfolded protein in the ER. The unfolded protein response involves increased expression and regulation of multiple ER foldases and chaperones. Thus, in one embodiment, manipulation of ER foldases or chaperones on an individual gene basis would not be considered an induction of UPR. Thus, in a preferred embodiment, UPR modulating activity results in an elevated UPR wherein an elevated UPR results in upregulation of ER chaperones and foldases and increased secretion of proteins.
- The nucleic acids encoding the UPR modulating proteins can be obtained from a variety of sources. Preferred organisms include but are not limited to Saccharomyces cerevisiae, Aspergillus spp. and Trichoderma spp. Also other suitable yeasts and other fungi, such as Schizosaccharomyces pombe, Kluyveromyces lactis, Pichia spp., Hansenula spp., Fusarium spp., Neurospora spp. and Penicillium spp. can be used. Homologous genes from other organisms can also be used. In one aspect, homologous genes refer to genes which are related, but not identical, in their DNA sequence and/or perform the same function are homologous with each other and are called each other's homologues.
- HAC1, PTC2, or IRE1 amino acid and nucleic acid sequences have been described for yeast. For example, for HAC1, see GenBank accession number E15694; for PTC2, see GenBank accession number U72498; for IRE1, see GenBank accession number Z11701. Sequences of GenBank accession numbers are incorporated herein by reference. GenBank is known in the art, see, e.g., Benson, D A, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. In one embodiment, HAC1, PTC2, or IRE1 are isolated from a species other than yeast, preferably a filamentous fungi, insect cell, mammalian cell or other eukaroyote. Sequences for HAC1 are provided in
FIGS. 7 , 8 and 28. Sequences for PTC2 are provided inFIGS. 24 and 25 . Sequences for IRE1 are provided inFIGS. 26 and 27 . - In one embodiment, the UPR modulating sequences are identified by hybridization to other nucleic acids. Additionally, sequence homology determinations can be made using algorithms.
- Thus in one embodiment, the UPR modulating nucleic acid hybridizes to a complement of a nucleic acid encoding HAC1, PTC2 or IRE1. In one embodiment, the HAC1, PTC2 or IRE1 encoding sequence is selected from the sequences provided in the respective figures. In one embodiment the stringency conditions are moderate. In another embodiment, the conditions used are high stringency conditions.
- “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
- “Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C.
- “Moderately stringent conditions” may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37° C. in a solution comprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1×SSC at about 37-50° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
- Homologous (similar or identical) sequences can also be determined by using a “sequence comparison algorithm.” Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection.
- An example of an algorithm that is suitable for determining sequence similarity is the BLAST algorithm, which is described in Altschul, et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. These initial neighborhood word hits act as starting points to find longer HSPs containing them. The word hits are expanded in both directions along each of the two sequences being compared for as far as the cumulative alignment score can be increased. Extension of the word hits is stopped when: the cumulative alignment score falls off by the quantity X from a maximum achieved value; the cumulative score goes to zero or below; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.
- The BLAST algorithm then performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, an amino acid sequence is considered similar to a protein such as a protease if the smallest sum probability in a comparison of the test amino acid sequence to a protein such as a protease amino acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- In one embodiment, the HAC1 protein provided herein has less than 80% sequence similarity than the HAC1 yeast protein, see for example, GenBank accession number E15694, more preferably, less than 70%, more preferably, less than 60%, more preferably less than 50%, more preferably, less than 45% or 40% similarity. In another embodiment, identity is substituted for similarity.
- In another embodiment, the HAC1 protein provided herein has at least 40% similarity to the amino acid sequence set forth in
FIG. 7 orFIG. 8 . More preferably, the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity. - In another embodiment, the HAC1 protein provided herein comprises a DNA binding domain that has at least 70% similarity to the DNA binding domain set forth in
FIG. 10 . More preferably, the similarity is at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity. - As used herein, DNA binding domain refers to the domain which binds to the conserved sequence called the UPR element in promoters of genes regulated by UPR. Embodiments of a DNA binding region are shown approximately at amino acids 84-147 of the T. reesei protein shown in
FIG. 10 , approximately at amino acids 53-116 of the A. nidulans protein shown inFIG. 10 and approximately amino acids 45-109 of the A. niger protein shown in FIG. 28. HAC1 homologs will have DNA binding domains which can be identified by activity or by alignment to the binding domains inFIG. 10 . - In one embodiment, the PTC2 protein provided herein has less than 80% sequence similarity than the PTC2 yeast protein, see for example, GenBank accession number U472498, more preferably, less than 70%, more preferably, less than 60%, more preferably less than 50%, more preferably, less than 45% or 40% similarity. In another embodiment, identity is substituted for similarity.
- In another embodiment, the PTC2 protein provided herein has at least 40% similarity to the amino acid sequence set forth in
FIG. 24 orFIG. 25 . More preferably, the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity. - In one embodiment, the IRE1 protein provided herein has less than 80% sequence similarity than the IRE1 yeast protein, see for example, GenBank accession number Z11701, more preferably, less than 70%, more preferably, less than 60%, more preferably less than 50%, more preferably, less than 45% or 40% similarity. In another embodiment, identity is substituted for similarity.
- In another embodiment, the IRE1 protein provided herein has at least 40% similarity to the amino acid sequence set forth in
FIG. 26 orFIG. 27 . More preferably, the similarity is at least 50%, more preferably, at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, and more preferably at least 95% or 98%. In another embodiment, identity is substituted for similarity. - Additionally, further homologs of the UPR modulating sequences can be identified for example by using PCR primers based on the sequences provided herein. In yet another embodiment, naturally occurring allelic variants of the sequences provided herein may be used.
- A protein has UPR modulating activity if it is able to regulate the induction of UPR. Regulate means causing an increase or decrease in the induction of the UPR. A UPR modulating protein can increase or decrease UPR induction whether or not there is a change in the amount unfolded protein in the ER. In a preferred embodiment, a UPR modulating protein has one or more of the following activities: HAC1 activity, PTC2 activity, IRE1 activity, or binds to HAC1.
- Modulating the amount of or activity of the UPR modulating protein can occur by a variety of methods. For example, to increase the presence or activity of a protein in a cell, one can over-express the nucleic acid encoding the UPR modulating protein. Over-expression as used herein means that the protein encoded by the said gene is produced in increased amounts in the cell. In one embodiment, over-expression can be used interchangeably with constitutive expression or upregulation. This can be achieved by increasing the copy number of the gene by introducing extra copies of the gene into the cell on a plasmid or integrated into the genome. Over-expression can also be achieved by placing the gene under a promoter stronger than its own promoter. The amount of the protein in the cell can be varied by varying the copy number of the gene and/or the strength of the promoter used for the expression. Thus, manipulation of genes to cause induction of UPR may involve insertion into the host of multiple copies of a gene with its native promoter either on a replicating autosomal plasmid or by integration into the chromosomal DNA. It may involve fusion of the gene with a promoter region and/or transcriptional control sequences from other genes to further increase expression or to allow controlled, inducible expression. Agonists and enhancers may also be used.
- In the case where it is desired to reduce the activity of a UPR modulating protein to result in elevated UPR, a number of methods may be used such as deletion of a gene or the use of antisense nucleic acids to reduce the expression of a gene. It may involve alteration of a gene to provide a mutant form of the protein or include the use of an inhibitor of a UPR modulating protein.
- In one embodiment, UPR is elevated by using a UPR inducing form of a recombinant nucleic acid encoding a UPR-modulating protein. In one embodiment, a UPR-inducing form of a recombinant nucleic acid encoding a UPR-modulating protein is a nucleic acid which has been modified to give rise to a translatable mRNA. The translatable form mimics the modified mRNA which appears in the cell on induction of UPR and which can be translated to an active UPR-modulating protein.
- In one embodiment, a UPR-inducing form of a recombinant nucleic acid includes coding sequence. Coding sequence as used herein includes the nucleic acid sequence which leads to the amino acid sequence of the protein in its active form. As used herein, a nucleic acid consisting essentially of a coding sequence explicitly excludes, lacks or omits at least internal sequence which does not get translated when the active protein is encoded. Internal sequence as used herein refers to sequence which is internal to the carboxyl terminus and the amino terminus. Examples of excluded internal sequence are shown in small letters in
FIGS. 7 , 8, 24, 26, 27 and 28. The sequence may be excluded by deletion or truncation by methods known in the art. - In one embodiment a nucleic acid comprises a sequence consisting essentially of coding sequence. In this embodiment, the nucleic acid may comprise vector sequence on either side of the coding sequence but the coding sequence excludes internal sequence which does not get translated in the encoded protein's active form.
- In another embodiment, a UPR modulating protein is a variant UPR modulating protein which has been varied to have increased activity. Thus in one embodiment, the activity of a UPR modulating protein is increased to elevate UPR. In one embodiment, the activity of a UPR modulating protein is increased by maintaining the protein in its active state. For example, IRE1 is phosphorylated when the UPR pathway is turned on. Therefore, in one embodiment herein, maintaining IRE1 in its phosphorylated induces an elevated UPR.
- In a preferred embodiment, IRE1 is mutated so as to constitutively have the activity of phosphorylated IRE1. In one embodiment, serine and/or threonine residues are substituted with aspartic acid to form to form an IRE1 variant having constitutive UPR inducing activity. Other substitutions to mimic a protein in its phosphorylated state are known in the art. Preferably, the mutations are performed on the nucleic acid encoding the protein.
- By the term “recombinant nucleic acid” herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid by polymerases and endonucleases, in a form not normally found in nature. Generally, a nucleic acid refers to DNA, RNA or mRNA and includes a gene or gene fragment. Thus, an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.
- Similarly, a “recombinant protein” is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. Generally, the term protein and peptide can be used interchangeably herein. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. In one embodiment, the definition includes the production of a protein from other than its host cell, or produced by a recombinant nucleic acid. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.
- A recombinant cell generally refers to a cell which has been manipulated to contain a recombinant nucleic acid or protein therein.
- The protein of interest to be secreted can be any protein. Wherein the protein is not naturally secreted, the nucleic acid encoding the protein may be modified to have a signal sequence in accordance with techniques known in the art. The proteins which are secreted may be endogenous proteins which are expressed naturally, but in a greater amount in accordance with the present invention, or the proteins may be heterologous. In a preferred embodiment, the proteins are heterologous. Heterologous as used herein means the protein is produced by recombinant means. Therefore, the protein may be native to the cell, but is produced, for example, by transformation with a self replicating vector containing the nucleic acid encoding the protein of interest. Alternatively, recombinant could be wherein one or more extra copies of the nucleic acid are integrated into the genome by recombinant techniques.
- In another embodiment, the protein of interest is selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase, alpha-amylase, glucoamylase, lignocellulose hemicellulase, pectinase and ligninase. In another embodiment, the protein of interest is a therapeutic selected from the group consisting of vaccines, cytokines, receptors, antibodies, hormones, and factors including growth factors.
- The cell in which the proteins are secreted is any cell having an upregulated protein response. Preferably, the host to be transformed with the genes of the invention can be any eukaryotic cell suitable for foreign or endogenous protein production, e.g., any S. cerevisiae yeast strain, (e.g., DBY746, BMA64-1A, AH22, S150-2B, GYPY55-15bA, vtt-a-63015) any Trichoderma spp. such as T. longibrachiatum and the T. reesei strains derived from the natural isolate QM6a, such as RUTC-30, RL-P37, QM9416 and VIT-D-79125, any Kluyveromyces spp/. Sch. pombe, H. polymorpha, Pichia, Aspergillus, Neurospora, Yarrowia, Fusarium, Penicillium spp. or higher eukaryotic cells.
- Examples of mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51).
- In an alternative embodiment, a plant cell can be utilized. In another embodiment, a baculovirus infected insect cell is utilized. The selection of the appropriate host cell is deemed to be within the skill in the art.
- Transfer of the genes into these cells can be achieved, for instance, by using the conventional methods of transformation described for these organisms. General aspects of mammalian cell host system transfections have been described in U.S. Pat. No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, etc. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).
- The nucleic acid (e.g., cDNA, coding or genomic DNA) encoding the UPR modulating protein may be inserted into a replicable vector. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.
- For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces α-factor leaders, the latter described in U.S. Pat. No. 5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 Apr. 1990), or the signal described in WO 90/13646 published 15 Nov. 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
- Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Req., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
- Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for
alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. - Transcription from vectors in mammalian host cells can be controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 Jul. 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
- Transcription of a DNA encoding the protein in eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a
position 5′ or 3′ to the coding sequence, but is preferably located at asite 5′ from the promoter. - Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5′ and, occasionally 3′, untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the protein. Still other methods, vectors, and host cells are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.
- In one embodiment, the gene is cloned into a suitable expression vector, such as pKK1 or similar vectors comprising the appropriate regulatory regions depending on the selected host. For example, these regulatory regions can be obtained from yeast genes such as the ADH1, GAL1-
GAL 10, PGK1, CUP1, GAP, CYC1, PHO5, or asparagine synthetase gene, for instance. Alternatively, also the regulatory regions of, for example, HAC1 can be used to express the gene in S. cerevisiae. The plasmid carrying the gene is capable of replicating autonomously when transformed into the recipient yeast strain and is maintained stably in a single copy due to the presence of a yeast centromeric sequence. Alternatively, a multicopy replicating plasmid could be used or integration of the plasmid into the yeast genomic DNA could be provided for using methods known in the art. - In one embodiment herein, to express HAC1 cDNA, preferably truncated in Trichoderma the coding region of the inducing form of the Trichoderma HAC1 gene is coupled for instance between the A. nidulans gpdA promoter and terminator and the expression cassette is transformed into a Trichoderma strain producing for instance bovine chymosin or another foreign protein. In the truncated form, the unconventional introns are removed, as well as any remaining terminal end adjacent to said intron. An uncoventional intron is one which is present in the mRNA in the cell which is not undergoing UPR, but which is removed from the mRNA upon induction of the UPR. UPR would be thus induced constitutively. A higher level of expression which was inducible according to the carbon source used for growth of the fungus could be achieved by fusion of the inducing form of HAC1 with the promoter of the T. reesei cbh 1 gene.
- For filamentous fungi the HAC1 gene is preferably integrated into the genome using methods known in the art. Suitable promoters in addition to the gpdA or cbh1 promoters or promoter of the HAC1 gene itself are for instance the other cellulase promoters, cbh2, egl1, egl2, or tef1, pgk, pki, the glucoamylase, alpha-amylase or the alcohol dehydrogenase promoter. In filamentous fungi transformation usually results in strains with varying copies of expression vector integrated into the genome (Penttilä et al., 1987) and from these the strain with optimal level of truncated HAC1 expression for growth and enhanced secretion can be screened.
- It is understood that the methods provided herein may further include cultivating said recombinant host cells under conditions permitting expression of said secreted protein. The proteins can be collected and purified as desired. In a preferred embodiment, hydrolytic enzymes are secreted. In another embodiment, the secreted proteins are used in improved alcohol production or in processes where efficient hydrolysis of raw material is desired.
- The following preparations and examples are given to enable those skilled in the art to more clearly understand and practice the present invention. They should not be considered as limiting the scope and/or spirit of the invention, but merely as being illustrative and representative thereof.
- In order to cause constitutive induction of the unfolded protein response in Saccharomyces cerevisiae, a truncated version of the yeast HAC1 gene was expressed from a centromeric plasmid. The truncated version does not include the intron of HAC1 that in normal conditions prevents the translation of the mRNA. Thus the mRNA expressed from the plasmid is translated to HAC1 protein constitutively and causes a constitutive induction of the unfolded protein response. The appropriate HAC1 gene fragment was first amplified from yeast chromosomal DNA by PCR. This fragment starts 24 bp before the translation start codon of the HAC1 gene and ends with a translation stop codon inserted after the proline codon at amino acid position 220 of the deduced protein. The oligonucleotide primers used were: 5′ ATC GCA GGA TTC CCA CCT ACG ACA ACA
ACC GCC ACT 3′ (forward primer) (SEQ ID No. 20) and 5′ TAC AGC GGA TCC CTA TGG ATT ACG CCA ATT GTC AAG3′ (reverse primer) (SEQ ID No. 21). BamHI restriction sites were included into both of the primers to facilitate cloning. The PCR reaction was carried out with the Vent DNA polymerase (New England Biolabs) in conditions recommended by the manufacturer. The PCR program used started with heating to 94° C. for three minutes followed by 30 cycles with denaturation at 94° C. for 45 seconds, annealing at 55° C. for 45 seconds and synthesis at 72° C. for one minute. The PCR product fragment of 690 bp was run in a 0.8% agarose gel and purified from the gel by the Qiaquick gel extraction kit (Qiagen) according to manufacturer=s protocol. The fragment was digested with BamHI and cloned into the BamHI site of the pZERO vector (Invitrogen) with methods known in the art. The HAC1 fragment was released from pZERO by BamHI digestion and cloned into the BgIII site of the vector pKK1 between the promoter and terminator of the yeast PGK1 gene with methods known in the art. pKK1 contains the LEU2 selectable marker gene and the centromere (CEN6) and ARS sequences for maintenance in yeast as a single-copy plasmid. The final expression plasmid was named pMS109 (FIG. 1 ). - The plasmid pMS109 and the control plasmid pKK1 were transformed into a yeast strain producing Bacillus amyloliquefaciens α-amylase. In this strain, the expression cassette with the α-amylase coding region inserted between the yeast ADH1 promoter and terminator had been integrated into the TRP1 locus of the yeast strain DBY746 (α, his3Δ1, leu2-3, ura3-52, trp1-289, Cyhr). Four pMS109 transformants and four strains transformed with the vector pKK1 were selected for cultivations. The cultivation medium was synthetic complete yeast medium without leucine (SC-Leu, described by Sherman 1991, Meth. Enzymol. 194, 3-21), buffered to pH 6.0 with 2% succinic acid and supplemented with 2% glucose as the carbon source. The 50 ml yeast shake flask cultures were inoculated to the initial OD600 (optical density at the wavelength of 600 nm) of 0.2 and growth was carried out for five days at 30° C. and 250 RPM. Samples were taken daily for monitoring yeast growth and α-amylase production. α-amylase activity was measured with the Phadebas Amylase Test (Pharmacia) according to the instructions of the manufacturer. Yeast cell density was determined by measuring OD600 (optical density at the wavelength of 600 nm) of the culture. The α-amylase amounts produced by each of the pMS109 transformants were higher than the amounts produced by any of the pKK1 transformants. The average production level of pMS109 transformants was 70% higher in the end of the cultivation than the average of pKK1 clones (
FIG. 2 ). The growth of the pMS109 strains was slightly retarded when compared with the control. - To analyse the effect of the constitutive UPR induction to yeast invertase production, four clones transformed with pMS109 and four clones transformed with the pKK1 vector, derived from the α-amylase producing strain described above, were cultivated in the SC-Leu medium buffered to pH 6.0 with 2% succinic acid and containing 2% sucrose as the carbon source. The 50 ml shake flask cultures were inoculated to the initial OD600 of 0.2 and grown subsequently for five days at 30° C. and 250 RPM. Yeast growth was followed by measuring the OD600 and samples were taken for invertase assays on days three, four and five. For each assay, cells were harvested by centrifugation from 1 ml of the culture. The cells were washed with 5 ml of 10 mM NaN3 and resuspended in 0.2 M NaAc buffer, pH5.0 with 10 mM NaN3. The invertase activity of the cells was measured by incubating them with 0.166 M sucrose in 0.2 M NaAc buffer, pH 5.0 for 6 minutes. The reaction was stopped by adding one volume of 0.5 M KPO4, pH 7.0 and by separating the cells rapidly from the reaction mixture by filtration. The glucose formed into the reaction mixture was measured by the GOD-Perid kit (Boehringer Mannheim) according to the manufacturer's protocols. The invertase production of the pMS109 transformants was about 2 times higher than that of the pKK1 transformants in all the timepoints that were tested (
FIG. 3 ). - The yeast HAC1 gene was disrupted by replacing it in the genome with a DNA fragment containing the G418 antibiotic resistance cassette flanked by 48 bp sequences from the 5′ and 3′ ends of the HAC1 open reading frame. The G418 resistance cassette consists of the E. coli kanamycin resistance gene cloned between the promoter and terminator of the Ashbya gossypii TEF gene encoding
translation elongation factor 1. The DNA fragment used in the disruption of the yeast HAC1 was produced by PCR from the kanMX2 module (Wach et al., 1994,Yeast 10, 1793-1808) with theoligonucleotide primers 5′ CCA CCT ACG ACA ACA ACC GCC ACT ATG GAA ATG ACT GAT TTT GAA CTA CTT GCC TCG TCC CCGCCG GGT CAC 3′ (forward primer) (SEQ ID No. 22) and 5′ AAT TAT ACC CTC TTG CGA TTG TCT TCA TGA AGT GAT GAA GAA ATC ATT GAC ACT GGA TGG CGG CGTTAG TAT CGA 3′ (reverse primer) (SEQ ID No. 23). The PCR reaction was done with the Dynazyme DNA polymerase (Finnzymes) in conditions recommended by the manufacture. The PCR program started by denaturation at 94° C. for 3 minutes, followed by 30 cycles of denaturation at 94° C. for 45 seconds, annealing at 52° C. for 30 seconds and elongation at 72° C. for 1 minute. A final elongation step of 5 minutes was performed at 72° C. The PCR product of about 1.5 kb was run in an 0.8% agarose gel and purified from the gel with the Qiaquick kit (Qiagen). The fragment was transformed into the yeast strain BMA64-1A (a, ura3-1, trp1-Δ, leu2-3, 112, his3-11, ade2-1, can1-100) with a method described (Gietz et al., 1992, Nucl. Acids Res. 20, 1425). The transformants were first grown over night on YPD plates (Sherman, 1991, Meth. Enzymol. 194, 3-21) and then replicated onto YPD plates with 200 μg/ml of the antibiotic G418. The transformants resistant to G418 were tested on plates with yeast mineral medium (Verduyn et al, 1992,Yeast 8, 501-517) with and without inositol. Chromosomal DNA was isolated from strains that were dependent on inositol, and Southern hybridization with the HAC1 protein-coding region was performed with methods known in the art. The result of the hybridization showed that the HAC1 gene had been disrupted in the strains dependent on inositol. - The effect of the HAC1 disruption on the production of two heterologous proteins, the Bacillus amyloliquefaciens α-amylase (Ruohonen et al., 1987, Gene 59, 161-170) and the Trichoderma reesei endoglucanase EGI (Penttilä et al., 1987,
Yeast 3, 175-185), was tested. The α-amylase was expressed from a multicopy plasmid with the LEU2 marker gene, B485 (Ruohonen et al., 1991, J. Biotechnol. 39, 193-203, the plasmid is called YEpαa6 in this article), where the α-amylase gene has been cloned between the yeast ADH1 promoter and terminator. The EGI was expressed from the plasmid pMP311 (Penttilä et al., 1987,Yeast 3, 175-185), where the endoglucanase cDNA has been cloned between the yeast PGK1 promoter and terminator in a multicopy vector with the LEU2 marker gene. The B485 and pMP311 plasmids were transformed into the HAC1 disruptant and its parental strain with a described method (Gietz et al., 1992, Nucl. Acids Res. 20, 1425), and transformants were selected on SC-Leu plates (Sherman, 1991, Meth. Enymol. 194, 3-21). Three B485 transformants derived both from the HAC1 disruptant and its parental strain were grown in 50 ml shake flask cultures in SC-Leu buffered to pH 6.0 with 2% succinic acid and supplemented with 2% glucose. The cultures were inoculated to the initial OD600 of 0.2, and growth was continued for four days at 30° C. and 250 RPM. The α-amylase activity in the culture supernatants was assayed as described in Example 1. The HAC1 disruptant strain produced less than 10% of the α-amylase amount produced by the wild type control strain (FIG. 4 ). To test the effect on EGI production, three pMP311 transformants derived from the HAC1 disruptant and three transformants derived from the parental strain were grown in 50 ml of SC-Leu (Sherman, 1991, Meth. Enzymol. 194, 3-21) with 2% glucose in shaker flasks. The cultures were inoculated to the initial OD600 of 0.2, and grown at 30° C. and 250 RPM for four days. Endoglucanase activity of the cultures was measured with the substrate 4-methylumbelliferyl-β-D-lactoside (Sigma). Supernatant samples were incubated at 50° C. for 3 hours in a reaction mixture of 0.25 mg/ml of the substrate and 0.1 M glucose in 50 mM NaAc, pH 5.0. The reaction was stopped by adding two volumes of 1 M Na2CO3, and the absorbance of the mixture was measured at the wavelength of 370 nm. The production of the endoglucanase EGI of the HAC1 disruptant was about 50% of the level produced by the parental strain (FIG. 5 ). - A homology search was performed against a public database (http://bioinfo.okstate.edu/pipeonline_db/anesquery.html) containing Aspergillus nidulans EST (expressed sequence tag) sequences with the yeast HAC1 protein sequence using the program BLAST (Altschul et al., 1990, J. Mol. Biol. 215, 403-410). The search identified one EST cDNA clone (c7a10a1.r1) which has homology to yeast HAC1p at the DNA binding domain. However, another region of the same cDNA clone, designated as EST c7a10a1.f1 in the database, had no obvious similarity with HAC1 and there was no annotation within the database to indicate similarity between the ESTs and HAC1. Therefore, it was unclear if the A. nidulans cDNA clone encoded a functional homolog of HAC1 or a different protein having a version of a DNA-binding motif. The region corresponding to the c7a10a1 EST cDNA was amplified by PCR from A. nidulans genomic DNA isolated with methods known in the art. The sequences of the ends of the EST cDNA clone found from the database were used to design the 5′ end primer (5′ GCC ATC CTT GGT
GAC TGA GCC 3′) (SEQ ID No. 24) and 3′ end primer (5′ CAA TTG CTC GCT CTTACA TTG AAT 3′) (SEQ ID No. 25). The PCR reaction was performed as described in Example 2. The PCR product of 1.6 kb in length was run in an 0.8% agarose gel, purified from the gel with the Qiaquick gel extraction kit (Qiagen) and cloned into the pGEM-AT vector (Promega) with methods known in the art. The whole fragment was sequenced from the resulting plasmid using internal oligonucleotide primers. - To isolate the HAC1 cDNA from Trichoderma reesei, the proper hybridisation temperature for cDNA library screening were determined by genomic Southern hybridization with the genomic hacA fragment cloned from A. nidulans as a probe. The probe fragment was labelled with 32P-dCTP using the Random primed DNA labelling kit (Boehringer Mannheim) as instructed by the manufacturer. The hybridization was performed as described (Sambrook et al., 1989, in Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) at 48° C., 50° C., 55° C. and 60° C. in a hybridization mixture containing 6×SSC, 5×Denhardt's, 0.5% SDS, 100 μg/ml herring sperm DNA (SSC is 0.15 M NaCl, 0.015 M Na-citrate, pH 7.0, 50×Denhardt's is 1% Ficoll, 1% polyvinylpyrrolidone, 1% bovine serum albumin). The filters were washed for 10 minutes at room temperature with 2×SSC, 0.1% SDS and for 30 minutes at the hybridization temperature with the same solution. The T. reesei cDNA library constructed into the vector λZAP (Stratagene, Stalbrand et al., 1995, Appl. Environ. Microbiol. 61, 1090-1097) was plated with the appropriate E. coli host strain, and the λ-DNA was lifted onto nitrocellulose filters (Schleicher & Schull) as instructed by the manufacturer. Hybridization of the filters was done for 18 hours at 55° C. in the same hybridization mixture as the Southern hybridization. The filters with λ-DNA were washed for 10 minutes at room temperature with 2×SSC, 0.1% SDS and for 30 minutes at 55° C. with the same solution. The λ-clones hybridizing with the probe were excised into pBluescript plasmids containing the cDNA inserts as instructed (Stratagene). The cDNA clone carrying the largest insert (in the plasmid pMS119,
FIG. 6 ) was chosen for sequencing, and the whole sequence of its insert was determined with the help of internal sequencing primers. The genomic copy of the T. reesei gene was isolated by hybridization of a genomic λ-library in the vector λEMBL3 (Kaiser and Murray, 1985, in DNA Cloning: a Practical Approach, pp. 1-47, ed. Glover, IRL Press, Oxford). The library was plated with the appropriate E. coli host strain and λ-DNA was lifted onto nitrocellulose filters (Schleicher & Schull) as instructed by the manufacturer. The filters were hybridized at 42° C. over night in a hybridization mixture containing 50% formamide, 5×Denhardt's, 5×SSPE, 0.1% SDS, 100 μg/ml herring sperm DNA and 1 μg/ml polyA-DNA (SSPE is 0.18 M NaCl, 1 mM EDTA, 10 mM NaH2PO4, pH 7.7). The filters were washed for 10 minutes at room temperature with 2×SSC, 0.1% SDS and 30 minutes at 65° C. in 0.1×SSC, 0.1% SDS. λ-DNA was isolated from clones hybridizing with the probe with a described method (Sambrook et al., 1989, in Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.), and the genomic region corresponding to the HAC1 cDNA was sequenced from this DNA with internal sequencing primers. - The sequences of the Trichoderma reesei HAC1 and Aspergillus nidulans hacA genes are shown in
FIGS. 7 and 8 , respectively. Comparison of the genomic and cDNA sequences from both fungi (the cDNA sequence of hacA available in the EST database) reveals a conventional intron with consensus border sequences at a conserved position in both of the genes. A second intron of 20 bp is found in the T. reesei HAC1 gene. This intron does not have theconsensus 5′ border sequence (GT). The sequence around the 5′ end of this intron is predicted to have a strong tendency to form a RNA secondary structure called hairpin loop. The area between the stems of the loop has a sequence very similar to the consensus sequence found at both of the intron borders of the unconventional intron of 252 bp found in yeast HAC1 (FIG. 9 , Gonzalez et al., 1999, EMBO. J. 18, 3119-3132). When the yeast UPR pathway is induced, the IRE1 protein cleaves the HAC1 mRNA at these intron borders, and thus initiates the splicing of the intron and formation of an active HAC1 protein. In the Aspergillus nidulans hacA gene there is a sequence almost identical to the hairpin-unconventional intron region of T. reesei HAC1. - It has been shown by RT-PCR studies that the 20 bp intron is removed from the T. reesei HAC1 and A. nidulans hacA mRNAs upon UPR induction (Example 4). The 250 bp intron in yeast HAC1 prevents translation of the mRNA probably by forming a specific secondary structure (Chapman and Walther, 1998, Curr. Biol. 7, 850-859). The 20 bp intron in the HAC1/hacA genes of filamentous fungi can not form such secondary structures, and thus the activation mechanism of these genes is different from yeast HAC1. The T. reesei HAC1 cDNA encodes an open reading frame of 451 amino acids and the A. nidulans hacA a protein of 350 amino acids, when the 20 bp introns have been removed from the both sequences. The putative T. reesei and A. nidulans HACI/A proteins have an identity of 37.4% with each other and both have a DNA binding domain conserved with yeast HAC1 protein (
FIG. 10 ). The yeast HAC1 binding site has approximately 64% similarity and 53% identity to the binding site of T. reesei, and approximately 65% similarity and 56% identity to the binding site of A. nidulans. At other regions there is no detectable homology between yeast HAC1p and the HACI of T. reesei or the HACA of A. nidulans. The HAC1 cDNA clone sequenced from T. reesei has a 5′ flanking region of 471 bp, containing two short open reading frames encoding 17 and 2 amino acids. The 5′ flanking region sequenced from A. nidulans hacA is 187 bp in length, containing one upstream open reading frame of 7 amino acids. - When the UPR pathway is induced in yeast, the unconventional intron of the HAC1 gene is spliced and thus the length of the HAC1 mRNA is reduced by 250 bp (Cox and Walter, 1996, Cell 87, 391-404). It was studied if UPR induction affects the length of the HAC1/hacA mRNA in T. reesei and A. nidulans. The T. reesei strain RutC-30 (Montenecourt and Eveleigh, 1979, Adv. Chem. Ser. 181, 289-301) was grown in a shake flask in a Trichoderma minimal medium (Penttilä et al., 1987,
Gene 61, 155-164) with 2% lactose as the carbon source. Growth was performed for 60 hours at 28° C. and 200 RPM, and the mycelium was diluted 1:10 into the same medium and grown for additional 21 hours. The culture was subsequently divided into two halves, and one half of it was treated with 10 mM dithiothreitol (DTT) to induce the UPR pathway (Saloheimo et al., 1999, Mol. Gen. Genet. 262, 35-45). Mycelial samples were collected from the culture treated with DTT and the untreated control culture before DTT addition and 30, 60, 90, 120 240 and 360 minutes after the addition of DTT. Total RNA was isolated from the samples with the TRIzol reagent (Gibco-BRL) according to manufacturer's protocols. RNA samples of 5 μg were treated with glyoxal and run in a 1% agarose gel in 10 mM Na-phosphate buffer, pH 7.0. Capillary blotting onto a Hybond-N nylon filter (Amersham) was done as instructed by the manufacturer. The full-length HAC1 cDNA that was used as a probe was labelled as described in Example 3. Hybridization was performed for 18 hours at 42° C. in 50% formamide, 10% dextran sulphate, 1% SDS, 1 M NaCl and 125 μg/ml of herring sperm DNA. The filter was washed in 5×SSPE for 15 minutes at 42° C., in 1×SSPE, 0.1% SDS for 30 minutes at 42° C. and in 0.1×SSPE, 0.1% SDS for 30 minutes at room temperature. The results (FIG. 11 ) show that the length of the HAC1 mRNA does not change in the control samples not treated with DTT. In the samples treated with DTT a shorter mRNA of about 2.2 kb appears in addition to the 2.5 kb mRNA observed in the control samples. The full-length HAC1 cDNA probe was removed from the Northern filter by incubating it in 0.1% SDS at 100° C. for 10 minutes. The filter was then hybridized with a probe containing a 160 bp sequence from the 5′ flanking region of the HAC1 gene. This probe was made by PCR from the plasmid pMS119 (FIG. 6 ) with the T3 primer (5′ AAT TAA CCC TCACTA AAG GG 3′) (SEQ ID No. 26) binding to the pBluescript vector as the forward PCR primer and theoligonucleotide 5′ TGG TTG ATG ACG ACG ATGCGA ACA GTC ATG ACAGGC AAC G 3′ (SEQ ID No. 27) as the reverse primer. The PCR reaction was performed as described in Example 2. The probe preparation was done as in Example 3. The Northern hybridisation with the short fragment was done as described above for the full-length HAC1 cDNA probe. The short probe fragment derived from the 5′ flanking region of the HAC1 cDNA hybridized with the full-length HAC1 mRNA of 2.5 kb but not with the 2.2 kb mRNA that appears when UPR is induced by DTT, indicating that the 5′ end is the segment absent in the 2.2 kb mRNA. It has previously been shown that the T. reesei pdi1 gene is controlled by the UPR (Saloheimo et al., 1999, Mol. Gen Genet. 262, 35-45). To show that the UPR is induced in this experiment with DTT, the filter was probed with the pdi1 and gpd1 probes. The pdi1 mRNA becomes more abundant in the mycelium treated with DTT, whereas the gpd1 mRNA remains at an almost constant level. - To analyse more closely the change that occurs in the T. reesei HAC1 mRNA upon UPR pathway induction, the mRNA populations in induced and uninduced conditions were studied by rapid amplification of cDNA ends by PCR (RACE-PCR). PolyA+ RNA was isolated from total RNA samples derived from a DTT-treated and an untreated control mycelia, using the OligoTex mRNA isolation kit (Qiagen) as instructed by the manufacturer. The Marathon cDNA amplification kit (Clontech) was used in the RACE-PCR procedure according to manufacturer's protocols. The HAC1-specific oligonucleotide used in the reaction was 5′ GGG AGA CGA CTG CTG
GAA CGC CAT 3′ (SEQ ID No. 28). It binds 500 bp downstream from the 5′ end of the full-length HAC1 cDNA. The isolated mRNA was used in synthesis of double-stranded cDNA. An oligonucleotide adapter was ligated to the ends of the cDNA, and the 5′ ends of the HAC1 cDNAs in each sample were amplified by PCR with the HAC1-specific primer and a primer supplied in the kit that binds to the ligated adapter. The PCR program consisted of 5 cycles with denaturation at 94° C. for 5 seconds and synthesis at 72° C. for 3 minutes followed by 5 cycles with denaturation at 94° C. for 5 seconds and synthesis at 70° C. for 3 minutes and 25 cycles with denaturation at 94° C. for 5 seconds and synthesis at 68° C. for 3 minutes. The PCR products were analysed in a 1% agarose gel. A fragment of the expected size (about 550 bp, including the 5′ flanking region of the HAC1 gene and the adapter ligated to the end), corresponding to the 2.5 kb mRNA, was obtained from the control sample derived from mycelia not treated with DTT. A second fragment of about 250 bp, corresponding to the 2.2 kb mRNA size, was obtained in the PCR from the sample treated with DTT in addition to the one observed in the control sample. The 550 bp fragment of the control sample and the 250 bp fragment from the DTT-treated sample were isolated from the agarose gel with the Qiaquick gel extraction kit (Qiagen) as instructed by the manufacturer, and cloned into the pCR2.1-TOPO vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. Two independent clones derived from the control RNA and carrying the 550 bp insert were sequenced. They had their 5′ end 8 bp and 16 bp downstream from the 5′ end of the full-length cDNA ( 8 and 16 in the sequence innucleotides FIG. 7 ) and the sequence continued until the end of the HAC1-specific primer as inFIG. 7 . Seven independent clones derived from the DTT-treated mycelium and carrying 250 bp inserts were sequenced. The 5′ ends of these fragments were each at different positions between nucleotides 254 and 336 in the sequence inFIG. 7 , and in each case the sequence continued until the end of the HAC1-specific primer as inFIG. 7 . This further confirms that the 5′ end of the T. reesei HAC1 mRNA is absent when the UPR pathway is induced by DTT. The upstream open reading frame (uORF) of 17 amino acids is in the region that is left out from the mRNA. Thus this uORF could be involved in the regulation, preventing translation initiation at the correct start codon and formation of the HACI protein. - The splicing of the 20 bp intron from the T. reesei HAC1 mRNA upon UPR induction was studied by reverse transcriptase-PCR (RT-PCR). The mRNA samples used in RACE-PCR (previous paragraph), one treated with 10 mM DTT and the other not treated, were subjected to first strand cDNA synthesis with the Riboclone cDNA synthesis system (Promega) according to manufacturer's instructions. A fragment of about 500 bp in length, covering the region with the 20 bp intron in the HAC1 gene, was amplified by PCR from the synthesized cDNA using the
forward primer 5′ CCC CGA GCA GTCCTT GAT GG 3′ (SEQ ID No. 29) and thereverse primer 5′ GTC GTT GATGTC GAA GT 3′ (SEQ ID No. 30). The PCR program consisted of denaturation at 94° C. for 2 minutes followed by 30 cycles with denaturation at 94° C. for 45 seconds, annealing at 50° C. for 30 seconds and synthesis at 72° C. for 1 minute. A final synthesis step of 5 minutes at 72° C. was performed. The DNA fragments obtained in the PCR were cloned into the pCR2.1 vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. Ten fragments derived from both the DTT-treated sample and the nontreated control sample were sequenced. Nine out of the ten fragments from control sample had the intron unspliced. Only two out of the ten fragments from the DTT-treated sample had the intron unspliced, showing that splicing of the intron occurs upon UPR induction by DTT. - To examine whether the 5′ flanking region and the 20 bp intron are removed from the Aspergillus nidulans hacA mRNA upon UPR induction similarly to the T. reesei HAC1 mRNA, Northern hybridisation and RT-PCR experiments were carried out. The A. nidulans strain FGSC A26 was grown for three days in shake flasks in a medium containing 3% glucose, 2.5% corn steep liquor, 15 g/l KH2PO4, 5 g/l (NH4)2SO4, 5 mg/l FeSO, 1.6 mg/l MnSO4, 1.4 mg/l ZnSO4, 3.7 mg/l CoCl2, pH 6.8. The culture was divided into two aliquots, and one aliquot was treated with 20 mM DTT and the other served as a control. Samples were withdrawn from both aliquots at 0, 30, 60, 120 and 240 minutes after the DTT addition. The mycelium was washed with 0.9% NaCl and stored frozen at −70° C. Total RNA was isolated from the mycelia with the Trizol reagent (Gibco-BRL) as instructed by the manufacturer. Agarose gel electrophoresis, Northern blotting and hybridization of the RNA samples was performed as described in the first paragraph of this example. The Northern was first probed with the full-length hacA genomic fragment shown in
FIG. 8 . The probe hybridizes with a single 1.7 kb mRNA band in samples not treated with DTT. In the samples treated with DTT for 120 and 240 minutes, an additional band of about 1.55 kb is detected, showing that the hacA mRNA is truncated upon UPR induction (FIG. 12 ). The Northern was then probed with a short probe derived from the 5′ end of the hacA gene. The probe fragment was made by PCR from the pGEM-AT vector carrying the hacA gene (Example 3) with the T7 primer (5′ GTA ATA CGA CTC ACTATA GGG C 3′) (SEQ ID No. 31) as the forward primer and hacA-specific oligonucleotide 5′ TTA GGA CAG AGGCCA CGG TGT 3′ (SEQ ID No. 32) as the reverse primer. The PCR reaction was performed as described in the previous paragraph. The 5′ end probe has the first 90 bp of the sequence inFIG. 8 . The short 5′ end probe hybridizes only with the 1.7 kb mRNA, showing that the hacA mRNA is truncated from the 5′ end when the UPR pathway is induced. - To test if the 20 bp intron is removed from the A. nidulans hacA gene when UPR is induced by DTT, RT-PCR was performed. The total RNA samples isolated from mycelia treated with 20 mM DTT for 240 minutes and from control mycelia were subjected to RT-PCR reactions with the Robust RT-PCR kit (Finnzymes, Finland) as instructed by the manufacturer, using the
forward primer 5′ CCC ATC CTT GGTGAC TGA GCC 3′ (SEQ ID No. 33) and thereverse primer 5′ AAG AGT CGG TGTCAG AGT TGG 3′ (SEQ ID No. 34). The DNA fragment of about 400 bp obtained in the PCR was cloned into the pCR2.1-TOPO vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. Twelve of the cloned fragments derived from DTT-treated and ten from control mycelia were sequenced. None of the fragments derived from the control mycelia had the intron spliced. Three of the fragments derived from the DTT-treated mycelia had the intron spliced. - The S. cerevisiae IRE1 gene was disrupted in the same way as the HAC1 gene (described in Example 2). A fragment where a G418 resistance cassette is flanked by sequences from the 5′ and 3′ ends of the IRE1 open reading frame was made by PCR. The
forward primer 5′ ATT AAT ATT TTA GCA CTT TGA AAA ATG CGT CTA CTT CGA AGA AAC ATG CTT GCC TCG TCC CCGCCG GGT CAC 3′ (SEQ ID No. 35) and thereverse primer 5′ AAG CAG AGG GGC ATG AAC ATG TTA TGA ATA CAA AAA TTC ACG TAA AAT GTC GAC ACT GGA TGG CGGCGT TAG TAT 3′ (SEQ ID No. 36) were used in the PCR reaction. The PCR reaction, yeast transformation, and selection and analysis of the disruptants were performed as described in Example 2 for HAC1 disruption. - To express different forms of the T. reesei HAC1 gene in the yeast HAC1 and IRE1 disruptants, four expression constructs were made into the multicopy expression vector pAJ401 (Saloheimo et al., 1994, Mol. Microbiol. 13, 11-21) with the URA3 marker gene and yeast PGK1 promoter and terminator to drive the expression. One of them has the HAC1 cDNA with the intact 5′ flanking region and does not have the 20 bp intron. This plasmid, pMS131 (
FIG. 13 ), was made by releasing the HAC1 cDNA from pMS119, which is the pBluescript vector (Stratagene) carrying the full-length cDNA, with EcoRI and Asp718 digestion, filling in the ends of the fragment with Klenow polymerase and ligating it to the EcoRI restriction site of pAJ401 with methods known in the art. The second construct has the T. reesei HAC1 cDNA truncated at the 5′ end but does not have the 20 bp intron. The truncated HAC1 cDNA fragment was made by PCR from the plasmid pMS119 (FIG. 6 ) with theforward primer 5′ CCG CAA CAC GAC ACGGCA GGC AAC 3′ (SEQ ID No. 37) andreverse primer 5′ CTA GGT AGA CGTTGT ATT TTG 3′ (SEQ ID No. 38). The PCR reaction was carried out as described in Example 2. The PCR product was run in a 0.8% agarose gel and purified from it with the Qiaquick gel extraction kit (Qiagen). The fragment was cloned into the EcoRV restriction site of the pZERO vector using the Zero Background Cloning kit (Invitrogen) according to manufacturer's protocols. The fragment was released from this vector with BamHI digestion and cloned between the EcoRI and XhoI restriction sites of the pAJ401 vector with methods known in the art. The resulting plasmid was named pMS132 (FIG. 14 ). The third and fourth expression plasmids have the 20 bp intron added to the HAC1 cDNA forms either with or without the 5′ flanking region. These plasmids were constructed by replacing a HpaI-KspI fragment of about 800 bp in pMS131 and pMS132 with a corresponding HpaI-KspI fragment from a cDNA which has the 20 bp intron, isolated from the cDNA library in λZAP together with the cDNA in the plasmid pMS119 (Example 3). - To test for complementation, the four expression plasmids and the vector pAJ401 alone were transformed into the yeast HAC1 and IRE1 disruptants as described (Gietz et al., 1992, Nucl. Acids Res. 20, 1425). Four transformants from each of the transformations were streaked on SC-Ura plates (Sherman, 1991, Meth. Enzymol. 194, 3-21) and grown at 30° C. for three days. The plates were then replicated onto mineral medium plates (Verduyn et al., 1992,
Yeast 8, 501-517) with inositol and on plates without inositol. These plates were incubated at 30° C. for three days and the streaks growing on them were replicated again onto the same plates. After growth of five days the inositol dependence of the transformants was evaluated (FIG. 15 ). Both pMS131 (HAC1 cDNA with 5′ flanking region and without intron) and pMS132 (without 5′ flanking region, without intron) could restore the ability of both the HAC1 and IRE1 disruptants to grow without inositol. Thus the T. reesei HAC1 encodes the functional homolog of the yeast HAC1 gene. When the 20 bp intron is added to pMS131, no complementation is obtained. When the intron is added to pMS132, the yeast disruptants grow very slowly without inositol. Thus the 20 bp intron weakens the ability of the T. reesei HAC1 gene to complement the yeast HAC1 and IRE1 disruptions. - A fragment of the T. reesei HACI protein containing the putative DNA binding domain and leucine zipper region was produced in E. coli as a fusion protein with the E. coli maltose-binding protein mal E. A DNA fragment encoding this part of the HACI protein was prepared by PCR from the HAC1 cDNA with the
oligonucleotide primers 5′ TCG AAC GGA TCC GAA AAG AAG CCC GTCAAG AAG AGG 3′ (forward primer) (SEQ ID No. 39) and 5′ ATC GCA GGA TCC CTA GGT TTG GCC ATC CCGCGA GCC AAA 3′ (reverse primer) (SEQ ID No. 40). The PCR reaction was performed as in Example 2. The PCR product of 360 bp was run in an 0.8% agarose gel and purified from the gel with the Qiaquick gel extraction kit (Qiagen). The fragment was digested with BamHI at the restriction sites included in the PCR primers and cloned into the BamHI restriction site of the vector pMAL-p2X (New England Biolabs) with methods known in the art. The HACI-malE protein was produced in E. coli and purified by amylose affinity chromatography using the pMAL Protein Fusion and Purification System (New England Biolabs) as recommended by the manufacturer. The E. coli cells were grown up to OD600 0.5 at 37° C., IPTG was added to the concentration of 0.3 mM, and production was carried out for 3 hour at 24° C. The HACI-malE fusion protein with the expected apparent molecular weight was purified. - The oligonucleotides used in binding reactions were annealed in the concentration of 100 mg/ml in 50 mM Tris, pH 8.0, 10 mM MgCl2, 1 mM spermidine and 5 mM DTT by heating them at 65° C. for 10 minutes and letting them cool down to room temperature during 2 hours. The oligonucleotides were labelled by incubating 100 ng of the annealed oligonucleotide in 10 mM Tris, pH 8.0, 5 mM MgCl2 with 20 μCi of 32P-dCTP and 2.5 U Klenow polymerase (Boehringer Mannheim) at 37° C. for 30 minutes. The binding reactions between the oligonucleotides having the putative UPR elements and the proteins were carried out with 0.5-2 μg of the HACI-malE fusion protein or 2 μg of the malE protein and 1 ng of the annealed and labelled oligonucleotide in a mixture containing 20 mM HEPES, pH 6.9, 50 mM KCl, 10 mM MgCl2, 0.25 mM EDTA, 0.5 mM DTT, 2% Ficoll, 5% glycerol and 100 μg/ml poly(dldC) DNA. The competing oligonucleotides were used in 20-200 times excess of the labelled oligonucleotide. The binding reaction mixtures were incubated for 30 minutes at 25° C. and run in a 5% polyacrylamide gel with 10% glycerol in 12.5 mM Tris-borate, pH 8.3, 0.6 mM EDTA for three hours. The gel was dried on a filter paper and exposed onto an X-ray film.
- The following oligonucleotides carrying the putative UPR elements of the pdi1 and bip1 promoters were used in the binding reactions (only the leading strand is given, the UPREs are given in bold):
- pdiUPREI+II, containing both of the putative UPR elements of the pdi1 promoter (Saloheimo et al. 1999, Mol. Gen. Genet. 262, 35-45).
-
(SEQ ID No. 41) 5′ CGG CTG AAC CAG CGC GGC AGC CAG ATG TGG CCA AAG GG 3′
pdiUPREI, containing the UPREI of the pdi1 promoter in a random context -
(SEQ ID No. 42) 5′ GGT ACC TGC TAA CCA GCG CGG CAT GAT TCA AC 3′
pdiUPREII, containing the UPREII of the pdi1 promoter in a random context -
(SEQ ID No. 43) 5′ GGA TCT TGC ATA GCC AGA TGT GGC CTC GAT TGA CT 3′
bipUPREI, containing the UPREI of the bip1 promoter (unpublished results) -
(SEQ ID No. 44) 5′ GGA TTA GAA AAC GCC AAC GTG TCC ATA ACG GTC 3′
bipUPREII, containing the UPREII of the bip1 promoter, the element is in a reverse orientation in the promoter (unpublished results) -
(SEQ ID No. 45) 5′ GGG CGT GGA GAA GCG AGA AGT GGC CTC TTC TTC TCC 3′ - The results (
FIG. 16 ) show that the HACI-malE fusion protein binds to the putative UPR element area found from the pdi1 promoter whereas the malE protein alone does not show any binding. The binding of the fusion protein is specific, since it is competed by an excess of unlabelled oligonucleotide. The fusion protein binds specifically also to the oligonucleotide pdiUPREII and not at all to pdiUPREI, and this indicates that the functional UPR element of the pdi1 promoter is UPREII. The HACI-malE fusion protein also binds specifically to both of the putative UPR elements found in the bip1 promoter. Alignment of the three T. reesei UPR element shows that the consensus sequence for binding is GC(C/G)A(G/A)N1-2GTG(G/T)C (FIG. 16 ) (SEQ ID No. 46). - The T. reesei HAC1 cDNA was expressed without its 5′ flanking region and without the 20 bp intron from the plasmid pMS132 (
FIG. 14 ). This plasmid and the control plasmid pAJ401 were transformed with a described method (Gietz et al., 1992, Nucleic Acids Res. 20, 1425) into the yeast strain producing Bacillus amyloliquefaciens α-amylase described in Example 1. Two strains carrying pMS132 and two strains with pAJ401 were grown for six days in shake flasks (250 RPM, 30° C.) in SC-Ura medium (Sherman, 1991, Meth. Enzymol. 194, 3-21) buffered to pH 6.0 with 2% succinic acid and growth and amylase production were assayed as described in Example 1. Cell samples were withdrawn from the culture for Northern analysis. The α-amylase production of the pMS132 transformants calculated per biomass was higher than that of the pAJ401 transformants fromday 3 until the end of the cultivation (FIG. 17 ). Growth of the pMS132 strains was slower than the growth of the control plasmid strains. Four pMS132 transformants and four pAJ401 transformants were grown in shake flasks (250 RPM, 30° C.) in SC-Ura with 2% sucrose as the carbon source, and invertase activity produced by the cells was assayed as described in Example 1. More invertase was produced by the pMS132 transformants than by the pAJ401 transformants (FIG. 18 ). - To show that the truncated T. reesei HAC1 cDNA is beneficial for α-amylase and invertase production by inducing the UPR pathway of yeast, Northern analysis was performed on the cell samples withdrawn from the cultures of pMS132 and pAJ401 transformants. Total RNA was isolated from the cells collected after 1, 2 and 3 days of growth with the RNeasy RNA extraction kit (Qiagen) as instructed by the manufacturer. The yeast KAR2 gene is under the UPR pathway control (Cox and Walter, 1996, Cell 87, 391-404), and therefore the Northern filter was probed with a fragment derived from KAR2. This fragment was produced by PCR from yeast chromosomal DNA with the
oligonucleotide primers 5′ GTG GTA ATA TTACCT TTA CAG 3′ (SEQ ID No. 47) (forward primer) and 5′ CAA TTT CAA TACGGG TGG AC 3′ (reverse primer) (SEQ ID No. 48). A fragment from the yeast TDH1 gene encoding glyceraldehyde phosphate dehydrogenase was used as a control probe, since this gene is expressed constitutively and is not expected to be affected by UPR. The TDH1 probe fragment was made from yeast chromosomal DNA by PCR with theoligonucleotide primers 5′ TGT CAT CAC TGCTCC ATC TT 3′ (forward primer) (SEQ ID No. 49) and 5′ TTA AGC CTT GGCAAC ATA TT 3′ (reverse primer) (SEQ ID No. 50). The PCR reaction was done as in Example 2 and the probes were prepared as described in Example 3. Northern blotting and hybridization were performed from the RNA samples as described in Example 4. The filter was exposed to the screen of the phosphoimager SI (Molecular Dynamics), and the signal intensities were quantified with the phosphoimager. The KAR2 signal intensities were normalized with reference to the TDH1 signal intensities. The results (FIG. 19 ) show that the KAR2 mRNA abundance is 2-4-fold higher in the pMS132 transformants than in the pAJ401 transformants in all the timepoints. - To induce the UPR pathway constitutively, a form of the T. reesei HAC1 cDNA that is truncated at its 5′ flanking region and does not have the 20 bp intron was expressed in T. reesei. The form of the HAC1 cDNA that was present in pMS132 was expressed in yeast as described in Example 5 was cloned with methods known in the art into the NcoI restriction site of the vector pAN52-NotI, between the gpdA promoter and trpC terminator of Aspergillus nidulans. The hygromycin resistance cassette consisting of the A. nidulans gpdA promoter and trpC terminator and the E. coli hygromycin resistance gene was subsequently cloned into the NotI restriction site of the pAN52-NotI carrying the HAC1 cDNA fragment. The resulting plasmid, named pMS136 (
FIG. 20 ), was transformed into T. reesei strain P37PΔCBHIpTEX-CHY22 as described (Penttilä et al., 1987,Gene 61, 155-164). Strain P37PΔCBHIpTEX-CHY22 was constructed by transformation of strain P37PΔCBHIPyr-26 (U.S. Pat. No. 5,874,276) with a version of the expression vector of pTEX-CHY. Vector pTEX-CHY is a derivative of pTEX in which the coding region for the T. reesei cellobiohydrolase I (CBHI) signal sequence, catalytic core and linker region (amino acids 1-476 of CBHI, Shoemaker, et al., 1983, Bio/Technology, 1:691-696) fused to the coding region of bovine prochymosin B (Harris et al., Nucleic Acids Research, 10:2177-2187. was inserted between the cbh1 promoter and terminator region by methods known in the art. Selection of the P37PΔCBHIpTEX-CHY22 transformants with pMS136 was performed on media with 100 μg/ml hygromycin. To obtain uninuclear transformant clones, the transformants were sporulated and single spores were plated on the selective medium with hygromycin. Purified transformants and the parental strain used in the transformation were grown in shake flasks (28° C., 200 RPM) in Trichoderma minimal medium (Penttilä at al., 1987,Gene 61, 155-164) supplemented with 3% whey and 0.2% peptone. Mycelial samples were collected from the cultures on the third, fifth and sixth cultivation days. Total RNA was isolated from the mycelia with the TRIzol reagent (Gibco-BRL) as instructed by the manufacturer. Northern blotting and hybridization were performed to the RNA samples as described in Example 4. The Northern filter was first probed with the full-length HAC1 cDNA, and an mRNA derived from the expression construct which is about 2.0 kb in length can be observed in two of the transformants in addition to the 2.5 kb band that is derived from the native HAC1 gene (FIG. 21 ). The HAC1 probe was removed from the Northern filter by incubating it in 0.1% SDS at 100° C. for 10 minutes. The filter was subsequently probed with the T. reesei pdi1, bip1 and gpd1 probes. Pdil encodes the protein disulphide isomerase and has been shown to be regulated by the UPR pathway (Saloheimo et al., 1999, Mol. Gen. Genet. 262, 35-45). Bip1 (unpublished) encodes the T. reesei homologue of the ER-specific chaperone protein Bip. The gpd1 gene encodes glyceraldehyde phosphate dehydrogenase and was used as the constitutive control probe. After hybridization the filter was exposed to the screen of the Phosphoimager SI (Molecular Dynamics) and the signals were quantified with the phosphoimager. The pdi1 and bip1 signals were normalized with respect to the gpd1 signals. The results show that in the two transformants which express the truncated HAC1 mRNA the pdi1 mRNA level is 4- and 7-fold higher than in the parental strain on the third culture day (FIG. 21 ). This indicates that the UPR pathway can be induced constitutively in Trichoderma reesei by the expression of HAC1 gene without its 20 bp intron and 5′ flanking region - A Trichoderma reesei strain where the HAC1 gene is mutated was unexpectedly generated during the transformation of the plasmid pMS136 into the strain producing CBHI-chymosin fusion protein (Example 7). When analysing the transformants by Northern hybridization it was noticed that one of the transformants (number 31) produced several forms of the HAC1 mRNA that are considerably shorter than 2 kb (
FIG. 21 4, 8 and 12). On the fifth and sixth day of the culture as described in Example 7 the unfolded protein response is induced in the parental strain of the transformation, presumably by the production of the heterologous protein chymosin. This is seen in the Northern analysis as appearance of a HAC1 mRNA of about 2.2 kb (truncated at the 5′ flanking region) and as the induction of the pdi1 mRNA onlanes days 5 and 6 (FIG. 21 ). It has previously been shown that the production of antibody Fab fragments induces the pdi1 gene (Saloheimo et al., 1999, Mol. Gen. Genet. 262, 35-45). In thetransformant number 31 the 2.2 kb HAC1 mRNA and the induction of the pdi1 and bip1 mRNAs are not detected, suggesting that the HAC1 gene of this strain is functionally impaired. To further verify this, a DTT treatment experiment of thetransformant number 31 was carried out. It was grown in shake flasks (28° C., 200 RPM) in the Trichoderma minimal medium (Penttilä at al., 1987,Gene 61, 155-164) with 3% whey and 0.2% peptone for three days. The culture was divided into two aliquots and one of them was treated with 10 mM dithiothreitol (DTT) and the other served as the control. Samples were taken from both aliquots at 0, 30, 60, 120 and 240 minutes after DTT addition. Total RNA was isolated from the mycelia and Northern hybridization was performed as described in Example 7. Hybridization of the Northern with the HAC1 probe reveals that the UPR induction by DTT is severely delayed in thetransformant number 31. The HAC1 mRNA of 2.2 kb is detected only 4 hours after DTT addition (FIG. 22 ) and a 2-fold induction of the pdi1 gene is also apparent in this timepoint. In a wild type strain the 2.2 kb HAC1 mRNA appears and the pdi1 induction takes place after 30 minutes of DTT treatment (Example 4,FIG. 11 ). - The chymosin levels produced by the control strain and the
transformant number 31 were measured daily from the media of the whey-peptone cultures described in example 7. The measurements were done from two parallel cultures with a milk clotting assay (Cunn-Coleman, et al., 1991, Bio/Technology, 9:976-981.Transformant number 31 produced roughly the same amount of chymosin as the parental strain on 2 and 3 of the culture. On the later days the chymosin levels in the culture of the mutant strain started declining, whereas the control strain could still increase significantly the chymosin amount in its culture medium (days FIG. 23 ). The difference between the two strains is evident in the late stages of the culture, where the UPR pathway is induced in the parental strain but not in thestrain number 31. This suggests that a functional HAC1 gene and induction of the UPR pathway in the late culture stages is needed for efficient production of CBHI-chymosin fusion protein in T. reesei. - The yeast protein phosphatase encoded by the PTC2 gene has been shown to be involved in the regulation of the UPR pathway (Welihinda et al., 1998, Mol. Cell. Biol. 18, 1967-1977). The IRE1 protein is phosphorylated when the UPR pathway is turned on (Shamu and Walter, 1996, EMBO J. 15:3928-3039), and Ptc2 dephosphorylates IRE1p and regulates the UPR negatively. A BLAST search (Altschul et al., 1990, J. Mol. Biol. 215, 403-410) was made with the yeast Ptc2 sequence against the public database containing Aspergillus nidulans EST cDNA sequences, and the cDNA clone i2c04a1 was found to be homologous to it within the database. The region corresponding to this cDNA was amplified by PCR from Aspergillus nidulans genomic DNA with the
oligonucleotides 5′ TTG AAC AGC AGATCG TTA CTG 3′ (forward primer) (SEQ ID No. 51) and 5′ TAT AAA GTT CGTCAA TAG TGG 3′ (reverse primer) (SEQ ID No. 52). The PCR reaction was carried out as described in Example 2. The resulting PCR fragment was cloned into the pCR2.1 vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. It was sequenced with internal oligonucleotide primers (FIG. 24 ). The optimal hybridization conditions for isolation of the T. reesei ptc2 cDNA were determined by Southern hybridization of T. reesei genomic DNA with the A. nidulans ptcB fragment as described in Example 3. A T. reesei cDNA library constructed in λZAP (Stratagene, Stalbrandt et al., 1995, Appl. Environ. Microbiol. 61, 1090-1097) was screened by hybridization with the A. nidulans ptcB fragment as described in Example 3. The λ-clones hybridizing with the probe were excised into pBluescript plasmids with the cDNA inserts as instructed (Stratagene), and the clone having the longest insert based on restriction enzyme digestion was chosen for sequencing. The insert of this cDNA clone is 1830 bp in length, encoding an open reading frame of 438 amino acids (FIG. 25 ). The putative Trichoderma PTCII protein (used interchangeably with PTC2) shows the highest identity among yeast proteins to Ptc2, 48%. It also shares 60% identity with the putative PTC2 protein from Schizosaccharomyces pombe. The ptcB fragment cloned from Aspergillus nidulans is 1264 in length (FIG. 24 ). Based on homology with other Ptc2 sequences, an intron has been identified in the fragment. The deduced amino acid sequence is 89% identical to T. reesei PTCII protein over an area of 117 amino acids. - A search with the program BLAST (Altschul et al., 1990, J. Mol. Biol. 215, 403-410) was made with the yeast IRE1 protein sequences against the public database containing Aspergillus nidulans EST cDNA sequences. The EST clone v1h01a1 was homologous to yeast IRE1 protein and include such annotation. The region corresponding to this EST cDNA was amplified by PCR from Aspergillus nidulans genomic DNA with the
oligonucleotides 5′ CGG AGG CAA GAGTCA TAG ACG 3′ (forward primer) (SEQ ID No. 53) and 5′ CAA TAT ATT TCT GAACCA GTA CG 3′ (reverse primer) (SEQ ID No. 54). The PCR reaction was carried out as described in Example 2. The resulting PCR fragment was cloned into the pCR2.1 vector with the TOPO TA cloning kit (Invitrogen) as instructed by the manufacturer. It was sequenced with internal oligonucleotide primers. The fragment was used as a probe in isolation of the T. reesei IRE1 gene. Optimal hybridization conditions were first determined with Southern hybridization of genomic T. reesei DNA as described in Example 3. A T. reesei genomic library constructed in λEMBL3 (Kaiser and Murray, 1985, in DNA Cloning: a Practical Approach, pp. 1-47, ed. Glover, IRL Press, Oxford) was then plated with the appropriate E. coli host strain and λ-DNA was lifted onto nitrocellulose filters (Schleicher & Schull) as instructed by the manufacturer. The filters were hybridized over night at 50° C. in a mix containing 6×SSC, 5×Denhardt's, 0.5% SDS, 100 μg/ml herring sperm DNA (SSC is 0.15 M NaCl, 0.015 M Na.citrate, pH 7.0, 50×Denhardt's is 1% Ficoll, 1% polyvinylpyrrolidone, 1% bovine serum albumin). The filters were washed for 10 minutes at room temperature with 2×SSC, 0.1% SDS and for 30 minutes at 50° C. with the same solution. λ-DNA was isolated from clones hybridizing with the probe with a described method (Sambrook et al., 1989). - Most of the protein-coding region of the genomic IRE1 gene was subcloned into pBluescript SK− as 2.1 kb and 2.4 kb BamHI fragments with methods known in the art. These fragments were sequenced with synthetic oligonucleotide primers. The two subclone fragments do not cover the whole open reading frame, and thus the 5′ end of the chromosomal gene was sequenced from DNA isolated from the λ-clone isolated from the genomic library. An IRE1 cDNA was isolated from a T. reesei library constructed in λZAP (Stratagene). The cDNA library was plated with the appropriate E. coli host and lifted onto nitrocellulose filters (Schleicher & Schüll) as instructed by the manufacturer. The probe fragment used in the screening was obtained by digesting the 2.4 kb genomic subclone plasmid with BamHI and SmaI. The fragment of about 600 bp was run in a 0.8% agarose gel and isolated from the gel with the Qiaguick gel extraction kit (Qiagen) with manufacturer's instructions. The probe was labelled with 32P-dCTP with the Random Primed DNA labelling kit (Boehringer Mannheim). The filters were hybridized at 42° C. over night in a hybridization mixture containing 50% formamid, 5×Denhardt's, 5×SSPE, 0.1% SDS, 100 μg/ml herring sperm DNA and 1 μg/ml polyA-DNA (SSPE is 0.18 M NaCl, 1 mM EDTA, 10 mM NaH2PO4, pH 7.7). The filters were washed for 10 minutes at room temperature with 2×SSC, 0.1% SDS and for 30 minutes at 65° C. in 0.1×SSC, 0.1% SDS. λ-clones giving a hybridization signal were converted into pBluescript plasmids by in vivo-excision as instructed (Stratagene). The T. reesei IRE1 cDNA was sequenced from one of the plasmids with internal oligonucleotide primers.
- The area sequenced from the T. reesei IRE1 gene is about 4.5 kb, and the open reading frame encodes a protein of 1233 amino acids (
FIG. 27 ). Comparison of the genomic and cDNA sequences revealed one intron. The T. reesei IREI protein starts with a predicted signal sequence of 25 amino acids. There is a putative transmembrane segment at positions 574-596 of the open reading frame. The N-terminal domain (before the transmembrane segment) presumably facing the lumen of the endoplasmic reticulum has 24% identity and 39% similarity over an area of 377 amino acids with yeast IRE1p. The C-terminal part with the kinase and RNAse domains is 42% identical and 59% similar over an area of 490 amino acids to yeast IRE1p. The cloned A. nidulans ireA fragment is 1570 bp in length (FIG. 26 ). It encodes the kinase and RNAse domains of the IREA protein. Based in comparison with the yeast and T. reesei IRE1 sequences, an intron is identified in the sequence of the ireA fragment. The deduced A. nidulans IREA amino acid sequence has 52% identity over an area of 507 amino acids to the T. reesei IREI protein. - The A. niger var. awamori hacA cDNA was isolated by heterologous hybridisation with the cloned Aspergillus nidulans hacA fragment described in Example 3. A cDNA library constructed from A. niger var. awamori RNA in the plasmid pYES2 (Invitrogen) was plated as E. coli colonies, lifted onto nitrocellulose filters and screened by colony hybridisation as described for the isolation of the T. reesei hac1 cDNA in Example 3. The hybridisation and the final washes were performed at 57° C. Positive colonies were found and examined by restriction analysis and sequencing of the cDNA ends. The longest cDNA was sequenced throughout its length from both strands. It is 1.68 kb long and encodes a protein of 342 amino acids (
FIG. 28 ). The encoded protein has 76% identity with A. nidulans HACA protein and 38% identity with T. reesei HACI protein. The A. niger var. awamori hacA cDNA has an upstream open reading frame encoding 44 amino acids. The region of the cDNA that, according to homology with the T. reesei and A. nidulans hac1/A genes, had a 20 bp intron was sequenced from five of the A. niger var. awamori hacA cDNA clones isolated. One of these clones did not have the 20 bp intron present, showing that the intron can be spliced out as is shown in Example 4 for the 20 bp introns of T. reesei hac1 and A. nidulans hacA genes. - The UPR-induced form of the A. niger var. awamori hacA cDNA was expressed in A. niger var. awamori strains producing Trametes versicolor laccase or bovine preprochymosin which were constructed in the following manner. Strains ΔAP3 and ΔAP4 (described in Berka, R. M. et al., 1990, Gene 86:153-162) are equivalent strains which are deleted for the pepA gene (encoding the major extracellular aspartic proteinase) and which have a pyrG null mutation.
- Strain ΔAP3 was transformed with pUCpyrGRG3 to create
strain ΔAP3pUCpyrGRG3# 11 which produces bovine preprochymosin. This strain secretes and accumulates active chymosin (an aspartic proteinase) in the culture medium. The plasmid, pUCpyrGRG3, consists of the GRG3 expression cassette (encoding the Aspergillus niger glaA promoter, preprochymosin open reading frame and glaA terminator) obtained from pGRG3 (Cullen, D. et al., 1987, Bio/Technology 5:369-376) and the Neurospora crassa pyr4 gene inserted into pUC19. Transformants of strain ΔAP3 with this plasmid were selected on the basis of uridine auxotrophy. Transformants were screened in liquid culture for chymosin production and strainΔAP3pUCpyrGRG3# 11 was chosen as the best producer. - Strain ΔAP4 was transformed with pGPT-LCC1 to create strain ΔAP4:pGPTIaccase which secretes
Trametes versicolor laccase 1. The plasmid, pGPT-LCC1, is a derivative of plasmid pGPTpyrG1 (described in Berka, R. M. and Barnett, C. C., 1989, Biotechnol. Adv. 7:127-154) which contains the N. crassa pyr4 gene as fungal selectable marker and the A. niger glaA promoter and A. niger var. awamori glaA terminator region separated by cloning sites. To create pGPT-LCC1 the open reading frame for the Trametes versicolor lcc1 cDNA (Ong, E. et al., 1997, Gene 196:113-119) was inserted between the glaA promoter and terminator regions in pGPTpyrG1. Transformants of strain ΔAP4 with this plasmid were selected on the basis of uridine auxotrophy. Transformants were screened in liquid culture for laccase production and strain ΔAP4:pGPTIaccase was chosen as the best producer. - For the over expression of hacA, the induced form of the A. niger var. awamori hacA cDNA was first created by deleting the 20 bp intron and truncating the 5′ flanking region by about 150 bp, which omitted the upstream open reading frame. This was done by methods known in the art. The resulting hacA gene fragment was then cloned into an A. niger var. awamori expression vector with methods known in the art. In the final expression construct, pMS152 (
FIG. 29 ), the hacA gene fragment is between the A. niger var. awamori glaA (glucoamylase gene) promoter and terminator. The A. nidulans amdS gene endoding acetamidase was in the plasmid as a selection marker for fungal transformation. - The hacA overexpression construct (pMS152) was transformed into either A. niger var. awamori
strain ΔAP3pUCpyrGRG3# 11 or strain ΔAP4:pGPTIaccase. The transformations were performed as described in Penttila et. al., 1987,Gene 61, 155-164. The transformants were selected for the ability to grow on acetamide as the sole nitrogen source. Transformants were passaged three times on selective medium before they were sporulated and single spores were plated on the selective medium. - For Southern analysis the purified transformants and the parental strains were grown in shake flasks (28° C., 200 rpm) in Clofine special medium (described in WO 98/31821). Mycelial samples for total-DNA isolations were collected on the third cultivation day. The isolations were done with the DNA EASY kit (Invitrogen) according to the manufacturer's instructions. 5 μg of the total DNA was cut with restriction enzyme HindIII and XhoI to obtain a 5.2 kb-fragment from the integrated pMS152 to indicate which transformants have the hacA overexpression cassette and samples were run in 1% agarose gel in 1×TBE-buffer. The treatment of the gels and capillary blotting onto a Hybond-N nylon filter (Amersham) were done as instructed by the manufacturer. A fragment of the A. niger var. awamori hacA cDNA labeled as described in Example 3 was used as a probe in the Southern hybridisation. The filters were hybridised at 42° C. over night in a hybridisation mixture containing 50% formamide, 5×Denhart's, 5×SSPE, 0.1% SDS, 100 μg/ml herring sperm DNA and 1 μg/ml poly (A)-DNA. Filters were washed as described in Example 4. A band of the expected size was obtained from all the transformants that were analysed, but not from the parental strains. This indicated that the obtained transformants were stable and that they contained intact hacA overexpression cassette.
- Eight transformants from the laccase-producing strain and four transformants from the chymosin-producing strain shown to contain the hacA overexpression cassette were cultivated again for Northern analysis and measurement of the enzymatic activities. The pMS152 transformants of the strain producing preprochymosin and the untransformed parental strain (ΔAP3pUCpyrGRG3#11) were cultivated in Clofine special medium in shake flasks (28° C., 200 rpm) in two parallel cultures for six days. Mycelial samples for RNA isolations were taken on the third day of the cultivation. The pMS152 transformants of the strain producing Trametes laccase and the untransformed parental strain (ΔAP4:pGPTIaccase) were cultivated in 8 g/litre Bacto Soytone (Difco), 12 g/litre Tryptone peptone (Difco), 15 g/litre (NH4)2SO4, 12.1 g/litre NaH2PO4.H2O and 3.3 g/litre Na2HPO4.7H2O. After autoclaving 5 ml/litre of 20% MgSO4 solution, 2 ml/litre of Cu/citrate solution (110 g/litre citrate*H2O, 125 g/litre CuSO4.5H2O), 1 ml/
80, 300 ml/litre Tween litre 50% maltose solution and 200 ml/litre of 100 mg/litre arginine was added to the medium. The cultivations were done in shake flasks (28° C., 200 rpm) in two parallel cultures for ten days. The mycelial samples for RNA isolations were taken on the second day of the cultivation. Total RNA's were isolated from all the mycelial samples using the TRIZOL reagent (Gibco-BRL) as instructed by the manufacturer. RNA samples of 5 μg were treated with glyoxal and run in 1% agarose gel in 10 mM Na-phosphate buffer, pH 7.0. Northern blottings and hybridizations were done as described in Example 4. A fragment of the A. niger var. awamori hacA cDNA labeled as described in Example 3 was used as a probe. An mRNA of the expected size from the hacA overexpression cassette of about 1.6 kb was observed in all the transformants studied in addition to the band of about 1.7 kb that is derived from the native hacA gene and that is also seen in the controls. This indicates that the 5′-truncated and intronless hacA coming from the overexpression cassette is expressed in the transformants. - Samples from the culture supernatants of the pMS152 transformants of the strain producing preprochymosin and the untransformed parental strain (ΔAP3pUCpyrGRG3#11) were taken on the fifth day of cultivation. The chymosin production levels were measured with a milk-clotting assay. The samples were diluted into buffer containing 10 g/litre sodium acetate and 5 ml/litre 1M acetic acid. 200 μl of the diluted sample was added to 5 ml of buffer containing 55 g/500 ml skim milk (Difco) at 30° C. The clotting of the milk was observed visually and the time that the clotting of the milk took was recorded and correlated to a known standard. All the four transformants produced 1.3-2.8 fold more chymosin than the parental strain (
FIG. 30 ). - Samples from the culture supernatants of the pMS152 transformants of the strain producing Trametes laccase and the untransformed parental strain (ΔAP4:pGPTIaccase) were taken on the fifth and seventh day of the cultivation. The laccase activity measurements were made from the supernatants and the results showed that all the transformants produce more laccase than the parental strain. Laccase activity was measured according to Niku-Paavola et al. (Niku-Paavola M-L, Karhunen E, Salola P, Raunio V (1988) Ligninolytic enzymes of the white-rot fungus Phlebia radiata. Biochem. J. 254: 877-884) using ABTS (Boehringer Mannheim; Mannheim, Germany) as a substrate. The production levels of the transformants in the fifth day samples were 3 to 7.6 fold higher than in the parental strain. On the seventh day of cultivation the transformants produced 2 to 5.4 fold more laccase than the parental strain (
FIG. 31 ). - These results demonstrate that overexpression of an inducing form of hacA enables production of higher levels of secreted heterologous proteins in A. niger.
- Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
Claims (29)
1-55. (canceled)
56. An isolated nucleic acid encoding a PTC2 protein wherein said PTC2 protein modulates unfolded protein response and wherein said PTC2 has at least 70% similarity to an amino acid sequence of FIG. 24 or FIG. 25 .
57. The nucleic acid of claim 56 isolated from Trichoderma reesei.
58. The nucleic acid of claim 56 isolated from Aspergillus nidulans.
59. The nucleic acid of claim 56 isolated from Aspergillus niger.
60. The nucleic acid of claim 56 wherein said PTC2 protein has an amino acid sequence as set forth in FIG. 24 .
61. The nucleic acid of claim 56 wherein said PTC2 protein has an amino acid sequence as set forth in FIG. 25 .
62. The nucleic acid of claim 56 wherein said nucleic acid comprises a coding nucleic acid sequence as set forth in FIG. 24 .
63. The nucleic acid of claim 56 wherein said nucleic acid consists essentially of a coding nucleic acid sequence as set forth in FIG. 24 .
64. The nucleic acid of claim 56 wherein said nucleic acid comprises a coding nucleic acid sequence as set forth in FIG. 25 .
65. A protein encoded by the nucleic acid of claim 56 .
66. A protein having unfolded protein response modulating activity and having greater than 70% similarity to the amino acid sequence of FIG. 24 or FIG. 25 .
67. A protein having an amino acid sequence as set forth in FIG. 24 or FIG. 25 .
68. A nucleic acid encoding a IRE1 protein having unfolded protein response modulating activity and having at least 60% to an amino acid sequence as shown in FIG. 26 or FIG. 27 .
69. The nucleic acid of claim 68 wherein said IRE1 protein has an amino acid sequence as shown in FIG. 26 or FIG. 27 .
70. The nucleic acid of claim 68 wherein said nucleic acid is isolated from Trichoderma reesei.
71. The nucleic acid of claim 68 wherein said nucleic acid is isolated from Aspergillus nidulans.
72. The nucleic acid of claim 68 wherein said nucleic acid is isolated from Aspergillus niger.
73. The nucleic acid of claim 68 wherein said IRE1 protein has an amino acid sequence as set forth in FIG. 26 .
74. The nucleic acid of claim 68 wherein said IRE1 protein has an amino acid sequence as set forth in FIG. 27 .
75. The nucleic acid of claim 68 wherein said nucleic acid comprises a coding nucleic acid sequence as set forth in FIG. 26 .
76. The nucleic acid of claim 68 wherein said nucleic acid consists essentially of a coding nucleic acid sequence as set forth in FIG. 26 .
77. The nucleic acid of claim 68 wherein said nucleic acid comprises a coding nucleic acid sequence as set forth in FIG. 27 .
78. The nucleic acid of claim 68 wherein said nucleic acid consists essentially of a coding nucleic acid sequence as set forth in FIG. 27 .
79. A protein encoded by the nucleic acid of claim 68 .
80. A protein having unfolded protein response inducing activity and having greater than 70% similarity to the amino acid sequence of FIG. 26 or FIG. 27 .
81. The protein of claim 80 wherein said protein has constitutive unfolded protein response inducing activity.
82. A protein having an amino acid sequence as set forth in FIG. 26 or FIG. 27 .
83-86. (canceled)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/272,629 US20140335591A1 (en) | 2000-03-24 | 2014-05-08 | Increased production of secreted proteins by recombinant eukaryotic cells |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53469200A | 2000-03-24 | 2000-03-24 | |
| US09/816,277 US20010034045A1 (en) | 2000-03-24 | 2001-03-23 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US10/663,450 US7662584B2 (en) | 2000-03-24 | 2003-09-15 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US12/639,921 US8753866B2 (en) | 2000-03-24 | 2009-12-16 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US14/272,629 US20140335591A1 (en) | 2000-03-24 | 2014-05-08 | Increased production of secreted proteins by recombinant eukaryotic cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/639,921 Continuation US8753866B2 (en) | 2000-03-24 | 2009-12-16 | Increased production of secreted proteins by recombinant eukaryotic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20140335591A1 true US20140335591A1 (en) | 2014-11-13 |
Family
ID=24131126
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/816,277 Abandoned US20010034045A1 (en) | 2000-03-24 | 2001-03-23 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US10/663,450 Expired - Fee Related US7662584B2 (en) | 2000-03-24 | 2003-09-15 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US12/639,921 Expired - Fee Related US8753866B2 (en) | 2000-03-24 | 2009-12-16 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US14/272,629 Abandoned US20140335591A1 (en) | 2000-03-24 | 2014-05-08 | Increased production of secreted proteins by recombinant eukaryotic cells |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/816,277 Abandoned US20010034045A1 (en) | 2000-03-24 | 2001-03-23 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US10/663,450 Expired - Fee Related US7662584B2 (en) | 2000-03-24 | 2003-09-15 | Increased production of secreted proteins by recombinant eukaryotic cells |
| US12/639,921 Expired - Fee Related US8753866B2 (en) | 2000-03-24 | 2009-12-16 | Increased production of secreted proteins by recombinant eukaryotic cells |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20010034045A1 (en) |
| EP (1) | EP1266018B1 (en) |
| AT (1) | ATE394496T1 (en) |
| AU (1) | AU2001250954A1 (en) |
| CA (1) | CA2403842C (en) |
| DE (1) | DE60133884D1 (en) |
| DK (1) | DK1266018T3 (en) |
| WO (1) | WO2001072783A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107723253A (en) * | 2017-09-29 | 2018-02-23 | 天津昕因达生物技术有限公司 | A kind of double-mass model cotransformation foreign gene cance high-expression gene engineering bacteria |
| CN110358781A (en) * | 2019-07-31 | 2019-10-22 | 湖北大学 | A kind of acidic mammalian chitinase encoding gene and application |
| WO2019213521A1 (en) * | 2018-05-04 | 2019-11-07 | Board Of Trustees Of Michigan State University | Expression of unfolded protein response proteins improves plant biomass and growth |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9821198D0 (en) | 1998-09-30 | 1998-11-25 | Danisco | Enzyme |
| US7312062B2 (en) | 1998-11-27 | 2007-12-25 | Novozymes A/S | Lipolytic enzyme variants |
| ES2673518T3 (en) * | 2004-03-31 | 2018-06-22 | Janssen Biotech, Inc. | Methods to modify protein production rates |
| WO2006028889A2 (en) * | 2004-09-02 | 2006-03-16 | Wyeth | Systems and methods for protein production |
| JP5631533B2 (en) * | 2004-12-23 | 2014-11-26 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | Gene expression technology |
| EP2410048B1 (en) | 2005-01-24 | 2016-08-10 | DSM IP Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
| GB0512707D0 (en) * | 2005-06-22 | 2005-07-27 | Delta Biotechnology Ltd | Gene expression technique |
| US8071089B2 (en) | 2005-11-01 | 2011-12-06 | Bio-Cat, Inc. | Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency |
| WO2007062936A2 (en) | 2005-11-29 | 2007-06-07 | Dsm Ip Assets B.V. | Dna binding site of a transcriptional activator useful in gene expression |
| US8232377B2 (en) | 2006-05-16 | 2012-07-31 | National Institute Of Advanced Industrial Science And Technology | Method for high-level secretory production of protein |
| KR100977446B1 (en) * | 2006-06-16 | 2010-08-24 | 한국생명공학연구원 | A novel gene of Hansenula polymorpha that regulates secretory stress response and a method of increasing the secretory expression efficiency of recombinant protein using the gene |
| EP2423315B1 (en) | 2006-06-29 | 2015-01-07 | DSM IP Assets B.V. | A method for achieving improved polypeptide expression |
| US8389269B2 (en) * | 2006-11-02 | 2013-03-05 | Dsm Ip Assets B.V. | Production of secreted proteins by filamentous fungi |
| US20100062491A1 (en) * | 2007-01-05 | 2010-03-11 | Novozymes A/S | Overexpression of the Chaperone BIP in a Heterokaryon |
| JP2010517587A (en) | 2007-02-15 | 2010-05-27 | ディーエスエム アイピー アセッツ ビー.ブイ. | Recombinant host cells for producing compounds of interest |
| DK2129685T3 (en) * | 2007-03-21 | 2014-02-10 | Danisco Us Inc | OVERPRESSION OF FOLDING AXES AND CHAPERONES IMPROVE PROTEIN PREPARATION |
| CA2704548A1 (en) * | 2007-11-01 | 2009-05-07 | Danisco Us Inc. | Signal sequences and co-expressed chaperones for improving protein production in a host cell |
| CN101952303A (en) | 2008-02-25 | 2011-01-19 | 诺维信公司 | Method for increasing expression yield of a protein of interest |
| CN102414323B (en) | 2009-04-22 | 2015-07-08 | 帝斯曼知识产权资产管理有限公司 | Process for production of recombinant polypeptide of interest |
| AU2010240861B2 (en) | 2009-04-24 | 2015-02-05 | Dsm Ip Assets B.V. | Carbohydrate degrading polypeptide and uses thereof |
| EP2258854A1 (en) | 2009-05-20 | 2010-12-08 | FH Campus Wien | Eukaryotic host cell comprising an expression enhancer |
| CA2768608A1 (en) | 2009-07-22 | 2011-01-27 | Dsm Ip Assets B.V. | Improved host cell for the production of a compound of interest |
| US20130011876A1 (en) | 2010-02-04 | 2013-01-10 | Dsm Ip Assetts, B.V. | Process for preparing filamentous fungal strains having a sexual cycle and a process for preparing sexually crossed filamentous fungal strains |
| MX2012009274A (en) | 2010-02-11 | 2012-12-05 | Dsm Ip Assets Bv | Host cell capable of producing enzymes useful for degradation of lignocellulosic material. |
| US9133448B2 (en) | 2010-02-11 | 2015-09-15 | Dsm Ip Assets B.V. | Polypeptide having cellobiohydrolase activity and uses thereof |
| FI20105633A0 (en) * | 2010-06-04 | 2010-06-04 | Valtion Teknillinen | Process for improved protein production |
| FI20105632A0 (en) | 2010-06-04 | 2010-06-04 | Valtion Teknillinen | Procedure for protein production in filamentous fungi |
| FI20105634A0 (en) | 2010-06-04 | 2010-06-04 | Valtion Teknillinen | Improved protein production by filamentous fungi |
| WO2011154908A1 (en) * | 2010-06-08 | 2011-12-15 | National University Of Ireland, Galway | Manipulation of hsp70 and ire1alpha protein interactions |
| EA201300054A1 (en) | 2010-06-29 | 2013-05-30 | ДСМ АйПи АССЕТС Б.В. | POLYPEPTIDE, possessing the activity of beta-glucose, and its application |
| CN103180337A (en) | 2010-06-29 | 2013-06-26 | 帝斯曼知识产权资产管理有限公司 | Polypeptides with swelling factor activity and uses thereof |
| EA201300056A1 (en) | 2010-06-29 | 2013-07-30 | ДСМ АйПи АССЕТС Б.В. | POLYPEPTIDE WITH ACTHYLXYLANESTERASE ACTIVITY AND ITS APPLICATIONS |
| MX2012014993A (en) | 2010-06-29 | 2013-02-26 | Dsm Ip Assets Bv | Polypeptide having carbohydrate degrading activity and uses thereof. |
| BR112012033703A2 (en) | 2010-06-29 | 2016-10-11 | Dsm Ip Assets Bv | polypeptide having beta-glucosidase activity and its uses |
| BR112012033404B1 (en) | 2010-06-29 | 2021-05-18 | Dsm Ip Assets B.V. | recombinant cell, method for preparing a polypeptide, composition, method for treating a substrate comprising carbohydrate material and use of a polypeptide |
| US8945898B2 (en) | 2010-07-01 | 2015-02-03 | Dsm Ip Assets B.V. | Recombinant host cell with deficiency in non-ribosomal peptide synthase production |
| WO2012060389A1 (en) * | 2010-11-05 | 2012-05-10 | 旭硝子株式会社 | Transformant of yeast of genus schizosaccharomyces and method for producing same |
| BR112013014457A8 (en) * | 2010-12-09 | 2017-12-19 | Pasteur Institut | uses of the enzyme 6-methylguanine-dna-methyltrasferase (mgmt, ec 2.1.1.63) to increase heterologous protein production, as well as expression vector, recombinant cells and fusion polypeptide comprising peptide secretion signal and snap protein |
| US9956236B2 (en) | 2011-02-07 | 2018-05-01 | Cornell University | Methods for increasing immune responses using agents that directly bind to and activate IRE-1 |
| US20150018406A1 (en) | 2012-03-09 | 2015-01-15 | Cornell University | Modulation of breast cancer growth by modulation of xbp1 activity |
| CN102604913B (en) * | 2012-04-05 | 2013-08-14 | 湖南尤特尔生化有限公司 | Preparation method and application of thermomyces lanuginosus lipase |
| WO2013181647A2 (en) | 2012-06-01 | 2013-12-05 | Danisco Us Inc. | Compositions and methods of producing isoprene and/or industrrial bio-products using anaerobic microorganisms |
| JP6468561B2 (en) | 2012-07-19 | 2019-02-13 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | AgsE deficient strain |
| CN102994541B (en) * | 2012-12-19 | 2015-04-15 | 江南大学 | Method for enhancing secretion of glucose oxidase by coexpression of UPR (unfolded protein response) key genes and downstream target genes |
| JP2016518829A (en) * | 2013-04-03 | 2016-06-30 | ノボザイムス アクティーゼルスカブ | Filamentous fungal cells containing an inactivating component of the selective autophagy pathway and methods of use thereof |
| EP3521431A1 (en) | 2013-09-25 | 2019-08-07 | Cornell University | Compounds for inducing anti-tumor immunity and methods thereof |
| US10590427B2 (en) | 2014-04-17 | 2020-03-17 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Recombinant host cell for expressing proteins of interest |
| SG11201608084TA (en) | 2014-04-17 | 2016-10-28 | Boehringer Ingelheim Rcv Gmbh | Recombinant host cell engineered to overexpress helper proteins |
| CN105112303B (en) * | 2015-09-06 | 2018-10-16 | 江南大学 | A kind of Aspergillus niger strain of production wine complex enzyme |
| US11046736B2 (en) | 2016-07-22 | 2021-06-29 | Novozymes A/S | Filamentous fungal host |
| EP3596199A1 (en) | 2017-03-13 | 2020-01-22 | DSM IP Assets B.V. | Zinc binuclear cluster transcriptional regulator-deficient strain |
| US20210032642A1 (en) * | 2018-04-06 | 2021-02-04 | Danisco Us Inc. | Increased alcohol production from yeast producing an increased amount of active hac1 protein |
| US12209236B2 (en) | 2018-05-25 | 2025-01-28 | Danisco Us Inc. | Overexpression of fumarate reductase results in an increased fermentation rate in yeast |
| CN113166211A (en) * | 2018-11-28 | 2021-07-23 | 诺维信公司 | Improved filamentous fungal host cells |
| WO2023039358A1 (en) * | 2021-09-09 | 2023-03-16 | Dupont Nutrition Biosciences Aps | Over expression of foldases and chaperones improves protein production |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US5364770A (en) * | 1985-08-29 | 1994-11-15 | Genencor International Inc. | Heterologous polypeptides expressed in aspergillus |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| FR2646437B1 (en) | 1989-04-28 | 1991-08-30 | Transgene Sa | NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME |
| US5665585A (en) * | 1992-09-03 | 1997-09-09 | Alko-Yhiot Oy | Recombinant production of glucoamylase P in trichoderma |
| US5541094A (en) * | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
| US5861271A (en) | 1993-12-17 | 1999-01-19 | Fowler; Timothy | Cellulase enzymes and systems for their expressions |
| JPH1084970A (en) * | 1996-07-23 | 1998-04-07 | H S P Kenkyusho:Kk | Novel transcriptional regulator |
-
2001
- 2001-03-23 AT AT01924287T patent/ATE394496T1/en not_active IP Right Cessation
- 2001-03-23 CA CA2403842A patent/CA2403842C/en not_active Expired - Fee Related
- 2001-03-23 DE DE60133884T patent/DE60133884D1/en not_active Expired - Lifetime
- 2001-03-23 EP EP01924287A patent/EP1266018B1/en not_active Expired - Lifetime
- 2001-03-23 DK DK01924287T patent/DK1266018T3/en active
- 2001-03-23 US US09/816,277 patent/US20010034045A1/en not_active Abandoned
- 2001-03-23 AU AU2001250954A patent/AU2001250954A1/en not_active Abandoned
- 2001-03-23 WO PCT/US2001/009401 patent/WO2001072783A2/en not_active Ceased
-
2003
- 2003-09-15 US US10/663,450 patent/US7662584B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 US US12/639,921 patent/US8753866B2/en not_active Expired - Fee Related
-
2014
- 2014-05-08 US US14/272,629 patent/US20140335591A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107723253A (en) * | 2017-09-29 | 2018-02-23 | 天津昕因达生物技术有限公司 | A kind of double-mass model cotransformation foreign gene cance high-expression gene engineering bacteria |
| WO2019213521A1 (en) * | 2018-05-04 | 2019-11-07 | Board Of Trustees Of Michigan State University | Expression of unfolded protein response proteins improves plant biomass and growth |
| US11674147B2 (en) | 2018-05-04 | 2023-06-13 | Board Of Trustees Of Michigan State University | Expression of unfolded protein response proteins improves plant biomass and growth |
| CN110358781A (en) * | 2019-07-31 | 2019-10-22 | 湖北大学 | A kind of acidic mammalian chitinase encoding gene and application |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040186070A1 (en) | 2004-09-23 |
| DK1266018T3 (en) | 2008-09-01 |
| ATE394496T1 (en) | 2008-05-15 |
| AU2001250954A1 (en) | 2001-10-08 |
| US8753866B2 (en) | 2014-06-17 |
| US20010034045A1 (en) | 2001-10-25 |
| WO2001072783A2 (en) | 2001-10-04 |
| EP1266018A2 (en) | 2002-12-18 |
| US20100221775A1 (en) | 2010-09-02 |
| CA2403842C (en) | 2012-09-25 |
| EP1266018B1 (en) | 2008-05-07 |
| US7662584B2 (en) | 2010-02-16 |
| CA2403842A1 (en) | 2001-10-04 |
| WO2001072783A3 (en) | 2002-07-18 |
| DE60133884D1 (en) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8753866B2 (en) | Increased production of secreted proteins by recombinant eukaryotic cells | |
| JP4769724B2 (en) | A novel Trichoderma gene | |
| Saloheimo et al. | Activation mechanisms of the HACI‐mediated unfolded protein response in filamentous fungi | |
| Kawahara et al. | Endoplasmic reticulum stress-induced mRNA splicing permits synthesis of transcription factor Hac1p/Ern4p that activates the unfolded protein response | |
| Lorenz et al. | Elongation and clustering of glycosomes in Trypanosoma brucei overexpressing the glycosomal Pex11p | |
| KR101952467B1 (en) | Filamentous fungi having an altered viscosity phenotype | |
| Saloheimo et al. | The protein disulphide isomerase gene of the fungus Trichoderma reesei is induced by endoplasmic reticulum stress and regulated by the carbon source | |
| KR20140135802A (en) | Methods and materials for treatment of pompe's disease | |
| CZ20021701A3 (en) | Locally controlled phytase mutagenesis from Escherichia coli | |
| Saloheimo et al. | Characterization of secretory genes ypt1/yptA and nsf1/nsfA from two filamentous fungi: induction of secretory pathway genes of Trichoderma reesei under secretion stress conditions | |
| DK2084272T3 (en) | CLONING, EXPRESSION AND USE OF SURE LYTHOPHOSPHOLIPAS | |
| EP3393501B1 (en) | Human alpha-n-acetylgalactosaminidase polypeptide | |
| Vasara et al. | Characterisation of two 14-3-3 genes from Trichoderma reesei: interactions with yeast secretory pathway components | |
| Landazuri et al. | Cloning and shake flask expression of hrIDS-Like in Pichia pastoris | |
| JP3794760B2 (en) | Phytase-producing yeast | |
| US7323325B2 (en) | Shrimp alkaline phosphatase | |
| de Craaff et al. | Isolation and expression of the | |
| Simão et al. | Structure, Expression, and Functional | |
| Khuu | Characterization of CGI58 and PXA1 in Plant Lipolysis | |
| TW201619385A (en) | Heat stable keratinase and uses thereof | |
| MXPA01003301A (en) | Peptidyl prolyl cis-trans isomerases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |